Development of physiologically based pathogen transport and kinetics model for inhalation of bacillus anthracis spores by Weir, Mark H.
Development of Physiologically Based Pathogen Transport and Kinetics Model for
Inhalation  of Bacillus anthracis Spores
A Thesis
Submitted to the Faculty
of
Drexel University
by
Mark H. Weir
in partial fulfillment of the
requirements for the degree
of
Doctor of Philosophy
August 2009
© Copyright 2009
Mark H. Weir.  All Rights Reserved.
ii
DEDICATIO S
To my Mother and late Father, you worked hard physically so I may have the
chance to work hard mentally.  My Mother instilled in me the daringness to dream and
both she and my Father instilled the will and work ethic to make those dreams reality.  
And to my best friends who have passed, your sacrifice in defense of our country
will never be forgotten, and has inspired me to research means of securing our country.
You were brothers to me, your presence, laughter and indomitable spirits will always be
cherished and missed.
iii
ACKNOWLEDGMENTS
First and foremost I need to acknowledge my advisor Charles N. Haas.  He took a
chance on me and never stopped challenging me throughout my time at Drexel.  I would
not be achieving one of my life goals without his inspiration and expert mentoring.  I
know there is still always more to learn from him and look forward to collaborating with
him in the future.
I would like to to thank my wife and friend, Joanna M. Pope.  She is my rock and
has kept my course true and on the straight and narrow.  Without her, her support and
love I am unsure as to where I would be right now.  
I would also like to thank Dr. Joseph Martin.  He was the first person I ever met
with at Drexel University and encouraged me to continue my course towards graduate
school.  And while here he has helped me in my research as well as morale, which are
equally important in the quest for higher education.
I would like to acknowledge the financial support of the Center for Advancing
Microbial  Risk  Assessment  (CAMRA)  funded  jointly  under  by  the  United  States
Environmental  Protection  Agency  and  Department  of  Homeland  Security  under  the
Science to Achieve Results (STAR) grant number R83236201.  Also this dissertation has
been inspired by my prior research and work with CAMRA.
This  research  was  performed  under  an  appointment  to  a  dissertation  award
program sponsored by the Department of Homeland Security (DHS), administered by the
Oak  Ridge  Institute  for  Science  and  Education  (ORISE)  through  an  interagency
iv
agreement between the U.S. Department of Energy (DOE) and DHS. ORISE is managed
by Oak Ridge Associated Universities (ORAU) under DOE contract number DE-AC05-
06OR23100. All opinions expressed in this paper are the author's and do not necessarily
reflect the policies and views of DHS, DOE, or ORAU/ORISE.
I would like to acknowledge the financial support of the Koerner Family, through
the  Koerner  Family  Fellowship.   Not  only  is  the  financial  support  gratefully
acknowledged, but the moral support of having Dr. Robert Koerner believe in the merits
of my research and my ability to succeed, not  just in my dissertation but as a future
professor.  
The financial support of the US Department of Education through the Graduate
Assistance for Areas of National Need (GAANN).  The financial support of the Geigrich
Family through the Steven Geigrich Memorial Scholarship.
The support of my previous mentors and professors can never be understated.  I
would like to thank specifically Dr. Marleen Troy from Wilkes University, who mentored
me and nominated me for the Alumni Support Scholarship.  Without her mentor ship and
encouragement I would not be where I am today.
I  would  also  like  to  acknowledge  the  assistance  and  expertise  of  the  Thesis
Advisory Committee.  Your knowledge and advice has been invaluable to the completion
of my dissertation.
And last but certainly not least my fellow graduate students and friends.  We have
supported each other over the years and look forward to working with you in the future.
  
vTable of Contents
 CHAPTER 1 BACKGROUND AND LITERATURE REVIEW.......................................1
ABSTRACT.........................................................................................................................1
 1.1 History of dose response modeling and analysis.....................................................1
 1.1.1 Current quantitative microbial risk assessment (QMRA) paradigm................3
 1.1.2 Current dose response paradigm......................................................................6
 1.2 Overview of Bacillus anthracis (B. anthracis) as a pathogen and microorganism..9
 1.2.1 Natural occurrence of B. anthracis ................................................................11
 1.2.2 Environmental survival..................................................................................12
 1.2.3 Possible routes of infection............................................................................13
 1.2.4 Modes of infection..........................................................................................14
 1.2.5 Prior and potential future use as a biological weapon....................................16
 1.3 Physiology and function of the compartments of the human respiratory system. .18
 1.3.1 Sinks and defenses of the human respiratory system.....................................25
 1.4 Interaction of B. anthracis with the unalveolated areas of the respiratory system 27
 1.4.1 B. anthracis-macrophage interaction..............................................................29
 1.4.2 Effect of B. anthracis lethal toxin..................................................................31
 CHAPTER 2  RESPIRATORY SYSTEM SIMPLIFICATION AND GOALS AND AIMS
FOR THE PROJECT.................................................................................34
 2.1 Problem definition: pathogen burden versus exposed dose...................................34
 2.2 Motivation in determining pathogen burden from exposed dose...........................35
 2.3 Simplified modeling of the human respiratory system as a three-region model....38
vi
 2.4 Goals and hypotheses of this dissertation .............................................................40
 2.4.1 Goals of this dissertation................................................................................40
 2.4.2 Hypotheses of this dissertation.......................................................................41
 2.5 General layout of this dissertation..........................................................................42
 2.5.1 Two-stage modeling approach........................................................................43
 2.5.2 Comparison to available dose response data..................................................45
 2.6 Concurrent work being performed modeling the in-vivo fate of B. anthracis.......46
 CHAPTER 3 DEVELOPMENT OF THE FIRST STAGE: THE STOCHASTIC MODEL
FOR BULK FLUID TRANSPORT OF B. ATHRACIS SPORES............49
 3.1 Review of the physiology of the human respiratory system..................................49
 3.1.1 Simplification of the human respiratory system into a three-region model.. .53
 3.2 Basics of Markov chain modeling..........................................................................55
 3.3 Definition of states for the Markov chain model...................................................57
 3.4 Definition of loss rates and transition probabilities for the Markov model...........60
 3.4.1 Establishment of loss rate functions and transition probabilities ..................61
 3.4.2 Transition probabilities for losses from state-one (Air in R1) .......................63
 3.4.3 Transition probabilities for losses from states-two, four and six (respiratory
system surface in R1,R2 and R3 respectively)...............................................64
 3.4.4 Transition probabilities for losses from state-three (air in R2).......................64
 3.4.5 Transition probabilities for losses from state-five (air in R3)........................66
 3.4.6 Definition of loss rate functional forms..........................................................69
 3.5 Choosing the optimum time step for the Markov chain model..............................78
 3.6 Work towards a coupled model..............................................................................82
vii
 CHAPTER 4 DEVELOPMENT OF THE SECOND STAGE: A DETERMINISTIC
MODEL FOR THE INTERACTION BETWEEN B. ANTHRACIS AND
ALVEOLAR MACROPHAGES IN THE LUNG OF THE HUMAN HOST
....................................................................................................................84
 4.1 Role of alveolar macrophages in the pathogenesis of B. anthracis.......................85
 4.1.1 Role of toxins in the subversion and lysis of alveolar macrophages..............88
 4.2 Processes and systems modeled in the deterministic second stage........................90
 4.2.1 Processes being modeled in the deterministic second stage...........................90
 4.2.2 Systems being modeled in the deterministic second stage.............................92
 4.3 Derivation of the mass balance for the deterministic second stage........................94
 4.4 Overview of numerical solutions to ordinary differential equations......................96
 4.5 Optimization of parameters of the deterministic second stage..............................97
 4.5.1 Model parameters obtained from open literature...........................................98
 4.5.2 Model parameters requiring fitting.................................................................99
 4.5.3 Available data for fitting model parameters...................................................99
 4.5.4 Overview of optimized model parameters and their fit................................102
 4.5.4.1 Choosing the best algorithm and optimization routine in MATLAB.. .102
 4.5.4.2 Optimization and fit of model parameters............................................103
 4.6 Future work towards a coupled two-stage model.................................................110
 CHAPTER 5   COUPLING OF A TWO STAGE MODEL OF B. ATHRACIS
TRANSPORT AND PATHOGENESIS FOR THE ESTIMATION OF
PATHOGEN BURDEN..........................................................................112
 5.1 Review of the two-stage modeling framework....................................................113
 5.2 Overview of the stochastic first stage...................................................................115
 5.2.1 Estimates of delivered dose from the stochastic first stage..........................118
viii
 5.2.2 Overview of dose response model fitting.....................................................120
 5.2.3 Effect of delivered dose from stochastic first stage on dose response
assessment.....................................................................................................121
 5.2.4 Extrapolation of first stage to other host species..........................................129
 5.3 Overview of the deterministic second stage and coupled model.........................134
 5.3.1 Estimates of vegetative cell dose from the coupled model..........................136
 5.3.2 Effect of delivered dose from first stage on dose response assessment.......137
 5.4 Evaluation of linear assumption for the low dose region of the dose response...141
 5.5 Summary of the effect of the modified dose on the dose response assessment...143
 CHAPTER 6 CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK
..........................................................................................................................................144
 6.1 Conclusions drawn from this work......................................................................144
 6.2 Recommendations for future research.................................................................145
LIST OF REFERENCES.................................................................................................149
APPENDIX A: LIST OF ACRONYMS AND SYMBOLS USED IN THIS THESIS....160
APPENDIX B: SOURCE CODE OF FIRST STAGE MARKOV CHAIN MODEL.....163
APPENDIX C: SOURCE CODE OF OPTIMIZATION OF PATHOGENESIS
PARAMETERS .....................................................................................174
APPENDIX D: SOURCE CODE OF COUPLED TWO STAGE MODEL....................177
APPENDIX E: SOURCE CODE OF BOOTSTRAP CODE USED FOR DOSE
RESPONSE MODEL FITTING.............................................................184
Vita...................................................................................................................................193
ix
List of Tables
Table 1: Example dose response data set of rhesus macaque exposed to aerosolized Ames
strain of B. anthracis (Druett et al., 1953)..............................................................8
Table 2: Persistence of B. anthracis in air and water.........................................................13
Table 3: Differences in partial pressure leading to the diffusion of oxygen into the blood
for the human adult male (Weibel, 1963).............................................................25
Table 4: Three region model proposed by Morrow et al. (1966).......................................39
Table 5: Three-region model of the respiratory system (Morrow et al., 1966)..................54
Table 6: Eight states defined for the Markov chain model................................................60
Table 7: Loss rates from Markov model states..................................................................61
Table 9: Loss rates from states in the Markov chain model..............................................77
Table 10: Point estimates of transition probabilities for the Markov matrix P..................77
Table 11: Growth rate data for vegetative cells inside macrophages (Hu et al., 2006). . .101
Table 12: Uptake rate data for spores deposited on macrophage surfaces (Hu et al., 2006)
..........................................................................................................................................101
Table 13: Inactivation rate data for macrophages inoculated with spores (Hu et al., 2006)
..........................................................................................................................................102
Table 14: Parameter best estimates from the optimization routine..................................104
Table 15: Hessian matrix outputted from completion of optimization............................107
Table 16: Variance matrix describing low diffusion of parameter estimates...................107
Table 17: Three region model of the human respiratory system (Morrow et al., 1966). .115
Table 18: Eight states defined of the Markov chain model for the first stage.................116
Table 19: Loss rates from states in the Markov chain model...........................................117
Table 20: Point estimates of transition probabilities for the Markov matrix P................118
xTable 21: Exposed dose and corrected delivered dose (Druett et al., 1953)....................122
Table 22: Unmodified dose response data for model fitting using exposed dose (Druett, et
al., 1953)...........................................................................................................123
Table 23: Goodness of fit test for the modeled dose response relationship using the
unmodified exposed dose.................................................................................124
Table 24: Determination of best fitting dose response model for delivered dose............125
Table 25: Goodness of fit test for the modeled dose response relationship using the
modified delivered dose...................................................................................127
Table 26: Determination of best fitting dose response model for delivered dose............128
Table 27: Physiological parameters for guinea pig and rhesus macaque respiratory system
..........................................................................................................................130
Table 28: Effect of physiological parameters on delivered dose correction factor..........133
Table 29: Conversion of LD50 to LD50dd for guinea pigs and rhesus macaques..........134
Table 30: Exposed dose and corrected pathogen burden.................................................138
Table 31: Goodness of fit test for the modeled dose response relationship using the
modified pathogen burden................................................................................139
Table 32: Determination of best fitting dose response model for pathogen burden........140
Table 33: Determination if additional parameter (x) can be justified for delivered dose 143
Table 34: Determination if additional parameter (x) can be justified for pathogen burden
..........................................................................................................................................143
xi
List of Figures
Figure 1: visualization of human characterization element of the analysis phase of the
ILSI risk framework.............................................................................................5
Figure 2: Mice exposed orally to F. tularensis.....................................................................7
Figure 3: Robert Koch's photomicrographs of B. anthracis source:
http://bioinfo.bact.wisc.edu/themicrobialworld/medical.html............................11
Figure 4: Basic depiction of human respiratory system.....................................................19
Figure 5: Depiction of human nasal cavity showing complexity of the passage for air and
contaminants to travel (National Cancer Institute, available at:
http://training.seer.cancer.gov/anatomy/respiratory/passages/nose.html ).........20
Figure 6: Depiction of the oral and nasal cavities of the respiratory system (National
Cancer Institute, available at  http://training.seer.cancer.gov/head-
neck/anatomy/overview.html .............................................................................21
Figure 7: Depiction of larynx, trachea and main bronchi..................................................22
Figure 8: Rubber cast of the human lung,  Johns Hopkins University,available at:
http://www.jhu.edu/chembe/hanes/Research/Therapeutic_Aerosols/Lung.jpg .23
Figure 9: Depiction of capillaries wrapping around alveoli for oxygen exchange, courtesy
of Mariana Ruiz Villarreal, available at:
http://upload.wikimedia.org/wikipedia/commons/4/46/Alveolus_diagram.svg   
............................................................................................................................24
Figure 10: Neutrophil taking in and destroying a B. anthracis vegetative cell; courtesy
Volker Brinkmann available at:
http://en.wikipedia.org/wiki/File:Neutrophil_with_anthrax_copy.jpg  Date
Accessed:  2 May 2009.....................................................................................27
Figure 11: Scanning electron micrograph of cilia on trachea epithelium, Louisa Howard,
Dartmouth College; available at:
http://remf.dartmouth.edu/images/mammalianLungSEM/source/9.html Date
Accesses: 30 March 2009.................................................................................29
Figure 12: Depiction of the phagocytosis process.............................................................31
Figure 13: Visual depiction of three region model from Morrow et al, (1966).................40
xii
Figure 14: Graphic depicting the coupling of the two stages together..............................45
Figure 15: Diffusion of oxygen from alveoli to the blood.................................................50
Figure 16: Depiction of the pharynx as it leads to the larynx. National Cancer Institute:
http://training.seer.cancer.gov/head-neck/anatomy/overview.html .................52
Figure 17: Three-compartment Markov model for the three-regions of the respiratory
system ..............................................................................................................57
Figure 18: Conceptual diagram of transition between states i through j...........................59
Figure 19: Example of streamlines in a straight pipe section, with no obstacle................71
Figure 20: Example of streamlines in a straight pipe section, with cylindrical obstacle  .71
Figure 21: Graphical depiction of impaction (a.) and interception (b.) ............................72
Figure 22: Numerical simulation results using ∆t of 0.0025 seconds................................79
Figure 23: Numerical simulation results using ∆t of 0.00125 seconds..............................79
Figure 24: Numerical simulation results using ∆t values of 0.0025 seconds and 0.00125
seconds.............................................................................................................80
Figure 25: Numerical simulation results using ∆t of   0.0003125 seconds........................81
Figure 26: Numerical simulation results using ∆t of 0.00015625 seconds........................81
Figure 27: Numerical simulation results using ∆t values of 0.0003125 seconds and
0.00015625 seconds.........................................................................................82
Figure 28: Pathogenesis of B. anthracis showing deposition (A.), uptake (B.),
germination and limited growth (C.)................................................................86
Figure 29: Depiction of the phagocytosis process.............................................................88
Figure 30: System diagram for spores transported with the bulk fluid into the alveolus. .93
Figure 31: System diagram depicting the uptake, germination and inactivation of spores
..........................................................................................................................93
Figure 32: Plot depicting the fit of growth rate data to the fitted model.........................105
xiii
Figure 33: Plot depicting the fit of uptake data to the fitted model.................................105
Figure 34: Plot depicting the fit of inactivation data to the fitted model.........................106
Figure 35: Normal probability plot of the residuals from the growth rate fit to data......109
Figure 36: Normal probability plot of the residuals from the uptake rate fit to the data. 109
Figure 37: Normal probability plot of the residuals from the inactivation rate fit to the
data.................................................................................................................110
Figure 38: Graphic depicting the coupling of the two stages together............................115
Figure 39: Dose correction from exposed to delivered dose from stochastic model results
........................................................................................................................120
Figure 40: Exponential model fit to the unmodified exponential dose response model..125
Figure 41: Histogram of exponential k parameter after 10,000 bootstrap iterations for the
unmodified exponential dose response model................................................126
Figure 42: Modified exponential dose response model for delivered dose fit to the data
........................................................................................................................128
Figure 43: Histogram of exponential k* parameter after 10,000 bootstrap iterations.....129
Figure 44: System diagram for spores transported with the bulk fluid into the alveolus 130
Figure 45: System diagram depicting the uptake, germination and inactivation of spores
........................................................................................................................131
Figure 46: Dose correction from exposed to pathogen burden from deterministic model
results..............................................................................................................133
Figure 47: Modified exponential dose response model for pathogen burden fit to the data
........................................................................................................................136
Figure 48: Histogram of exponential  parameter after 10,000 bootstrap iterations.........136
xiv
Abstract
Development of a Physiologically Based Pathogen Transport and Kinetics Model for
Inhaled Bacillus anthracis spores.
Mark H. Weir
Charles N. Haas
The current quantitative microbial risk assessment paradigm relies heavily on the
dose response assessment phase.  This phase fits a mathematical model to available dose
response data for the pathogen of concern.  In current dose response model fitting the
dose that is used is the dose to which the host organism (typically test animals) is exposed
to.  This dose does not take into account the natural sinks of the respiratory system, or the
infection processes.   This work has successfully modeled the bulk fluid transport and
deposition as well as the pathogenesis of inhaled Bacillus anthracis (B. anthracis) spores.
The two stages of the infection process (transport and deposition being the first stage and
the pathogenesis process being the second) have been modeled as a coupled two stage
model, with a stochastic model for transport and deposition, and a deterministic model
for the pathogenesis process.  The first stage stochastic model allows for an estimation of
the dose delivered to a sensitive location (alveolus for B. anthracis spores) by developing
a constant correction factor from exposed dose to the delivered dose.  The coupled model
allows an estimation of the pathogen burden after 60 minutes of inhalation simulated by
the first stage, again by the development of a constant correction factor from exposed
dose to the pathogen burden.   This framework is  analogous to physiologically based
physiochemical (PBPK) models which changed chemical risk assessment over 20 years
ago, which model the transport and metabolism of chemical contaminants post exposure.
xv
PBPK models allow for a more complete picture as to what the body is experiencing post
exposure to chemical contaminants in the natural or built environment.  This framework
has been developed for inhalation of  B. anthracis spores, but can be adapted to other
pathogens with the first stage remaining unchanged if the pathogen can be considered to
behave as  a  particle  in bulk fluid,  and adapting the second stage to the pathogenesis
unique to the pathogen.    
1 CHAPTER 1 : BACKGROU D A D LITERATURE REVIEW
ABSTRACT
The  basics  of  quantitative  microbial  risk  assessment  (QMRA)  and  the  dose
response assessment phase specifically must be established in order to determine the most
effective  means  of  developing  advancements  in  the  field.   Before  the  modeled  dose
response relationship for inhalation exposure to Bacillus anthracis (B. anthracis) spores
can be adapted to take into account the dynamics of inhalation and pathogenesis, the
pathogen  and  the  human  respiratory  system  must  be  understood  further.   The  open
research areas for advancing QMRA, the biology of B. anthracis,  the physiology of the
human respiratory tract and pathogenesis of  B. anthracis have been over viewed.  This
information will be used in further chapters to simplify the human respiratory system and
develop a model that can describe the pathogenesis of inhaled B. anthracis.  
Keywords: Bacillus anthracis, QMRA, bioterrorism, dose response, mechanistic
adaptations, inhalation, respiratory system, pathogenesis. 
 1.1 History of dose response modeling and analysis
Although the definitions have remained the same the field of risk assessment has
had and will evolve.  Risk is still the probability that a detrimental or otherwise harmful
or  dangerous  event  will  transpire.   Quantitative  risk  assessment  is  the  quantification
(development of a measure) of a deleterious event occurring from a concrete situation
(scenario which has or is likely or probable to occur).  
Risk assessment began with chemical and radiological concerns as shown in part
2by the Clean Air  Act  (CAA)  42 USC §  7401 et  seq  (1970),  specifically the  section
defining and control of hazardous air pollutants found in 42 USC § 7412 et seq (1970)
(Zimmerman, 1990; Congressional Quarterly Inc. Staff, 1990).  With the development of
new chemical agents used throughout the United States (US) as well as the development
of nuclear power, concerns were raised as to the potential risks associated with them.  As
the science developed it was recognized that risk assessment was intrinsically linked with
politics  and  regulation.   As  the  risks  were  quantified  regulations  were  being
recommended especially with the advent of the US Environmental Protection Agency
(EPA) and the eventual passing of the Clean Water Act.  
With the passage of the CWA came the recognition that risk assessment was a
required independent field.  Again this was to quantify the risks posed from chemical and
radiological agents.  Not until the late 1970s and early 1980s was this desire to quantify
the risks posed by microorganisms which have the potential to cause infection  and/or
disease,  also  known  as  pathogenic  microorganisms  (Smith,  2004).   Herein  lies  the
beginning of microbial risk assessment.
Since the experiences of John Snow and the Broad Street pump in 1854, it has
been known that water contaminated with microorganisms can cause disease.  However
as known from respiratory and cutaneous infections, water is not the only transporter of
microorganisms.   Also  not  all  microorganisms  cause  disease  and  this  is  why  the
distinction  of  pathogenic  and  non-pathogenic  organisms  exists.   Since  there  are
beneficial, inert and potentially harmful (pathogenic) microorganisms, not all pose a risk
to human health.  
3The  burgeoning  field  of  quantitative  microbial  risk  assessment  (QMRA)  was
concerned with the risk posed from exposure to pathogenic microorganisms, starting with
water-borne exposure (Smith, 2004).  QMRA has expanded to include other routes of
exposure and vectors for pathogenic microorganisms.  With this expansion into wider use
as well as the development of QMRA, a paradigm (description of a concept) needed to be
set, especially considering the interdisciplinary nature of risk assessment and QMRA.
 1.1.1 Current quantitative microbial risk assessment (QMRA) paradigm
The  current  paradigm  for  risk  assessment  was  developed  by  the  National
Research  Council  (NRC)  as  part  of  the  National  Academy  of  Sciences  (NAS)  and
recorded in a set of guidelines initially intended for federal agencies (NAS, 1983).  The
paradigm is an interdisciplinary approach, such as risk assessment and QMRA is itself.  It
follows  both  the  thought  processes  as  well  as  the  steps  in  analysis  which  the  risk
assessment should follow, as shown in the bulleted list below (NAS, 1983).
• Hazard identification:  “Determine whether exposure to an agent can cause an
increase in the incidence of a health condition (cancer, birth defect, etc.)  ...”
• Dose-response assessment:  “Characterizing the relation between the dose of an
agent administered or received and the incidence of an adverse health effect in
exposed populations and estimating the incidence of the effect as a function of
human exposure to the agent.  ...”  
• Exposure  assessment:   “Measuring  or  estimating  the  intensity,  frequency  and
duration of human exposures to an agent currently present in the environment or
of  estimating hypothetical  exposures  that  might arise from the  release of  new
4chemicals into the environment.  ...” 
• Risk characterization:  “... Process of estimating the incidence of a health effect
under  the  various  conditions  of  human  exposure  described  in  exposure
assessment.   It  is  performed  by  combining  the  exposure  and  dose  response
assessments.  ...”  
Since  the  NRC  framework  for  risk  assessment  is  concerned  with  chemical
exposure an expert  panel developed a framework which would be more applicable to
pathogen exposure (ILSI, 1996).  The current science of QMRA generally follows this
framework  outlined  by  ILSI,  (1996).   The  framework  developed  a  risk  assessment
process  which  consists  of  three  main  phases;  problem  formation,  analysis  and  risk
characterization.  The problem formation phase informs the analysis phase which is made
of two main components;  characterization of  exposure and characterization of human
health effects.  
5The element of the analysis phase which dose response is most concerned with is
the characterization of human health effects (ILSI, 1996).  As can be seen in Figure  1
which is a visual depiction of the human health effect characterization element (adapted
from ILSI (1996)) this element is comprised of three main parts.  
1. Host  characterization:   In  the population being exposed, are there host  factors
which  may  influence  whether  they  would  be  classified  into  a  sensitive
subpopulation.  This will  allow the population to be separated into risk levels
(high, low or median).
2. Health effects:  What severity and type of illness will the pathogen cause, gleaned
from clinical or epidemiological data.
3. Dose response analysis:  Develops a quantitative relationship between the dose
Figure 1: visualization of human characterization element of
the analysis phase of the ILSI risk framework
6(amount of pathogen which the host or population is exposed to) and the amount
of the exposed population which experience either morbidity or mortality.    
As can be seen from the visual depiction in Figure 1 the different portions of the
human health effects characterization all flow towards the host-pathogen profile, which
will inform the characterization of the risk.  The methods and tools affect the overall
analysis and needs of the analysis may require development of new methods or tools as
well,  thus  the  interdependent  arrow.   The  host  characterization  will  inform the  dose
response  analysis  (whether  or  not  to  include  sensitive  subpopulations)  which
communicates with the health effects in order determine if the relationship between dose
and  morbidity or mortality should be analyzed.  Thus the overall  framework of risk
assessment  is  a  set  of  interdependent  processes  and  analyses  that  must  inform  one
another.      
The dose response assessment phase is arguably the most important phase in the
QMRA paradigm (Smith, 2004).  Without knowing how different levels of the stressor
affect  the individual a sizable portion of quantified risk estimate will not be possible.
Therefore advancements  in  the dose  response  assessment  will  garner  benefits  for  the
entire risk assessment.  
 1.1.2 Current dose response paradigm
The dose response assessment is the phase where the changes or reactions of the
organism (host or affected individual) caused by a stressor(s) are described for different
levels  of  doses  (amount  to  which  the  host  is  exposed).   Taking this  description  and
developing a mathematical relationship or descriptive equation is the main focus of the
7dose response assessment.  
The dose response relationship and assessment can be depicted graphically using
an  x-y plot  as  shown in  Figure  2.   This is  an example  of  a  modeled  dose response
relationship for mice exposed orally to Francisella tularensis.  The unit of dose, colony
forming units (CFU), are plotted on the x-axis in order to show how the probability of
response (in this case death of the host) changes with an increase or decrease in the dose
(microorganisms ingested by the host) (Haas et al., 1999).  
Two dose response models (equations 1 and 2) have been used extensively in
order to describe the dose response relationship in QMRA (Haas  et al., 1999).  These
models are fitted to dose response data, a sample of which can be seen in Table 1 where
the positive (host died or was infected) and negative (host survived or was not infected)
Figure 2: Mice exposed orally to F. tularensis
8responses are recorded for each dose.  The dose response models are fitted by comparing
the predicted response from the model to the measured response, which is known from
the data.
Exponential Model:  P risk =1−exp−r⋅dose  (1)
Beta Poisson Model:  P  risk =1−[1dose 50 ⋅2
1 / −1]
−
        (2)
Table 1: Example dose response data set of rhesus macaque exposed to aerosolized Ames
strain of B. anthracis (Druett et al., 1953)
Dose
(Spores)
Positive
Responses
Negative
Responses
Number of
Subjects
70,320 1 7 8
77,040 4 4 8
108,720 5 3 8
137,520 6 2 8
155,520 5 3 8
160,800 3 5 8
240,000 8 0 8
300,000 7 1 8
398,400 8 0 8
The  fitting  of  the  dose  response  data  can  be  performed  using  the  maximum
likelihood estimation (MLE).  Using this method the predicted response being a function
of the dose (di) and model parameter(s), in the case of equation 1, r and equation 2, 50
and  α.   This  predicted  response  is  directly compared  to  the observed  response  from
9available dose response data.
The set of parameters that optimize the fit of the dose response model describes
the dose response relationship.  These parameters are now specific to the pathogen, type
of exposure route, host species and doses of the pathogen.  If one or more of these factors
are altered, the optimal set of dose response parameters may change.  
It  must be emphasized that this model is dose dependent as well, meaning that
changing the doses will alter the fit,  and therefore the resulting model and optimized
parameters.  By adapting the dose in order to take into account losses during respiration
or kinetics of microbial survival and division the resulting dose response can be modified
in order to take these factors into account.  
 1.2 Overview  of  Bacillus  anthracis  (B.  anthracis) as  a  pathogen  and
microorganism
Anthrax is  caused by  B. anthracis and has been known as  a zoonotic disease
(shared by humans and animals) for millenia, even before the term zoonotic was coined.
It  is speculated as the cause of the plague of Athens (Sternbach, 2003, McSherry and
Kilpatrick, 1995) and documented as the possible cause of large scale livestock losses by
the Roman poet Virgil (Sternbach, 2003).  The nomenclature for B. anthracis follows that
the bacterium is rod-shaped (Bacillus) with  anthracis taken from the Greek  anthrakis
which means coal, referring to the large black lesions formed from the most common
form of the disease.  
The physician and researcher Casimir Davaine (1812-1882) was the first to isolate
B. anthracis from sheep suffering from anthrax (Théodoridés 1966).   Davaine's  work
gave a good description of the bacteria (then still known as “sheep-blood” bacteria) and
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its role in infectious disease as well as it robustness against efficacy, as can be seen in the
following quote.
“The 'spleen-blood' bacteria are free, straight, inflexible and cylindrical filaments
varying between  4 and 12/1000 of  a  millimeter  in  length,  extremely  thin;  the
longest sometimes have one or very rarely two inflexions at an obtuse angle; with
high magnification, it is possible to distinguish traces of a division into segments;
they ave no spontaneous movement at all.  When dried up they keep their shape
and appearance.  Sulphuric acid and potassium in concentrate solution do not
destroy them.”
The Prussian physician and one of the founders of microbiology Robert  Koch
later used B. anthracis to conclusively prove that bacteria cause disease in 1877 and this
finding served as a prototype of Koch's postulates (Théodoridés 1966).  Robert Koch also
was the first to photograph the discovery of B. anthracis, which can be seen in Figure 3.
Robert Koch also demonstrated that B. anthracis forms endospores and the developed the
first experimental antrhax by injecting pure culture into animals.  The prior experiments
from Davaine used blood drawn from animals which succumbed to anthrax, injecting this
sample into other animals.  
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B. anthracis is a large gram-positive endospore-forming rod, having a width of 1-
1.2 µm and typically from 3-5 µm in length.  The bacterium can be easily cultivated in
aerobic  and  anaerobic  conditions  (Koehler  2006).   B.  anthracis is  very similar  both
genotypically  and  phenotypically  to  both  Bacillus  cereus and  Bacillus  thuringienis,
making both of these bacteria good candidates for surrogates (Koehler, 2006).  All three
have similar spatial dimensions as well as the ability to develop an oval endospore in
response to environmental stress.        
 1.2.1  atural occurrence of B. anthracis 
Typically herbivorous domesticated animals such as, sheep, cattle and horses are
exposed  (ingestion  or  subcutaneous  if  lacerations  are  present)  to  B.  anthracis  in  the
environment and can become infected.  The flesh, hides, bones and excrement of these
animals  will  be  contaminated,  thereby,  acting as  a  vector  to  those  working with  the
remains  of  animals  which  have  succumbed  to  the  disease  or  were  affected  before
slaughter.  
B. anthracis spores have been found in soil samples throughout the world where
Figure 3: Robert Koch's photomicrographs of B. anthracis source:
http://bioinfo.bact.wisc.edu/themicrobialworld/medical.html
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anthrax is endemic.  The US has areas of recognized natural infections namely Arkansas,
California, Louisiana, Mississippi, Nebraska, South Dakota and Texas, with other areas
of infection in other states.  Even if B. anthracis is present in a region, the disease among
humans and animals is irregular and rare with one to two cases of cutaneous anthrax each
year  (Ashford  et  al.,  2002).   However  intentional  release  of  B.  anthracis via
contamination of US mail in the Autumn of 2001 caused 11 cases of inhalation and 11
cases of cutaneous anthrax in the US that year (Inglesby et al., 2002).      
 1.2.2 Environmental survival
B. anthracis is a hardy bacterium in the natural environment due primarily to the
endospore  which  is  formed in  order  to  protect  the bacilli  from environmental  stress.
Once the spore forms it can remain in the environment for upwards of 10-12 years.  As
discussed  previously  Casimir  Davaine  first  attempted  efficacy  experiments  with  B.
anthracis with the bacilli even able to resist the effects of diluted acid as well as other
potential disinfectants.  
Stability of potential bioterror agents both in the environment and on fomites has
been  reviewed (Sinclair  et  al 2008).   In  Sinclair  et  al.  (2008)  it  was  shown that  B.
anthracis encapsulated in an endospore had a high survival rate in untreated air and much
lower in water.  In Sinclair et al, 2008 survival on fomites was not discussed, however,
survival in air and water were determined and are shown in Table 2 
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Table 2: Persistence of B. anthracis in air and water
Suspension
Medium
Environmental Conditions Environmental
Decay Rate
Aerosol
Relative Humidity = 35%
4.64(10-7) min-1
Temperature = 20ºC
Water
pH ≈ 7
0.26 min-1
Temperature = 20ºC
 1.2.3 Possible routes of infection
Anthrax can develop from multiple  exposure routes.   Dermal  contact  with the
spores  or  bacilli  in  cutaneous abrasions  causes  cutaneous anthrax.   This  form of  the
disease starts with swelling and reddening at the site of infection with development to
lesions on the skin and deterioration of the cutaneous and subcutaneous regions (CDC,
2003; Swinderski, 2004).  This can progress to a systemic infection and disease once the
bacilli  reach the blood stream, multiplying in the blood eventually causing sepsis and
death (Swinderski, 2004).  
Ingestion is another potential route of exposure, developing the far less common
gastrointestinal anthrax.  This is a route of exposure which has not received as much
focus in medical or risk research due to the very low incidence worldwide.  However the
ingestion route is of real concern, despite the comparatively low survival rate in water
(compared to survival in air and in the soil matrix) and the resultant disease can progress
quickly  with  widespread  damage  to  the  host.   Once  ingested  the  dynamics  and
mechanisms of infection are not clearly understood, however, it is known to affect the
large and small intestines typically causing lesions in both, with highest incidence in the
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colon.  Again as in the cutaneous form of the disease, once the bacilli are introduced into
the bloodstream widespread infection and sepsis are almost definite outcomes that must
then  be  treated  more  aggressively,  for  host  survival  (Evans  and  Brachman,  1998;
Sirisanthana and Brown, 2002).
Naturally occurring inhalational anthrax is rare and was typically considered an
occupational hazard for those working with animals, animal parts and hides.  Previously
known  as  “wool-sorters  disease”  a  non-malicious  incident  of  inhalational  anthrax  is
perhaps the most serious and life threatening form of the disease.  This route of exposure
will be discussed further in the pathogenesis section of this chapter.  With the advent of
bioterrorism and interest in using  B. anthracis as a preferred agent, especially with the
ease of dissemination as shown in the anthrax attacks in the autumn of 2001, this route of
exposure has become of great interest in homeland security and public health research
(Jernigan et al., 2001).      
As can be seen, the route of infection with which to be concerned depends on the
scenario  being examined.   Despite  cutaneous  anthrax  being  the  likeliest  form of  the
disease in a natural exposure scenario, ingestion and inhalation are the likeliest to be used
in  a  bioterror  attack.   For  ease  of  dissemination  and  low  decay  rate  in  the  air  the
inhalation route is widely considered the likeliest route of exposure in a bioterror attack. 
 1.2.4 Modes of infection
As  discussed  earlier,  B.  anthracis develops  an  endospore  in  response  to
environmental stress.  The optimal environmental conditions for the spore to germinate
into the bacillus is a warm moist environment, which is preferably high in electrolytic
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compound concentrations.  The human body, especially the circulatory system contains
ample amounts of locations and targets, which the spore can use for germination.
Germination is possibly the most important step in the infection process, since
growth of additional bacilli can only take place from vegetative B. anthracis.  There are
cells all mammalian hosts that can allow for the germination and growth of B. anthracis.
All mammals contain white blood cells (leukocytes), a class of blood cells which
are a primary portion of the immune system.  Neutrophils are the most abundant form of
leukocytes (Nathan, 2006).  Responding within an hour to tissue damage neutrophils are
likely the first cells which B. anthracis will come in contact with in the dermal exposure
scenario.   This  is  an  important  note  since  B.  anthracis can  germinate  and  grow  in
leukocytes despite their integral role in the immune system (Titball and Munchee 1987).
Despite neutrophils' purpose of encountering and destroying pathogens that the internal
systems of the body they act as a vector for the germination and limited growth of  B.
anthracis.   This  is  the main reason for  the typically rapid development  of  cutaneous
anthrax after exposure to contaminated surfaces, soil, hides or other vectors.
When  discussing  inhalational  anthrax  a  different  cell  is  responsible  for  the
germination and limited growth of B. anthracis in the mammalian host.  Macrophages are
produced from the division of monocytes (cells which main purpose is replacement of
macrophages and dendritic cells.  The macrophage is the cell that allows for germination
and limited growth for inhalation exposure, (limited by cell lifespan in presence of the
anthrax toxins associated with B. anthracis).  
The alveolar macrophage is named due to its location in the alveoli of the lung,
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tasked with the function of  protecting the  alveolar  surface  from deposited particulate
mater and pathogens.  The alveolar macrophage has been termed the 'Trojan horse' for B.
anthracis,  so  coined in  Guidi-Rotani  et  al. (2002)  due  to  the interaction between  B.
anthracis and the alveolar macrophage.  This interaction will be elaborated on in section
1.4.1  describing how the phagocytosis process is the driving force behind the 'Trojan
horse' effect.        
 1.2.5 Prior and potential future use as a biological weapon
The Centers for Disease Control and Prevention (CDC) have compiled three lists
of potential bioterror agents.  The first list (category A) is the group of pathogens which
have the highest concern for a bioterror attack.  Category A agents are listed here due to
the threat to national security they may pose as well as the following:
• Ease of dissemination or communicability
• High mortality rates, potentially causing major public health impact
• Possibility of causing public panic or social deterioration
• Requires special attention for preparedness. 
The  ease  of  dissemination  was  proven,  in  the  autumn of  2001,  where  letters
contaminated with B. anthracis spores were distributed into the US postal system.  There
existed specific targets most  noticeably including the offices of Senator Tom Daschle
(South Dakota), with the motivation behind the attacks still not completely understood.
The Autumn 2001 attack infected 22 people, five of whom died, of 22 cases 11 were
cutaneous and 11 were inhalational forms of the disease (Kanafani  et al 2003; Inglesby
and Henderson et al. 2002).  
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In 1979, Sverdlovsk Russia, an accidental release of  B. anthracis from a Soviet
bioweapons plant resulted in a widespread epidemic of inhalation and cutaneous anthrax
(Inglesby et al., 2002.; Alibeck and Handelman, 1999).  This epidemic in Sverdlovsk was
the result  of  weaponized  B. anthracis, which at  the time was being developed in  an
extensive bioweapon development  program by the former Soviet  Union (Alibeck and
Handelman, 1999).  
In 1995 the Iraqi government admitted to development program for producing and
weaponizing  B. anthracis  (Zilinskas,  1997).   This  later  case  of  the Iraqi  bioweapons
program highlighted the fact that obtaining and weaponizing B. anthracis is a relatively
inexpensive  and  straightforward  processes.   This  raises  concerns  about  the  ease  of
terrorists obtaining and weaponizing B. anthracis.  
In  each  of  the  cases  of  the  2001  anthrax  attacks  in  the  postal  system,  the
Sverdlosk epidemic in 1979 and the Iraqi bioweapons development program, inhalation
was  the  exposure  route  for  dissemination.   This  is  because  the  inhalation  route  is
considered the  route  that  will  be more likely to  cause the systemic and more severe
disease.   This  exposure  route  is  also  preferred  for  malicious  release  since  unlike
cutaneous anthrax the diagnosis of inhalation anthrax is typically performed only after the
disease has established a foothold in the host when successful medical countermeasures
are less effective (unless  the spores  were discovered or  the host  was in a  population
suspected of being exposed).  This difference in relative ease of diagnosis is because in
the range of 1-5 (typically 1-2) days post exposure, the cutaneous form develops a lesion
which is  indicative of cutaneous anthrax,  while inhalational  anthrax symptoms in the
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same time frame are simply influenza-like symptoms.  The influenza-like symptoms of
inhalational anthrax rapidly develop into more severe symptoms of septicemia (infection
of the blood) and eventual host death.  The higher difficulty in diagnosis as well as the
higher lethality makes inhalation exposure (aerosolized spores) the preferred method of
release for large scale bioweapons as well as those likely to be used by bioterrorists.
 1.3 Physiology and function of the compartments of the human respiratory system
The human body can be described as a set of numerous processes that operate in
either  series  or  parallel.   For  a  human to  be  considered  healthy all  the  systems  and
processes  must  be  functional.   Also  many  of  the  processes  are  interdependent;  the
neuromuscular system (nerves communicating with the muscles for movement) cannot
perform its functions without oxygenated blood from the cardiovascular system.  If one
of the systems are disrupted then the remaining are adversely affected.  Thus if one of the
systems are halted and not restarted or supported externally the remaining systems will
eventually fail as well, the time period of course being dependent on the critical nature of
the system which originally was disrupted or halted (Thibodeau and Patton,  1997).  
Before  the  processes  of  the  cardiopulmonary  system  are  discussed  the  basic
physiology must be addressed.  The cardiovascular system is comprised of the heart and
all of the blood vessels.  The heart  is a constantly operating pump most likened to a
positive displacement pump(i.e. diaphragm pump).  The heart delivers the oxygenated
blood to the organs and deoxygenated blood from the organs to be reoxygenated.  The
structure for oxygen transfer will be detailed once the structure of the respiratory system
has been discussed (Page, et al., 2002).  
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The respiratory system can be separated into two major sections, the upper and
lower respiratory tracts (URT and LRT respectively).  The URT are comprised of the;
nares, nasal cavity, oral cavity, pharynx and the larynx, with the remaining portions being
the LRT (Figure  4).  The respiratory system is a series of air vessels that are meant to
transport  air  to  structures  called  alveoli  which  are  the  air  exchange  locations  in  the
respiratory system.  An overview of the respiratory system can be seen in Figure 4, and
each of these intermediate portions will be discuss further.
As can be seen in Figure 4, external air enters the respiratory system via the nose
and mouth, so the respiratory system will be discussed starting from this location and
moving downward until the alveoli are reached..  The nares (nostrils) are the entrance to
the nasal cavity, which is one of the first locations which act as a sink for aerosolized
contaminants or pathogens.  The nasal cavity is interestingly complex in that there are a
Figure 4: Basic depiction of
human respiratory system
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number of structures that force the air through smaller diameters and different conducting
airways.  The picture in Figure  5 (National Cancer Institute, 2009)  shows a simplified
depiction  of  the  internal  structure  of  the  nasal  cavity and  the  relative  complexity  of
available  locations  for  air  to  pass  through.     These  structures  are  the  first  level  of
contaminant or pathogen removal in the respiratory system.  The nasal cavity typically
allows  a  higher  level  of  removal  for  larger  contaminant  diameters  and  soluble
compounds, due to the mucus layer, which covers approximately 98% of the nasal cavity
(100% of the remaining respiratory system not including oral  cavity)  (McClellan and
Henderson, 1995).       
The oral cavity is the opening of the mouth with a direct entrance into the pharynx
at the back of the throat.  Figure 5 shows how the nasal cavity and oral cavity meet using
the pharynx to connect each other (National Cancer Institute2 2009).  There is not a large
amount of removal of contaminants or pathogens in the oral cavity which is why it is
Figure 5: Depiction of human nasal cavity showing complexity of the
passage for air and contaminants to travel (National Cancer Institute,
available at:
http://training.seer.cancer.gov/anatomy/respiratory/passages/nose.html   ) 
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generally advisable to breath nasally in order to take advantage of the innate removal
mechanism of the nasal  cavity.   In  Figure  6 the passage from the main inlets for the
respiratory system to the larynx (windpipe) are shown which will deliver the air deeper
into the respiratory system (Weibel, 1963).  
The larynx connects the URT to the LRT and main bronchi (Figure  7).  At the
entrance of the larynx is the epiglottis which prevents water and food from entering the
respiratory system (acts as a one-way flap valve).  The larynx connects to the trachea
which progresses to the main bronchi (Figure 7).  The right bronchus is longer than the
left (5 cm compared to 2.5 cm respectively), but the left bronchus is wider being 15 mm
in diameter as compared to 13 mm.  The airway branches at the main bronchi, with the
first  main  bifurcation  angle  (division  into  two branches).   Further  bifurcation  angles
occur deeper into the lung as the bronchiole and terminal bronchiole trees develop.  These
Figure 6: Depiction of the oral and nasal cavities of the
respiratory system (National Cancer Institute, available at
http://training.seer.cancer.gov/head-neck/anatomy/overview.html 
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bifurcation angles as well as the decreasing diameters further along the branches is also a
removal  mechanism,  specifically  for  inhaled particles  specifically.   However  detailed
modeling of these angle are not essential in order to develop a sufficient understanding of
the deposition characteristics of in haled particles especially for stochastic (allowing for
random elements in the modeled system) transport and deposition models (Koblinger and
Hofmann, 1985; Cheng et al, 1997).      
From the main bronchi the respiratory system proceeds on a tortuous path.  The
next set of air vessels from the main bronchi are the bronchioles, and their purpose is to
deliver air to the alveoli.  On this path the vessels continue to decrease in diameter and
bifurcation angles continue to change.  The tortuous path not only allows for increased
deposition of contaminants, but also allows for the large number of terminal bronchioles
and alveoli  (up to 3,000,000 alveoli)  to fit  into the relative small  space in the lungs.
Figure 8 is a picture of one of the original rubber casts of the human lung (image taken by
Figure 7: Depiction of
larynx, trachea and main
bronchi
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Institute of Anatomy,  University of  Bern).   The various  bifurcations into smaller and
smaller bronchioles on the path to the terminal bronchioles and the alveoli can be seen in
Figure 8.  
As the name implies the terminal bronchiole are the end of the bronchioles which
have  multiply  bifurcated  from  the  left  and  right  bronchi.   The  terminal  bronchioles
deliver air to the alveoli, where the gas exchange occurs.  Around the circumference of
the alveoli are capillaries that allow oxygen to be delivered delivered to the blood and
carbon dioxide can exit the blood and thus the body as depicted in Figure 9.
Figure 8: Rubber cast of the human lung,  Johns Hopkins
University,available at:
http://www.jhu.edu/chembe/hanes/Research/Therapeutic_Aerosols/
Lung.jpg 
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Since the alveoli are where the gas exchange process occurs these are where the
respiratory system becomes the cardiopulmonary system.  As oxygenated blood is carried
to throughout the body thus the concentration of oxygen in the blood decreases over time.
As the blood is deoxygenated by demand from the organs, it requires reoxygenation, and
while  this  happens  the  blood  carbon  dioxide  concentration  increases  which  demands
removal.  Therefore as discussed earlier the heart circulates the deoxygenated blood back
to  the  lungs,  while  using  the  lungs  to  reoxygenate  the  blood,  and  this  circulation
continues.   The difference  in  partial  pressures  of  oxygen and  carbon  dioxide is  how
oxygen  is  diffused  into  and  carbon  dioxide  is  removed  from  the  blood,  thus
reoxygenating the blood (Fishman, 1986; Weibel, 1963).  Table 3 shows the differences
in the partial pressures on both the alveolar and capillary sides of the alveoli.  As the
blood passes by the alveoli the oxygen diffuses  into the blood due to the lower partial
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pressure of oxygen in the blood PO2 and the higher partial pressure of oxygen in the
alveoli.  As can be seen in Table  3 the partial pressure of oxygen is 104 millimeters of
mercury (mmHg), which is different from the partial pressure of oxygen in air in the
external environment (160 mmHg), this difference in partial pressure is due to moisture
in the alveoli.  This same diffusion process allows the removal of carbon dioxide from the
blood, thereby being exhaled (Weibel, 1963).  
Table 3: Differences in partial pressure leading to the diffusion of oxygen into the blood
for the human adult male (Weibel, 1963)
Location O2 or CO2 Partial Pressure (mmHg)
Alveoli
O2 104 
CO2 40
Blood
O2 40
CO2 45
 1.3.1 Sinks and defenses of the human respiratory system
Since  the  respiratory  system is  the  only way the  unaltered  human  body (not
lacerated  or  otherwise  injured)  has  the  blood  coming  into  intimate  contact  with  the
external environment, the respiratory system must have associated defense measures.  As
discussed earlier in order for the blood to be reoxygenated the cardiovascular system
must interact directly with the respiratory system.
One of the main and simplest defenses for the human respiratory system are the
sinks themselves and the inability of the vast majority of deposited materials from being
reaerosolized (Weibel,  1963).  This lack of reaerosolization is due to the mucus layer
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coating  the  respiratory  system,  which  is  meant  to  trap  the  deposited  particles  and
pathogens.   In  order  for  the  mucus  layer  to  not  become over  laden  with  deposited
contaminants,  a  process  called  the  mucociliary  escalator  moves  the  deposited
contaminants upwards to be coughed out (or in some cases ingested), thereby removing
93% of contaminants (pathogens, particles and non-soluble chemical contaminants)  in 12
hours post deposition (Weibel, 1963; Koblinger and Hofmann, 1985; Levitzky, 2007).  
The next line of defense is when the immune system responds to the presence of a
pathogen.  Either neutrophils or monocytes are delivered to where the pathogen has been
deposited.  The pathogens are then taken into the neutrophil which destroy the pathogen
and perhaps also destroyed in the processes (Figure 10).  If a monocyte responds to site
of  deposition then the monocyte  either  divides  into a  macrophage  or a  dendritic  cell
(Litchman et al., 2005).  If the monocyte divides into a macrophage then the same uptake
and  destruction processes  as  with  the neutrophils  occur,  with  the exception,  than  the
macrophage will attempt to move to the lymph nodes to activate the rest of the immune
system.  A dendritic cell will bond with the pathogen and transport it to the local lymph
nodes in order to develop an aquired immune response to defend against the pathogen,
but does not actively destroy the pathogen itself (Burke and Lewis, 2002).       
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These responses require the pathogen to deposit in the conducting airways of the
respiratory system.  The alveoli are different, in that deposition need not be detected by
the  body  thus  delivering  neutrophils  or  monocytes  to  the  deposition  location.   As
discussed  previously  the  alveoli  contain  macrophages  cells  as  a  constant  barrier  to
pathogens  or  other  contaminants  from  entering  the  blood.   Like  the  neutrophil  a
macrophage risks being destroyed by the same contaminant(s) which the body is being
protected from.    
 1.4 Interaction of  B. anthracis with the unalveolated regions of  the respiratory
system
When  B.  anthracis  spores  are  inhaled  they  dynamically  interact  with  the
respiratory  system.   Some  of  the  spores  will  inevitably  be  lost  to  the  sinks  of  the
Figure 10: Neutrophil taking in and destroying a B. anthracis
vegetative cell; courtesy Volker Brinkmann available at:
http://en.wikipedia.org/wiki/File:Neutrophil_with_anthrax_copy.jpg
Date Accessed:  2 May 2009
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respiratory  system  while  others  will  likely  be  transported  to  the  site  of  highest
vulnerability namely the alveoli.  
As  discussed  earlier,  the  process  of  phagocytosis  provides  a  vehicle  for  B.
anthracis spore germination to occur.  Therefore the location of greatest susceptibility to
and risk for B. anthracis to germinate and potentially colonize in the alveoli.  Deposition
in the upper areas of the respiratory system can be considered a loss of the spores from
the system since germination and colonization in these regions (region-1, region-2 and
the unalveolated portions of region-3) is typically negligible (Inglesby et al., 2002).  
Once the spores are deposited on the respiratory system surface (unalveolated)
they are trapped by the mucus lining which covers the respiratory system.  Once trapped
on  the  mucus  lining  the  mucociliary  escalator  is  used  by  the  body  to  remove  the
deposited spores (as well as particles or non soluble contaminants).   The mucociliary
escalator is the continuous beating of cilia (Figure  11) upwards leading the mucus and
deposited  spores  to  the  oropharynx  (entrance  to  oral  cavity  from  the  pharynx)  for
expectoration (removed by coughing) (Levitzky, 2007; Weibel, 1963).  This process as
discussed earlier removes 93% of deposited spores within 12 hours post deposition, and
this rate continues until the deposited spores are completely removed (Levitzky, 2007).    
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 1.4.1 B. anthracis-macrophage interaction
The  pathogenesis  of  inhaled  B.  anthracis,  takes  involves  the  phagocytosis
process.  Phagocytosis (Figure 12) is the process, or more accurately a chain of processes
working in series where foreign particles such as a B. anthracis spore are destroyed by a
phagocyte (cell which uptakes and destroys foreign material, specifically in this case a
macrophage).  Phagocytosis begins when the foreign material  comes into contact  and
bind with the phagocyte's receptors.  The phagocyte then extends itself around the spore
and engulfs it, and this process is the uptake of the spore (Majno and Joris, 2004).  Once
Figure 11: Scanning electron micrograph of cilia on trachea
epithelium, Louisa Howard, Dartmouth College; available at:
http://remf.dartmouth.edu/images/mammalianLungSEM/source/9.html
Date Accesses: 30 March 2009
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inside the phagocyte, the spore is engulfed in a compartment, which is partially made up
of the phagocyte membrane, which is now termed the phagosome.  The phagosome then
comes  in  contact  with  a  lysosome  or  a  digestive  enzyme  granule  (more  typically  a
lysosome).  The lysosome fuses with the phagosome developing a phagolysosome, the
phagolysosome then begins  to  breakdown the phagosome.   This  thereby destroys  the
spore, digesting the phagosome gaining energy and generating waste material (Hampton
et al., 1994; Majno and Joris, 2004). 
The  speed  of  phagocytosis  depends  on  the  phagocyte  being  discussed.
Neutrophils are typically the fastest of the white blood to conduct phagocytosis (typically
under five to nine minutes).  However neutrophils are a more selective phagocyte, since
the receptors are protein molecules that recognize antigens, and thus are more effective
against pathogens when compared to other phagocytes, by processing pathogens faster
when an antigen is recognized.  The macrophage is a more aggressive phagocyte in that it
will engulf large quantities of contaminants, and does not rely solely on the receptor's
recognition of  antigens.   However  macrophages  as  well  as  dendritic  cells  act  slower
compared to other phagocytes (entire process taking typically on the order of hours rather
than minutes) and have been documented not processing the foreign material completely
(Hampton  et  al.,  1994).   Macrophages have been documented taking up and initially
processing  bacteria,  but  due  to  taking  up  even  more  bacteria  outside  of  the  cell
occasionally allows live bacteria to be expelled in the waste material (Hampton  et al.,
1994).  This typically allows for monocytes to be delivered to the macrophage's location
which continues the protection, but an aggressively growing and robust bacteria such as
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B. anthracis can gain from this potentially advantageous scenario.          
The longer amount  of time that  the macrophage takes to progress through the
phagocytosis process is also advantageous to the pathogenesis of B. anthracis.  The lethal
components of  B. anthracis include the toxin proteins associated with the spores  and
vegetative  cells.   The  toxin  proteins  comprise  the  means  of  compromising  the  host
immune defenses and assist in degrading the health and condition of the host.  The three
toxin proteins are the lethal  factor,  the edema factor and the protective antigen.  The
combinations of proteins produce two exotoxins which are the toxins which exact the
damage to the macrophage and host (Dixon et al., 2000).  
 1.4.2 Effect of B. anthracis lethal toxin
The lethal  factor  (LeTx) toxin is  the combination of  the lethal  toxin with  the
Figure 12: Depiction of the phagocytosis process
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protective  antigen.   LeTx has  been  shown to  cause both macrophage  and  host  death
(Dixon et al, 2000; Kimpel et al, 1994; Duesbery et al., 1998; Vitale et al., 1998).  Along
with the detrimental  effects  to both the macrophage and the host  the LeTx has  been
implicated in halting the phagolysosome formation by blocking the fusion of phagosome
and lysosome (Duesbery et al., 1998; Dixon et al., 2000).  The combination of the longer
amount of time for the macrophage to complete the phagocytosis processes, combined
with  the  ability  of  LeTx  to  block  the  lysosome-phagosome  fusion,  results  in  the
macrophage becoming a back door for inhalational anthrax.  
As has been shown when the macrophage contacts  B. anthracis spores and thus
protects the human body, it is exposing itself to the associated toxins, and thereby may
lose  the  ability  to  proceed  through  the  phagocytosis  processes.   There  are  further
difficulties for the macrophage due to the uptake of  B. anthracis  spores.  As discussed
earlier  B.  anthracis spores  are  developed  to  protect  the  vegetative  cells  from
environmental  stress,  and  the  vegetative  cells  will  not  germinate  until  a  conducive
environment is encountered again (Hedlund, 1988; Wilson  et al.,  2002).  The internal
environment of the human host (specifically the blood) as well as the macrophage are
conducive  environments  for  vegetative  cell  survival  and  growth  (Burke  and  Lewis,
2002).   Since  LeTx  is  capable  of  blocking  the  lysosome-phagosome fusion,  thereby
reducing or eliminating the ability of the macrophage to destroy the spores, this is also an
ideal location for cell growth (Hedlund, 1988).  
The macrophage is not devoid of the ability to destroy the spores and vegetative
cells,  despite this  ability being severely limited by the presence of  LeTx.   Since the
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macrophage provides a moist warm environment with high concentration of electrolytic
compounds, the spores germinate readily and quickly.  Once the spores have germinated
the vegetative cells are also encountering an environment conducive to growth, therefore,
growth of the vegetative cells commences (Dixon et al., 2000; Guidi-Rontai, 2002).
As has been shown, the cells that are meant to protect the host from pathogens
and  other  inhaled  contaminants  also  provide  an  environment  which  allows  for
germination  and  growth  of  B.  anthracis.   In  knowing  this,  however,  modeling  the
pathogenesis  of  inhalational  anthrax  becomes  more  straightforward.   Since  the
pathogenesis for inhalational anthrax is at a single target location, namely the alveoli and
more  specifically  a  target  cell  in  the  alveolar  macrophages,  with  highly  structured
processes for uptake, germination and growth of B. anthracis a descriptive model can be
developed.
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 CHAPTER 2 :  RESPIRATORY SYSTEM SIMPLIFICATIO  A D GOALS
A D AIMS FOR THE PROJECT
ABSTRACT
The  research  needs  for  the  advancements  of  quantitative  microbial  risk
assessment (QMRA) are wide and varied, but can be accomplished one phase at a time.
The dose response assessment which is  can be considered one of the most important
phases has been recognized as in need of advanced research.  The dose currently used
modeling the dose response relationship is the dose that the host has been exposed to.
This dose does not consider the losses incurred during transport through the respiratory
system  or  the  growth  of  the  pathogens  during  the  development  of  infection.   This
oversight may allow for a loss in the understanding of the overall infection process.  By
incorporating a more detailed understanding, greater insight and prediction of the risk, by
improving the modeled dose response relationship may occur.  The goals and aims of this
project as well as practicable description of respiratory system will be outlined for the
completion of the research work.    
Keywords: Bacillus anthracis, QMRA, bioterrorism, inhalation, human respiratory
system, three-region model.    
 2.1 Problem definition: pathogen burden versus exposed dose
Currently when performing the dose response assessment the exposed dose (i.e.,
inhaled or ingested number of organisms) is used in the model fitting.  Using the example
data in Table 1 the rhesus monkeys in this case were exposed to an aerosol containing the
quantity of spores recorded in the table.  This dose does not take into account sinks in the
respiratory system that protect the body from pathogens or other harmful contaminants in
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the air.   
Using the exposed dose for modeling the dose response relationship may allow
uncertainties into the analysis.   The  exposed population is  assumed to  inhale and be
affected by the dose that they are exposed to.  This does not take into account the various
sinks which the pathogen will encounter during inhalation, or the growth and inactivation
dynamics the pathogens will encounter in the host..  
As will be discussed in further detail later in the dissertation the exposed dose is
not equal to the dose which the host must  manage and defend itself from.  The host is
affected  from  the  pathogens  delivered  to  a  sensitive  location  and  pathogen  burden.
Pathogen burden is defined typically as the load of infectious agents that the host must
manage and counteract in order to defend itself using the immune system and survive.
Pathogen burden can also signify the pathogen load which the host must manage and
defend against once the infection process has occurred and replication or multiplication
of the pathogen occurs.  
Estimating the pathogen burden involves not only modeling the delivered dose,
but also modeling the kinetics and pathogenesis of the selected infectious agent.      
 2.2 Motivation in determining pathogen burden from exposed dose
The field of chemical toxicology has been advanced greatly by the development
and continued work in physiologically based pharmacokinetic (PBPK) models.  PBPK
models  are  sophisticated  models  which calculate  absorbed dose and metabolism of  a
chemical  contaminant  to  which  the  host  tissues  are  exposed.   PBPK  models
compartmentalize  the  physiology  of  the  human  host  in  order  to  determine  the
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pharmacokinetics (complex set of processes in which mass is exchanged between defined
parts) between and within different organs or organ groups of the host.  PBPK models
have been especially useful in interspecies extrapolation (Nestorov, 2007; Corley et al.,
2005;  Maruyama  et  al., 2006)  and  interdose  (i.e.  low  dose  modeling)  interpolation
(Simmons  et  al., 2005).   PBPK  models  have  also  been  used  not  only  for  healthy
individuals  and populations,  but  also in sensitive groups such as  children (Bjorkman,
2005) and the elderly (Clewell et al., 2004).  
PBPK models have shown that they have the power and sophistication to handle
different  concerns  that  are  raised  in  quantitative  risk  assessment  (Nestorov,  2007;
Weihsueh et al., 2006).  As previously discussed, one of the gaps in knowledge in QMRA
is the quantitative description of pathogen fate within the host.  When a host is exposed to
a pathogen, be it inhalation, ingestion or other exposure route a number of processes need
to occur before the infection process occurs and resultant disease begins to progress.  If
these processes can be modeled, the resulting model or set of models will be analogous to
PBPK models.
The framework from ILSI, (1996) concluded with some recommendations on how
to  further  the  science  of  QMRA  and  improving  risk  estimates.   Some  of  these
recommendations  pertain  to  characterization  of  the  exposure  and  pathogen  while  the
following can also pertain to the dose response relationship in order  to improve risk
estimates.  
1. Incorporation of factors that determine or increase susceptibility.
The  adult  male  human  respiratory  system  has  been  modeled  in  this  work,
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however,  this  framework  can  be  modified  for  susceptible  subpopulations  such  as
children.   Only simple alterations such as respiratory system volumes and respiration
rates need be changed.  
2. Accounting for heterogeneous populations of microorganisms in the environment
This  recommendation  from  ILSI,  (1996)  pertains  mainly  to  environmental
concentrations of pathogens, however, this is also necessary for understanding the dose
response  relationship.   In  using  the  exposed  dose  for  modeling  the  dose  response
relationship assumes a homogeneous delivery of that number of pathogens to affect the
host.  However this is not the case rather the exposed dose will be different from the dose
which is delivered to a specific location such as the alveoli for  B. anthracis due to the
dynamics of respiration.     
3. The effect of incubation time as well as growth and inactivation dynamics.
Once  the  B.  anthracis spores  are  inhaled  there  are  steps  in  the  pathogenesis
process which determine the amount of vegetative cells (the cells which cause the disease
anthrax).   This  time  period  can  be  critical  in  being  able  to  mount  a  treatment  or
prevention program.      
The framework that has been developed to make the QMRA equivalent to PBPK
models  will  develop  a  modification  to  the  dose  used  in  dose  response  models.   As
previously  mentioned  the  exposed  dose  which  is  currently  used  in  dose  response
modeling as well as assessment, is not necessarily the dose the host experiences.  This
difference in the dose affects the relationship between the dose response relationship and
the time post exposure.  Developments have been made to determine the dependence  of
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time post-inoculation on the dose response relationship (Huang  et al 2009, Huang and
Haas  2009).   This  framework  not  only  allows  enhanced  accuracy  and  a  greater
descriptive quality to the dose response models but a further understanding of the time
dependence of post-exposure dose response.  The important distinction and difference is
post-exposure rather  than post-inoculation,  generating  the  ability to  use  the  exposure
estimate from environmental sampling, taking into account the respiratory system's sinks
and kinetics of growth and inactivation to model the pathogen burden.  This pathogen
burden is used to develop a risk estimate for the exposed population.   
 2.3 Simplified modeling of the human respiratory system as a three-region model
The complexity of the respiratory system has been discussed previously, however,
this level of complexity is not feasible to model if rapid computational time and accuracy
is desired.  Therefore simplifying assumptions must be made in order to make it possible
to model the respiratory system.  Just as water distribution systems must be skeletonized,
justifiable simplifications  must  be made without reducing the complexity to the level
where accuracy is not sacrificed.  
With the increased interest and development of nuclear power in the 1960s an
international  commission was established  in  order  to  determine  the  risks  posed  from
exposure  from  radiological  material.   In  order  to  develop  more  radiological  risk
assessments more reliable and predictive dose response models were needed (Morrow et
al.,  1966).   While developing these dose response models the commission realized in
order  to  model  the  deposition  and  interaction  of  inhaled  radiological  particles  the
respiratory system must be simplified as well.  In 1966 the result was the development of
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a three-region model  (Table  4,  and Figure  13)  that  simplifies  the respiratory system,
based on the function and placement of physiological compartments of the respiratory
system (Morrow  et  al,  1966).   The three-region  model  can be and has  been  used to
develop  both  deterministic  and  stochastic  models,  however,  stochastic  models  have
proven to be more reliable in using the three region model (Koblinger and Hofmann,
1985).  In this case the three region model has been used to develop a stochastic model
for transport and deposition of pathogens in the respiratory system.       
Table 4: Three region model proposed by Morrow et al. (1966)
Included Anatomical Structures
Region
 umber
Region  ame
Nares, nasal cavity, oral cavity, nasopharynx,
laryngopharynx, larynx
1 Nasopharynx
Trachea, bronchi, first branches of bronchioles 2 Trachiobronchial
Respiratory bronchioles, acinus, alveolar sacs 3 Pulmonary
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 2.4 Goals and hypotheses of this dissertation 
 2.4.1 Goals of this dissertation
As has been seen thus far there exist a number of sinks present in the respiratory
system which may remove the spores before reaching the alveoli where germination and
growth can occur.  This dissertation has four main goals; first in determining how the
dose exposed to a host can be affected by taking into account transport and deposition of
B. anthracis  spores.  This will model the sinks that the respiratory system presents to
inhaled pathogens by depositing and removing the spores from the bulk fluid.  Next the
pathogenesis of  B. anthracis spores, specifically the interaction between the spores and
alveolar macrophages will be modeled, in order to determine the effect on the exposed
dose.  Both of these will modify the dose from an exposed dose to a pathogen load.
The next two goals are determining if the modification of the dose affects the
Figure 13: Visual depiction of three
region model from Morrow et al, (1966)
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modeled dose response relationship.   First  the model that  describes  the transport  and
deposition of spores via inhalation and exhalation during an aerosol exposure will allow
for  a  delivered  dose  modification  to  the  exposed  dose.   And  lastly  the  model  that
describes  the  pathogenesis  of  B.  anthracis will  be  combined  with  the  transport  and
deposition  model  to  determine  if  there  is  an  affect  to  the  modeled  dose  response
relationship using the pathogen load modification to the exposed dose.  
 2.4.2 Hypotheses of this dissertation
In order to attain the goals of this dissertation three hypotheses have been outlined
which must be answered.
1. The bulk fluid transport and deposition of B. anthracis spores can be modeled and
used to develop a modification to the exposed dose, which will affect the modeled
dose response relationship.
The physics of bulk fluid transport and deposition of B. anthracis spores has been
well  established.   Prior  work  on  modeling  these  processes  has  shown  the  ability  to
describe these processes both stochastically and deterministically.  This is a necessary
first step in determining the amount of spores that will reach sensitive locations in the
respiratory system (in  the case of  B. anthracis,  the alveoli).   A model for  bulk fluid
transport  and  deposition  will  describe  the  delivered  dose  which  is  a  more  accurate
estimate of inhaled spore exposure, compared to the exposed dose.  
2. Engineering modeling principles  can be used to model the pathogenesis of  B.
anthracis,  specifically the interaction between  B. anthracis spores and alveolar
macrophages. 
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Once the spores have been delivered to the sensitive location (alveoli) the spores
must germinate into vegetative cells as part of the pathogenesis of  B. anthracis.  The
steps  in  the  pathogenesis  of  B.  anthracis can  be  modeled  as  a  system  of  ordinary
differential equations (ODEs) that can interrelate all of the processes.  Since the processes
which make up phagocytosis are all dependent on each other, this system of interacting
ODEs is an ideal method of modeling these processes.   
3. The  bulk  fluid  transport  and  deposition  model  combined  with  the  model
describing the spore macrophage interaction will have an affect on the modeled
dose response relationship on inhaled B. anthracis spores.
For model to develop a real depiction of the infection process both the transport
and the pathogenesis must be included in the model.  This is emphasized with a pathogen
such as inhaled B. anthracis spores that must be delivered to a sensitive location for its
specific  pathogenesis.   The  first  stage  which   models  the  bulk  fluid  transport  and
deposition  of  the  spores  through  the  respiratory system.   This  stage  will  inform the
amount of spores delivered to region in the respiratory system which will be used to
compute the initial concentration of spores for the second stage to model the pathogenesis
of B. anthracis spores.  
 2.5 General layout of this dissertation
Extensive work has been performed on modeling the transport and deposition of
inhaled particles in the human respiratory system (Balashazy et al., 2008; Choi and Kim,
2007; Hanna et al., 2001; Koblinger and Hofmann, 1990; Park and Wexler, 2007).  The
respiratory system has been modeled both stochastically using Markov chain (MC) and
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Markov  chain  Monte  Carlo  (MCMC)  as  well  as  deterministically,  using  numerical
techniques.   The  level  of  complexity  has  included  the  use  of  computational  fluid
dynamics  (CFD)  simulations  of  transport  and  deposition  (McClellan  and  Henderson,
1995; Maruyama, et al., 2006).  However there has not been prior work on modeling the
pathogenesis of inhalational  B. anthracis.  Combining the two, modeling the transport
and deposition of the spores as well as the pathogenesis will allow for modifying the
dose, allowing improved estimates on the dose response relationship.  
The first steps in being able to accomplish this modification of the dose are to
establish the framework for the overall model.  The interaction between B. anthracis and
alveolar macrophages as  well  as the bulk fluid transport  and deposition,  need not be
modeled with one entire deterministic or stochastic model.  These are two separate yet
equally important stages in the infection process.   Therefore two models coupled and
working  together  will  be  able  to  represent  the  dynamics  of  these  two  stages  of  the
infection processes which work in series for an infection and disease to take hold.       
 2.5.1 Two-stage modeling approach
In trying to understand the heterogeneity of responses from similar or the same
doses even when keeping populations homogeneous a two stage model framework was
developed (Meynell and Maw, 1968).  This framework developed takes into account the
exposure and growth of Salmonella typhimurium (S. typhimurium).  The work of Meynell
and  Maw,  (1968)  looked  to  answer  why a  heterogeneous  response  is  observed  from
homogeneous exposures.   They concluded that  a two-stage model of infection,  which
could account for transport and replication of S. typhimurium after ingestion was capable
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of accounting for the heterogeneous response from a homogeneous exposure.  The same
strategy is being used in this work as well, in modeling a dose response relationship using
the  exposed  assumes  a  homogeneous  dose.   The  two-stage  model  will  alter  this
homogeneous dose to a heterogeneous one which can better describe the dose which
affects the host.  
This basic framework of a two-stage model has also been used in order to model
the two stages of the infection process in this work.  This first stage is a stochastic model,
which will follow the transport of the spores in the respiratory system and predict the
deposition in the three regions of the respiratory system.  Despite the advancements in
computational tools to develop a numerical solution to a deterministic model stochastic
models have proven to be robust in transport and deposition models for the respiratory
system  (Koblinger  and  Hofmann,  1985;  Simmons  et  al.,  2005).   Stochastic  models
typically can function better, more reliably and more accurately with very low numbers
of  spores,  much  more  so  than  deterministic  models.   At  low numbers  of  organisms
deterministic  models  are  noisy,  because  of  the  stochastic  nature  of  the  systems  and
processes at these low levels of organism numbers (Loettgers, 2007; Baas et al., 2009).  
In  modeling  the  pathogenesis  of  B.  anthracis a  deterministic  model  has  been
developed for the second stage.  This deterministic stage, models the deposition of spores
on the alveolar macrophages, the uptake, inactivation and germination of spores and the
growth and decay of B. anthracis vegetative cells within the alveolar macrophage.  There
will still be the problems with lower numbers of organisms as discussed earlier.  However
the processes are much more structured and the ability for the spores to move from their
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deposition  location  and  eventual  location  inside  the  macrophage  is  well  understood,
especially  within  such  tight  spatial  constraints.   Therefore  the  internal  noise  in  the
numerical solution should be held to a minimum in such a spatially constrained scenario
(Loettgers, 2007).
The  two  stages  have  been  coupled  together  with  the  stochastic  stage
'communicating' with the deterministic stage.  Figure 14 shows a graphic representation
of a stochastic model (matrix of  p) coupled to a deterministic model.  This coupling is
taking the results from the stochastic stage (specifically the dose in region-3 bulk fluid) at
a chosen time step and using this value as the initial dose for the deterministic stage.    
 2.5.2 Comparison to available dose response data
In order to determine if the modified dose using the two-stage model has an effect
on the dose response relationship, a modeled dose response relationship with unmodified
dose data is required.  A dose response data set for B. anthracis inhalation exposure has
been chosen where the dose response model with the unmodified dose has been modeled.
This model fitting will be performed again without the modifications to the dose, then the
model will be fitted again with modifications from the first stage to determine the effect
of delivered dose, and then the model will be fitted again using the modified dose from
Figure 14: Graphic depicting the coupling of the two stages together
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the coupled model.  This will show how the dose response model is affected by dose
modifications from both the first stage and the coupled model.  
 2.6 Concurrent work being performed modeling the in-vivo fate of B. anthracis
Two  other  research  groups  are  attempting  to  develop  analogous  models
concurrently but independent of this work.  There is only one research group that has
demonstrated their framework, however not  in detail  (Gutting  et al.,  2008),  while the
second, at the Syracuse Research Corporation (SRC) has shown the need for such models
and  described  a  potential  framework.   The  framework  described  in  Gutting  et  al
establishes a stochastic deterministic model.  This model is being built around the rabbit
lung, since there is concurrent testing and evaluation of rabbit dosing studies.  There are
four main points where their framework differs from the this framework:
1. The  Gutting  et  al framework  is  focusing  primarily  on  the  interactions  of
antibodies with the bacteria.
2. They assume a growth rate of B. anthracis within macrophages is equal to that in
the blood, rather than developing and fitting a growth rate from available or their
own gathered data.
3. Their framework includes transport of the alveolar macrophages from the alveolar
surface to the lymphatic system. 
4. Their  model  is  a  stochastic  deterministic  model,  and  their  hybrid  is  meant  to
account  for  biological  variability  more  effectively  than  only  a  deterministic
model.
This  dissertation  has  not  included  the  transport  from  alveolar  surface  to  the
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lymphatic system a potentially complicating inclusion due to a lack of data in order to fit
a mechanistic model to, the work in Gutting  et al intends to include this.  While this
process  is  important  to  a  more  inclusive  model  of  the  pathogenesis  and  disease
progression, the low availability of data and not being critical in the pathogenesis of B.
anthracis this  process  was  not  included  in  this  work.   Possibly  the  most  important
difference between these two frameworks is the fact that the Gutting et al framework is
attempting to develop a mechanistic dose-response model which can potentially replace
traditional dose response models for inhalational anthrax.  While this work's aim is to
develop both stochastic and mechanistic modifications to the dose used in traditional dose
response models.  Another potential problem with the framework from Gutting  et al is
that  they are not  modeling the  transport  and  deposition of  the spores  throughout  the
respiratory system.  Rather Gutting et al intend to use the deposition fractions Yeh and
Schum, (1980) developed for inhaled particles.  While the work of Yeh and Schum is
substantial and its use is defensible a stochastic or deterministic transport and deposition
model can allow the researcher to simulate  host  stress (increase in breathing rate)  or
steady breathing.  Having the transport and deposition model allows the framework being
presented  here  to  be  more  adaptable  and  descriptive  with  a  transport  and  deposition
model included.
While  the  full  framework  from  the  researchers  at  SRC have  not  been  made
available for overview, they aim to answer the same problems with the current state of
dose response modeling as in this work and for Gutting et al.  In laying out the problems
with the current state of dose response modeling and potential solutions (Coleman et al.,
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2008) it is likely that the entire model will be deterministic in nature for both transport
and pathogenesis modeling.          
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 CHAPTER 3 : DEVELOPME T OF THE FIRST STAGE: THE STOCHASTIC
MODEL FOR BULK FLUID TRA SPORT OF B. A THRACIS SPORES
ABSTRACT
It has been discussed earlier about furthering the dose response assessment phase
of QMRA by including the main constituents of the infection process for inhaled Bacillus
anthracis.  The infection process progresses in two main stages, the first stage being the
transport  of  the  pathogen  to  a  sensitive  location  and  the  second  stage  being  the
pathogenesis  process  that  initiates  the  infection.   The  combination  of  the  two stages
describes the overall infection process.  Therefore in order to develop a model for the
overall infection process both of these stages must be included.  The first stage will be
modeled  first  as  a  stochastic  model  that  will  describe  the  bulk  fluid  transport  and
deposition of inhaled Bacillus anthracis spores.    
Keywords:  Bacillus anthracis, inhalation, Markov chain, deposition, transport,
bioterrorism 
 3.1 Review of the physiology of the human respiratory system
The respiratory systems has one primary function, which is to reoxygenate the
blood via inhalation and remove carbon dioxide via exhalation.  Therefore respiration
brings air from the external environment into intimate contact with the blood stream.  The
lungs  are  the  main  and  largest  structure  of  the  respiratory  system.   The  lungs  are
comprised of three compartments; air, blood and tissue.  This is the alveolated section of
the respiratory system,  meaning that  the lungs  contain  the  alveoli,  or  air  sacs  where
reoxygenation occurs (Hasleton and Curry, 1996; Weibel, 1963).
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In order to accomplish reoxygenation,  air  is  inhaled and transported through a
series  of  structures  until  final  transport  to  the  alveolated  region of  the lung.    As is
depicted in Figure 15 when air enters the alveoli the partial pressure of oxygen in the air
drops to 104 mmHg (millimeters  of  mercury)  due to the moisture present  within the
alveoli.  The deoxygenated blood has a partial pressure of 40 mmHg.  This difference in
partial pressure drives the diffusion of oxygen from the air in the alveoli to the blood.
The same diffusion process driven by differences in partial pressure allows for removal of
carbon dioxide from the blood. 
The alveoli of the lung are primarily made up of three types of cells which are
specifically  called  pneumocytes,  due  to  their  specialized  tasks  in  alveolar  cell
regeneration and gas exchange maintenance.  Type I, or squamous pneumocytes are the
cells  which  make  up  the  structure  of  the  alveolar  wall.   Type  II  or  great  alveolar
pneumocytes secrete a pulmonary surfactant which lowers the surface tension of water
that  allows  for  membrane  separation.   The  surfactant  release  is  continuous  due  to
Figure 15: Diffusion of oxygen
from alveoli to the blood
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exocytosis (direction of secretory vesicles through cell membrane) in order to allow for
the continued ease of membrane separation (Weibel, 1963).  The membrane separation
must be allowed to continue without impediment, since this separation is required for
oxygen  to  diffuse  into  the  blood.   The  third  type  of  pneumocytes  are  the  alveolar
macrophages, which as discussed are tasked with encountering and destroying foreign
material and pathogens.  
These processes of surfactant secretion, membrane separation allow for oxygen
and  carbon  dioxide  to  diffuse  into  and  out  of  the  blood  during  respiration.   These
processes working continuously are necessary for continued health, however, allow for
ease of transfer of chemical or pathogenic contaminants into the blood as well.      
As discussed previously the respiratory system is essentially an air distribution
system,  the  obvious  goal  being  to  reoxygenate  the  blood.   Air  is  drawn  into  the
respiratory system through either the nares (nostrils), or the mouth.  Air passes through
the nasal and/or oral cavity interacting with any of the sinks associated with these areas.
The nasal cavity having more sinks associated with it (compared to nearly zero for the
oral  cavity)  will  allow  for  a  lower  amount  of  pathogens  continuing  through  the
respiratory system (Koblinger and Hofmann, 1985).  
Once entering the respiratory system through the nasal cavity (and/or oral cavity)
the air (and any aerosolized particles, pathogens, radiological or chemical contaminants)
will  then  reach  the  pharynx  (back  of  the  throat)  and  eventually  transported  to  the
laryngopharynx which is the junction between the pharynx and larynx as shown in Figure
16 (National Cancer Institute(2) 2009).
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Air then passes through the epiglottis, which can be likened to a two-way flap
valve, and which prevents food or water from entering the respiratory system, entering
the larynx.  The larynx then bifurcates (separation into two branches) thereby splitting
into the main bronchi.  The right bronchus is longer than the left (5 cm compared to 2.5
cm respectively), but the left bronchus is wider being 15 mm in diameter as compared to
13 mm, this difference in size allows the lungs to fit into the chest (Hasleton and Curry,
1996; Weibel, 1963).  
The air is split by the main bronchial bifurcation and considered to be a uniform
division in  the airflow,  with  50% of  the inhaled air  entering the left  and  right  main
bronchi.  The air continues on a sinuous path through structures called bronchioles.  The
bronchioles  are  numerous  and  amazingly  complex  in  the  various  bifurcations  and
decreasing diameters, allowing for continual deposition throughout the bronchioles.  The
bronchioles lead to the terminal bronchioles that have the connections to the alveoli.
The alveoli are connected to the terminal bronchioles by the acinus which is the
Figure 16: Depiction of the pharynx as it leads to the larynx.
National Cancer Institute: http://training.seer.cancer.gov/head-
neck/anatomy/overview.html 
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duct leading to the alveolus.  The small diameter of the acinus (between 1 and 5  µm)
serves  as  a  significant  barrier  to  particles  greater  than  the  acinus  diameter  (  Guidi-
Rontani, 2002; Weibel, 1963).  During inhalation the air passes through the acinus which
when connecting to the alveolus is a rapid expansion, thereby generating a rapid headloss
to the fluid (air).  And during exhalation the fluid experiences another loss of energy by
being drawn into a rapid contraction, by passing into the acinus again.  These dynamics
allow for a relatively low deposition rate compared to the rest of the respiratory system.
The flow regime encountered in the alveolus is highly turbulent with a system of eddies
being generated inside the alveolus (Haber et al., 2003; Balásházy et al., 2008).  This is
yet another protection the body musters before needing to expend leukocytes.     
 3.1.1 Simplification of the human respiratory system into a three-region model
As has been demonstrated, the respiratory system is complex.  Modeling the full
complexity of the entire respiratory system, taking into account all of the bifurcations and
diameter changes is infeasible (Haber et al., 2003; Hofmann and Koblinger, 1990).  Prior
work  has  performed  this  for  the  upper  respiratory  tract  (URT)  and  a  portion  of  the
bronchioles,  however,  when extended deeper  into  the bronchioles  and  the respiratory
bronchioles a full model of the entire respiratory system is again deemed computationally
infeasible (Balásházy  et al.,  2008; Haber  et al., 2003;  Koblinger and Hofmann, 1985;
Koblinger and Hofmann et al., 1990; Yeh, H-C. and Schum, 1980).
The most computationally effective means of modeling the respiratory system is
to model it in pieces.  There has been a great amount of work in modeling deposition and
bulk fluid transport in the alveoli and the upper bronchi (Balásházy et al., 2008; Haber et
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al., 2003;  Koblinger and Hofmann, 1985; Yeh, H-C. and Schum, 1980; Snyder, B. and
Olson, D.E., 1989).  But little to no work has been performed in developing a model of
transport  and  deposition  of  particles  or  pathogens  for  the  entire  respiratory  system
(Koblinger and Hofmann, 1985).  
Therefore  a  simplified  model  of  the  respiratory  system  must  be  developed.
Simplifications are necessary in modeling complex systems just as in water distribution
modeling.  In modeling water distribution systems the entire system cannot be modeled
feasibly therefore the distribution systems are skeletonized,  simplified to  the point  of
being able to model the system without loosing the ability to describe the entire system.
This type of simplification can also be made for the respiratory system (Morrow et al.,
1966; Walski, 2003).     
It was recognized in the early 1960s due to the concerns of radiological exposure
that in order to improve radiological dosimetry, transport and deposition of radiological
material must be modeled for the entire respiratory system (Morrow et al 1966).  This
simplification shown in Table  5 is the three-region model developed by Morrow  et al.
(1966).       
Table 5: Three-region model of the respiratory system (Morrow et al., 1966)
Included Anatomical Structures
Region
 umber
Region
Symbol
Region  ame
Nares, nasal cavity, oral cavity, nasopharynx,
laryngopharynx, larynx
1 R1 Nasopharynx
Trachea, bronchi, first branches of bronchioles 2 R2 Trachiobronchial
Respiratory bronchioles, acinus, alveolar sacs 3 R3 Pulmonary
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As shown in Table  5 the first  region includes the structures of the respiratory
system until the larynx is reached.  The second region includes the trachea to the main
bronchi and the first generation of bronchioles (from the first main bifurcation to the next
bifurcation experienced).  The third region using the Morrow et al., (1966) framework
includes the remaining bronchioles and the alveolar sacs.  In this work the third region
does not include the alveolar sacs, rather the third region will end at the entry to alveolar
sacs (acinus).   
All  of the intermediate structures,  such as all  of the bifurcations and diameter
changes of the bronchioles are not required in the simplification of the respiratory system
(Koblinger and Hofmann, 1985).  Using this simplification is most useful in stochastic
models since only knowledge of the area and volume of the spaces being modeled is
necessary.        
 3.2 Basics of Markov chain modeling
When particles  such  as  pathogens  are  inhaled  into  the  respiratory system the
pathogens can be transported via air currents or deposit on the respiratory system walls.
If  only  considering  one  well-mixed  compartment  for  transport  and  deposition  of
pathogens,  an analytical  solution to  a  differential  equation can be derived.   However
expanding this to two or more compartments, the difficulty of this derivation increases,
until  five  or  more  compartments  are  reached  making  this  task  infeasible,  making
numerical methods a necessity (Ross, 2007).  In general a differential equation solution is
deterministic, which when model inputs are the same, the equation produces the output is
always the same (Nicas and Sun, 2006; Hofri, 1984)  Also, a differential equation model
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assumes continuous variables such as pathogen concentration, while stochastic models
relax this assumption (Nelson, 2003; Walski, 2003).
An alternative method to modeling pathogen transport  and deposition between
different compartments is a Markov chain model (Markov model).  There are two types
of Markov models,  discrete and continuous-time Markov models.   A continuous-time
Markov model determines the amount of pathogens in a state during the present time step
independent of the previous time step.  While discrete-time Markov models determine the
amount of pathogens in a current state at the present time step dependent on the previous
time step.  Since the amount of pathogens in a specific portion of the respiratory system
at the present time during respiration is dependent on the previous time, a discrete-time
Markov model has been used.  
A Markov model is a method of stochastic modeling that works by utilizing a
matrix comprised of transition probabilities which are related to loss rates (Ross, 2007).
This matrix takes into account the rates of losses of the pathogen in different states at
each time step.  The transition probabilities are constructed from first-order rate constants
(denoted by the symbol λ) units of inverse time (min-1).  Using the constant λ to describe
the rates of a quantity of pathogens from a state (see full state definition in section 3.3 )
being lost during a small time interval defined as [t, t + ∆t].  Then using the product of
t∆⋅λ  gives the quantity of pathogens present at time  t which are lost within the time
interval [t, t + ∆t].
First the states that the model will be running on must be determined and defined.
Figure  17 shows the basic system that must be modeled.  This visual depiction is not
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intended to resemble the actual physiology or dimensions of the three-regions.  Rather the
three-regions are being depicted as three boxes, since this will be a three-box Markov
chain.   Each  compartment  is  assumed  well  mixed  with  a  flow  in  and  through  all
compartments from inhalation of Q.  There is also a possibility that the pathogen can be
transported  from a  lower  to  higher  region  (region-two to  region-one)  by the  reverse
airflow  B during  exhalation.   Pathogens  in  each  compartment  will  also  have  the
possibility of depositing and losing viability, these processes will be expanded on when
describing the states to be used in the Markov model.
Now that  the basics  of  Markov  chain modeling are established the individual
components of the Markov chain must also be established.  As shown in the description
above  the  Markov  chain  both  the  states  and  the  loss  rates  for  the  pathogens  being
transported and deposited.     
 3.3 Definition of states for the Markov chain model
A state  is  defined  as  a  location  or  compartment  where  the  pathogen  has  a
Figure 17: Three-compartment Markov model for
the three-regions of the respiratory system 
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probability of being present within a time interval [t, t + ∆t].  This definition means that
the  ability of  pathogens  to  transport  between  states  requires  the  states  to  be  able  to
communicate with each other.  To establish transport between states first the ability of
one a microorganisms to be able to transition within one state must be established.  The
ability of a microorganism in state i to remain in state i is defined by equation 3, where
the probability of a microorganism transitioning from state i to state i (Pii
0) with possible
values (X) from the stochastic process (Ross, 2007).
P ii
0=P [ X 0=i∣X 0=i ]=1      (3)
Therefore since state i can communicate with itself, then it follows that state i can
communicate with state j and any number of other states as given by three properties of
states (Ross, 2007): 
1. A microorganism can transition in state i for all i which are greater than or equal
to zero.
2. A microorganism in state j can transport to state i since a microorganism in state i
can transport to state j.
3. If  a  microorganism  in  state  j can  transport  to  state  k,  thereby  since  a
microorganism in state  j can transport to state  i, a microorganism in state  i can
transport to state k and a microorganism can transport from state k to state i.
The  first  two  properties  are  shown  from equation  3,  however,  the  Chapman-
Kolmogrov equation defines transition probabilities (which will be discussed later) when
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including  the  third  state  (k).   The  Chapman-Kolmogrov  equations  allows  for  the
computation  of  n  and  m transitions  from  one  state  to  another  by  summing  over
intermediate  states,  leading  to  equation  4  (Ross,  2007).   A conceptual  diagram  of
microorganisms transporting from one state to another can be seen in Figure 18.
P ik
n + m=∑
r=0
∞
P ir
n
P rk
m P ij
n
P jk
m 0        (4)
With the potential of microorganisms present in one state being transported to
another state established, the states must be defined.  Since states are essentially locations
or compartments in which the pathogen has a probability of being present the air in each
region will be separate states.  This will allow the model to capture the transport of the
pathogen in the air moving through the respiratory system.  The surface of the respiratory
system of each region will comprise a state in order to determine the pathogen deposition
in each region.  Since the pathogen can loose viability or die while being transported or
deposited, this death or loss of viability will be another state.  And finally the pathogen
being exhaled back to the external environment, this will be captured by the eighth and
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final state.  Table 6 shows the eight states for the Markov model.
Table 6: Eight states defined for the Markov chain model
State  umber Description
1 Air in R1
2 Respiratory system surface in R1
3 Air in R2
4 Respiratory system surface in R2
5 Air in R3
6 Respiratory system surface in R3
7
Death  or  loss  of  viability  of  the  pathogen
during transport, and during or after deposition
8
Exhalation of pathogen to external environment
from R1
 3.4 Definition of loss rates and transition probabilities for the Markov model
Now that  the  states  have been determined,  in  order  to  establish the  transition
probabilities, the loss rates from the states must be defined.  The Markov model will be
built around the 88×  P matrix (equation 5), therefore, the transition probabilities will be
defined by defining the incremental portions (i.e. P11) of the matrix (Ross, 2007).  The
transition probabilities will be built from first order loss rates (Table 7).  These loss rates
are first order since processes such as spores death rate has been shown empirically to be
first order.  The loss rates in Table 7 will be used to generate transition probabilities to
describe the loss of B. anthracis from each state.  
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2827262524232221
1817161514131211
pppppppp
pppppppp
pppppppp
pppppppp
pppppppp
pppppppp
pppppppp
pppppppp
P                    (5)
Table 7: Loss rates from Markov model states
Loss Rate Symbol Loss From State Described
λR 1-2 Pathogen transport from R1 to R2
λR 1s Deposition of pathogen in R1
λR 2-3 Pathogen transport from R2 to R3
λR 2-1 Pathogen transport from R2 to R1
λR 2s Deposition of pathogen in R2
λR 3-2 Pathogen transport from R3 to R2
λR 3s Deposition of pathogen in R3
λdeath
1 Death or loss of viability of pathogen 
λexh Pathogen exhaled to external environment
1: Death rate assumed same for all compartments
 3.4.1 Establishment of loss rate functions and transition probabilities 
The following structure is used when defining the transition probabilities.  The
term  tij ∆⋅λ  is the probability that a pathogen present in state-i will be transported to
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state-j within  the  time  step  ∆t.   Then  the  overall  rate  at  which  a  pathogen  will  be
transported from state-i is defined as the sum of the loss rates for removal from state-i
which will be denoted with  λι.  Thus the probability that a pathogen will be present in
state-i after  ∆t (denoted as  pii) can be defined with an exponential survival probability
shown in equation 6 unless ∆t is very small then equation 7 is also relevant (Nicas and
Sun, 2006; Ross, 2007).
( )tp iii ∆⋅−= λexp             (6)
pii=1−i⋅ t                                                (7)
In turn the probability of moving from state-i to state-j can be defined as the rate
of loss  λij divided by the overall removal rate, in this example  λi.  This allows for the
determination of the unconditional probability of a pathogen in state-i  moving to state-j
during  ∆t, which is the complement of the probability of the pathogen being in state-i
multiplied by the conditional  probability shown in equation 8 (Nicas  and Sun,  2006,
Ross, 2007).  
[ ]ii
i
ij
ij pp −⋅= 1λ
λ
(8)
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 3.4.2 Transition probabilities for losses from state-one (Air in R1) 
There is  an airflow on inhalation and exhalation which transport  the pathogen
between  region-one  to  region-two.   Spores  can  be  deposited  on  the  respiratory tract
surface transferring the pathogen from state-one to state-two.  The spores can also loose
viability while in transport which is also considered a loss from state-one into state-seven.
The transition probabilities will start with an unconditional probability of the pathogen
being  present  in  the  airflow  in  region-one  (equation  9).   There  are  then  conditional
probabilities that describe: the loss to deposition, loss from transport to region-two and
loss of viability or pathogen death (equations 10 through 12).  The remaining portions in
the first column of the P matrix will be zero since these states are not directly affected
from state-one losses.
( )( )tp deathsRR ∆⋅++−= − λλλ 12111 exp          (9)
[ ]11
121
1
12 1 pp
deathsRR
sR −⋅
++
=
− λλλ
λ
       (10)
[ ]11
121
21
13 1 pp
deathsRR
R −⋅
++
=
−
−
λλλ
λ
        (11)
[ ]11
121
15 1 pp
deathsRR
death −⋅
++
=
− λλλ
λ
        (12)
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 3.4.3 Transition probabilities for losses from states-two, four and six (respiratory
system surface in R1,R2 and R3 respectively)
Due to a  thick mucus layer  which coats  the respiratory tract,  once a  spore is
deposited on the respiratory tract surface it remains and is removed from consideration in
the Markov model.  The only loss from these states is the loss of viability of the spores.
This is captured using an unconditional probability that the spore dies or looses viability
while  deposited  in  this  state  (equations  13,  15  and  17  for  state-two,  four  and  six
respectively).  The survival probability in this case is the compliment of the unconditional
probabilities (equations 14, 16 and 18 for states-two, four and six respectively).  
( )( )tp death ∆⋅−= λexp22      (13) 2227 1 pp −=                 (14)
( )( )tp death ∆⋅−= λexp44       (15) 4447 1 pp −=                 (16)
( )( )tp death ∆⋅−= λexp66      (17) 6667 1 pp −=                (18)
 3.4.4 Transition probabilities for losses from state-three (air in R2)
The airflow on inhalation and exhalation transports the pathogen from region-two
to region-three.  There is also an airflow term that can allow the spores to move from
region-two  to  region-one.   Spores  can  be  deposited  on  the  respiratory  tract  surface
removing the pathogen from state-three.  The spores can also loose viability or die while
in transport which is also considered a loss from state-three.  The transition probabilities
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will start with an unconditional probability of the pathogen being present in the airflow in
region-two (equation 19).  There are then conditional probabilities that describe; the loss
to deposition, loss from transport to region-three, loss from transport to region-one and
loss of viability or pathogen death (equations 20 through 23).  The remaining portions of
the  P matrix  will  be zero since these states  are not  directly affected from state-three
losses.
( )( )tp deathsRRR ∆⋅+++−= −− λλλλ 2321233 exp (19)
[ ]33
23212
12
31 1 pp
deathsRRR
R −⋅
+++
=
−−
−
λλλλ
λ
(20)
[ ]33
23212
2
34 1 pp
deathsRRR
sR −⋅
+++
=
−− λλλλ
λ
(21)
[ ]33
23212
32
35 1 pp
deathsRRR
R −⋅
+++
=
−−
−
λλλλ
λ
(22)
[ ]33
23212
37 1 pp
deathsRRR
death −⋅
+++
=
−− λλλλ
λ
(23)
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 3.4.5 Transition probabilities for losses from state-five (air in R3)
There is a reverse airflow term that can allow the spores to move from region-
three to region-two.  There is an exhalation term that is introduced, since the air has filled
the lung the air now beginning to leave the lungs through exhalation.  Spores can be
deposited on the respiratory tract surface removing the pathogen from state-five (air in
R3).  The spores also loose viability while in transport which is also considered a loss
from state-five.  The transition probabilities will start with a probability of the pathogen
not being present but remaining in state-five from time t to t+∆t(equation 24).  There are
then conditional probabilities that describe; the loss to deposition, loss from transport to
region-two, loss from exhalation and loss of viability or pathogen death (equations 25
through 28).  The remaining portions of the P matrix will be zero since these states are
not directly affected from state-five losses.
( )( )tp deathsRexhR ∆⋅+++−= − λλλλ 32355 exp (24)
[ ]55
323
23
53 1 pp
deathsRexhR
R −⋅
+++
=
−
−
λλλλ
λ
(25)
[ ]55
323
3
56 1 pp
deathsRexhR
sR −⋅
+++
=
− λλλλ
λ
(26)
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[ ]55
323
57 1 pp
deathsRexhR
death −⋅
+++
=
− λλλλ
λ
(27)
[ ]55
323
58 1 pp
deathsRexhR
exh −⋅
+++
=
− λλλλ
λ
(28)
These transition probabilities are used to complete the P matrix shown in equation
8.  The P matrix filled with the transition probabilities shown in equation 29 (on the next
page) is multiplied with itself for each of the time intervals [t, t + ∆t] in order to estimate
the amount of pathogens present in each state.    
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 3.4.6 Definition of loss rate functional forms.
3.4.6.1   Loss rate functional forms for bulk fluid transport
The transition probabilities have been defined in the prior sections as functions of
the first order loss rates (λ's).  It is now necessary to estimate the numerical values of the
loss rates from the literature.  While λdeath is a given value (Sinclair et al., 2008) the rest of
the loss rates are based on the transport or deposition physics in each of these states.
Each of the loss rates must be first order (units of min-1) which is necessary since in order
to  develop  a  probability  of  the  pathogen  being  in  a  certain  state  is  determined  by
multiplying the loss rates with the time interval [t, t + ∆t].  
The  derivation  of  the  Markov  model  begins  with  the  initial  condition  of  the
concentration of spores in region 1 being the exposure amount, and the concentration of
spores  in  the  other  regions  being  zero.   Therefore,  when  the  host  inhales  air  and
pathogens, both are transported throughout the respiratory system based on a volumetric
flow rate Q in units of volume per time (in this case cm3/min).  The air and pathogens are
also exhaled with a volumetric flow rate of exhalation B also in units of cm3/min.  Both Q
and  B can be considered the same value since the time of non-stressed inhalation and
exhalation are the same (Weibel, 1963).  Both Q and B are the same value of 125 cm3/min
based on typical respiration rates used by Heyder et al., (1986) since their impaction rates
will be used later.  These flow rates will be divided by the volume of the region in the
respiratory system which is associated with the state that the air or pathogens are located
during that time interval, developing a first order loss rate.  Therefore for the transport
from R1 to R2 the volumetric flow rate for inhalation and exhalation will be divided by
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the volume of R1.   Therefore the loss rates for transport  from R1 to R2 and R2 to R3
(equations 30 and 31 respectively) will be the sum of Q and B divided by the volume of
R1 (VR1) to allow for air exchange between regions and to keep well mixed conditions.
The  exhalation  rate  alone  is  the  flow  rate  which  affects  the  losses  associated  with
transport from lower regions to higher (R2 to R1) as shown in equations 32 and 33 for
transport from R2 to R1 and R3 to R2 respectively.     
R12=
Q + B
V R1
      (30)
R21=
B
V R2
    (32)
R23=
Q + B
V R2
     (31)
R32=
B
V R3
   (33)
3.4.6.2   Loss rate functional forms for pathogen deposition
The  bulk  fluid  flow  in  a  pipe  section  (or  respiratory  system  vessel)  can  be
visualized  using  streamlines  (Figure  44).   A  pathogen  will  typically  follow  the
streamlines while being transported in the bulk fluid.  Should an obstacle be present, the
streamlines will conform around the obstacle in order to flow past it (Figure  45).  The
pathogen being transported will also follow the streamlines around the obstruction, while
some may be deposited on the obstruction as can be seen with one of the streamlines
coming into contact with the side of the obstruction in Figure 45. 
When a pathogen (or aerosolized particle) is inhaled there are four main means of
depositing  the  pathogen  on  the  respiratory  system  surface.   The  pathogen  can  be
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deposited gravitationally (sedimentation).  
If the pathogen is being transported within a curved streamline, such as from a
bronchiolar bifurcation angle, inertia of the pathogen during transport may not allow the
pathogen  to  follow  the  curved  streamline,  thereby  depositing  the  pathogen  on  the
respiratory system surface (Figure 21 a.).  The pathogen can also intercept the respiratory
system surface directly such as shown in Figure 21 b (an example of a particle impacting
the bifurcation angle).  Lastly the pathogen can also be affected by Brownian motion,
where the pathogen or particles collide which may lead to further collisions with other
Figure 20: Example of streamlines in a straight pipe
section, with cylindrical obstacle present 
Figure 19: Example of streamlines in a straight pipe
section, with no obstacle
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particles, or the respiratory system surface (McClellan and Henderson, 1995; Cai and Yu,
1988).  
The  processes  of  sedimentation  and  inertial  impaction  have  been  used  as  the
primary deposition mechanisms in the first stage stochastic model.  Since inhalation and
exhalation  develop  relatively  high  velocities  of  airflow,  Brownian  motion  can  be
considered negligible for particles and spore-forming pathogens such as B. anthracis with
a diameter of 1 µm or greater (Cai, and Yu, 1988; McClellan and Henderson, 1995).  Also
interception  is  considered  negligible  for  spherical  particles  in  the  low  micron  range
(1-4  µm), since this deposition method is more of a driving force for fibers and larger
particles (Cai and Yu, 1988; Chung  et  al.,  1996; Heyder  et  al.,  1986; McClellan and
Henderson, 1995).     
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Sedimentation  is  driven  by  the  terminal  settling  velocity  of  the  particle  or
pathogen.  The terminal settling velocity which is the maximum velocity a particle or
pathogen can travel  at,  due to gravity.   The Stoke's  settling velocity (equation 34) is
typically used in order to determine the terminal settling velocity (vts) which determines
the  gravitational  settling  rate  based  on  the,  fluid  density  (ρ), particle  density  (ρp),
acceleration due to gravity (g), area and volume of the particle (Ap and Vp respectively)
and the coefficient of drag (Cd) which is a function of Reynold's number (Re) shown in
equation 35, 36 and 37 for laminar transitional and turbulent flows respectively (Crowe et
al., 2001).  Bulk fluid flows through the respiratory system are typically laminar with a
Re ranging from 500 – 2000 throughout the respiratory system.
v ts= 2gC D⋅V pA p⋅ p−     (34)
C D=
24
Re
+
3
Re
+0.34          (36)
C D=
24
R e
                    (35)
C D=0.34 to0.40           (37)
If the function for determining the settling velocity shown in equation 36 is used
then an iterative solution must be implemented in order to determine that the value of CD
used  is  correct  (Crowe  et  al.,  2001;  Droste,  1997).   This  will  require  further
computational  time  when  executing  the  stochastic  model,  and  may  introduce  errors
should the iterative solution output an incorrect result.  An alternative is an approximation
developed for particles transported in air (equation 38) which is applicable for particles in
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with diameters up to 50 µm based on the aerodynamic particle diameter (dp) (Crowe et
al., 2001; Droste, 1997, Nicas and Sun, 2006).  
v ts=0.0018⋅d p
2 [1 + 0.166d p ]    (38)
In order to use the settling velocity, it must to be converted into the gravitational
sedimentation rate.  This is accomplished in equation 39, 40 and 41 for R1, R2 and R3
respectively, where the sedimentation rate is determined by dividing  vts by the distance
which the particle must travel while depositing.  If modeling a room then the distance is
typically the height of the room or in a pipe either the entire diameter of the pipe or
distance from the midpoint of the pipe (Crowe  et al., 2001; Droste, 1997).  For air the
diameter  of the pipe is  typically used and in this case the effective diameter of each
region (dR1, dR2 and dR3).  
R1s=
v ts
d R1
       (39) R2s=
v ts
d R2
      (40) R3s=
v ts
d R3
      (41)
There are methods of calculating the deposition fraction from inertial impaction
typically assuming Poiseuille flow conditions (Fletcher, 1992; Finlay, 2001).  However
typically these relations are only valid for particles up to 1 µm and have potentially high
uncertainty at the higher end of particle size (Fletcher, 1992; Finlay, 2001; McClellan and
Henderson, 1995).  The work of Heyder et al, 1986 has developed empirical models fitted
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to deposition data for human for deposition rates due to inertial impaction, which are
widely accepted (Gutting et al., 2008) and have been used in this work (Table 8).
Table 8: Deposition rates for inertial impaction and Brownian motion of inhaled
particles (Heyder et al., 1986)
Aerodynamic
Diameter of
Particle (µm)
Location of
Inertial
Impaction 
Rate of Deposition
from Impaction
and Diffusion
(min-1)
Associated Inertial and
Diffusion Deposition
Rate Symbol
1
Nasal cavity 0.0022 DIR1
Larynx 0.0000
Σ = DIR2
Main bronchi 0.0000
Bronchioles 0.0038 DIR3
2
Nasal cavity 0.0055 DIR1
Larynx 0.0000
Σ = DIR2
Main bronchi 0.0000
Bronchioles 0.0067 DIR3
3
Nasal cavity 0.0083 DIR1
Larynx 0.00017
Σ = DIR2
Main bronchi 0.00017
Bronchioles 0.0060 DIR3
4
Nasal cavity 0.0100 DIR1
Larynx 0.0005
Σ = DIR2
Main bronchi 0.0005
Bronchioles 0.0048 DIR3
Therefore as discussed the overall deposition of pathogens will be modeled using
the physics of sedimentation and inertial impaction.  This changes equations 39 through
41  in  order  to  include  the  deposition  for  both  inertial  impaction  and  sedimentation.
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Sedimentation is  still  of  a  concern despite  the vertical  (parallel  with  the  direction of
gravity) orientation of the overall structure of the respiratory system.  However with the
various bifurcations and arrangement of the bronchioles there are large sections where the
structure  of  the  bronchioles  are  perpendicular  with  the  direction  of  gravity  (when
standing or sitting upright) therefore sedimentation must included as well.  Therefore the
deposition loss rates which are used are shown in equations 42 through 44 for R1, R2 and
R3 respectively which will include the values for inertial impaction rate from Table 8.  
R1s=
v ts
d R1
+ DI R1 (42) R2s=
v ts
d R2
+ DI R2 (43) R3s=
v ts
d R3
+ DI R3 (44)
The estimates for the loss rates functional forms can be seen in Table 9.  Each of
these loss rates are used in the transition probabilities functions shown in equations 9
through  28.   This  allows  for  the  transition  probability  matrix  show  in  equation  29.
Estimates for the transition probabilities from the previously described functional forms
can be seen in Table 9.  
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Table 9: Loss rates from states in the Markov chain model
Loss Rate
Symbol
Loss From State Described Loss Rate Value (min-1)
λR 1-2 Pathogen transport from R1 to R2 2.789
λR 1s Deposition of pathogen in R1 1.126
λR 2-3 Pathogen transport from R2 to R3 2.252
λR 2-1 Pathogen transport from R2 to R1 0.0765
λR 2s Deposition of pathogen in R2 0.0765
λR 3-2 Pathogen transport from R3 to R2 6.713(10
-4)
λR 3s Deposition of pathogen in R3 0.00143
λdeath
* Death or loss of viability of pathogen 4.641(10-5)
λexh Pathogen exhaled to external
environment
0.011
*: Death rate assumed same for all compartments
Table 10: Point estimates of transition probabilities for the Markov matrix P
State
 umber
1 2 3 4 5 6 7 8
1 9.99(10-1) 1.93(10-7) 8.71(10-4) 0.00(100) 0.00(100) 0.00(100) 3.44(10-6) 0.00(100)
2 0.00(100) 1.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 3.44(10-6) 0.00(100)
3 3.52(10-4) 0.00(100) 9.99(10-1) 4.47(10-7) 7.03(10-4) 0.00(100) 3.44(10-6) 0.00(100)
4 0.00(100) 0.00(100) 0.00(100) 1.00(100) 0.00(100) 0.00(100) 3.44(10-6) 0.00(100)
5 0.00(100) 0.00(100) 2.39(10-5) 0.00(100) 1.00(100) 3.64(10-6) 3.44(10-6) 2.39(10-5)
6 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 1.00(100) 3.44(10-6) 0.00(100)
7 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 1.00(100) 0.00(100)
8 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 1.00(100)
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 3.5 Choosing the optimum time step for the Markov chain model
As has been discussed Markov chain models the amount of pathogens present in a
present state within some time interval [t, t + ∆t].  This means that at each time step the
Markov chain calculates the number of pathogens in each state.  This is performed for all
time steps by multiplying the P matrix by itself as many times as necessary in order to
reach the maximum time desired (such as modeling 1 hour of breathing).  
The determination of the optimum time step size is necessary in order for the
Markov chain to not be affected by the time step being too high.  Higher time steps (1
second time steps being higher than 0.1 seconds) may overlook intermediate results and
thereby not providing a proper numerical simulation of the transport and deposition of the
pathogens in the respiratory system.  
An initial time step of 0.0025 seconds was initially chosen for testing purposes in
order to ensure that the Markov chain model had been programmed properly.  Then the
time step (∆t) of 0.0025 seconds was halved in order to determine if these two ∆t values
provided results that were similar enough.  This was done qualitatively by viewing the
plots in Figure 22 and 23 for ∆t of 0.0025 and 0.00125 seconds respectively, and Figure
24 which is Figure 22 overlaid on Figure 23.
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Figure 22: Numerical simulation results using ∆t of 0.0025 seconds
Figure 23: Numerical simulation results using ∆t of 0.00125 seconds
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As can be seen in Figure 24 the simulation results for the two time steps do not
match especially at the higher times.  This dictated the decrease in time steps once again.
Starting from a ∆t of 0.00125 seconds the time steps were halved.  This was performed
until the results from the numerical simulations matched or came very close to matching.
This comparison was performed qualitatively since the plots are in log-scale on the y-axis
the difference in the plotted lines can be seen easily.  
The times steps  which eventually matched, where a  ∆t of 0.0003125 seconds,
which matched closely with a ∆t of 0.00015625 seconds.  Figures 25 and 26 shows the
numerical simulation results using a  ∆t of 0.0003125 seconds and a  ∆t of 0.00015625
seconds respectively.  An overlay plot of numerical simulation results for ∆t of 0.0003125
and 0.00015625 seconds showing a good match between the two time steps can be seen
in Figure 27.   
Figure 24: Numerical simulation results using ∆t values of 0.0025
seconds and 0.00125 seconds
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Figure 25: Numerical simulation results using ∆t of   0.0003125 seconds
Figure 26: Numerical simulation results using ∆t of 0.00015625 seconds
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As can be seen in Figure 27 the numerical simulations for a ∆t of 0.0003125 and
0.00015625 seconds are very close to each other.  The maximum degree of difference
between the two time steps being 70, 25 and 54 organisms for R1, R2 and R3 respectively.
This means that the optimum time step will be 0.0003125 seconds since making the time
step any lower would not affect the numerical simulation results.       
 3.6 Work towards a coupled model
As previously discussed the overall model that is developed in this thesis is a two-
stage model in order to capture all of the sinks in the respiratory system as well as the
pathogenesis of inhaled B. anthracis.  The Markov chain (stochastic) model is the first of
the two-stage model.  The second stage model is developed in the next chapter.
Figure 27: Numerical simulation results using ∆t values of 0.0003125 seconds
and 0.00015625 seconds
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The second stage will be a deterministic model that will describe the pathogenesis
of  inhaled  B.  anthracis spores.   The  stochastic  first  stage  serves  as  input  to  the
deterministic second stage.  This coupling will be where the results of the first stage will
be used as the initial concentration for the deterministic second stage.  The coupled model
will be single program coded in MATLAB.  The stochastic stage will simulate inhalation,
transport  and deposition of the spores that  will  provide the total number of available
spores to the deterministic model.  The coupling will take the number of organisms after
the stochastic stage has simulated one hour of breathing,  and provide this number of
spores to the deterministic model.  As mentioned previously the initial value will be a
concentration of spores, this will be determined by dividing the dose delivered to the
bronchioles by the volume of the bronchioles,  allowing for an initial concentration of
delivered spores.    
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 CHAPTER 4 : DEVELOPME T OF THE SECO D STAGE: A
DETERMI ISTIC MODEL FOR THE I TERACTIO  BETWEE  B.
A THRACIS A D ALVEOLAR MACROPHAGES I  THE LU G OF THE
HUMA  HOST
ABSTRACT
As has been discussed the main portions of the infection process can be split into
two main stages, the first stage being the transport and deposition of the pathogen to a
target location and the second stage being the pathogenesis process.  The pathogenesis
process is the main process(es) which are responsible for the development and replication
of the pathogen in the host's cells or tissues, and survival in the host.  Bacillus anthracis
(B. anthracis) compared to other inhaled pathogens has a very specific and dangerous
pathogenesis, which allows survival of the spores and development and growth of the
bacilli in the host.  Due to the associated toxins specifically the lethal factor toxin (LeTx)
when the alveolar macrophage uptakes the spores the inactivation of the spores by the
macrophage is limited.  Then the spores now exposed to an environment more conducive
to survival of the bacilli will germinate and the bacilli will then grow in the macrophage.
The processes for B. anthracis to be taken into the alveolar macrophage, inactivation and
germination  of  the  spores  in  the  macrophage  and  growth  of  the  bacilli  have  been
modeled.   This  second stage  model  is  a  deterministic  model  with  rate  constants  for;
uptake, germination, inactivation and growth of B. anthracis in alveolar macrophages. 
Keywords:   Bacillus  anthracis,  inhalation,  alveolar  macrophage,  pathogenesis,
deterministic modeling, mass balance.
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 4.1 Role of alveolar macrophages in the pathogenesis of B. anthracis
As discussed  previously,  the  Type  II  or  great  alveolar  pneumocytes  secrete  a
pulmonary surfactant which is released in order to reduce the surface tension of water and
allows for membrane separation.  The membrane separation allows for eased oxygen and
carbon dioxide transfer from the air in the alveoli to the bloodstream in the capillaries
(Weibel, 1963).  Due to the membrane separation, inhaled particles, chemical/radiological
contaminants and pathogens in the air can be allowed easy access to the bloodstream.
For this reason the alveoli must have a constant defense against inhaled contaminants.
The pathogenesis of  B. anthracis revolves around the alveolar macrophages for
germination  and  limited  growth.   Figure  28 shows  the  steps  of  pathogenesis  of  B.
anthracis following the deposition, uptake, germination and limited growth.  As will be
discussed  further  in  section 4.1.1  the  growth  is  limited  by  the  reduced  lifespan  of
macrophage  in  the  presence  of  the  toxin  proteins  associated  with  B.  anthracis,
specifically the lethal factor toxin.   
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Macrophages are leukocytes (white blood cells), which are also known as natural
killer cells, since the sole purpose of these cells is to destroy foreign materials which
enter the host.  Alveolar macrophages are as the name suggests, macrophages located in
the alveoli of the lung.  They serve as a barrier between inhaled foreign materials entering
the lungs and the surface of the alveoli.  The alveolar macrophages are located on the
surface of the alveoli and engage in a process known as phagocytosis.  In this process, the
macrophages  take up and destroy inhaled contaminants (i.e. particles  and pathogens).
The pathogenesis of inhaled  B. anthracis, occurs via this phagocytosis process (Burke
and Lewis, 2002; Haleston and Curry, 1996; Weibel, 1963).
Phagocytosis (Figure  29) is a set of processes working in series where foreign
Figure 28: Pathogenesis of B. anthracis
showing deposition (A.), uptake (B.),
germination and limited growth (C.)
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particles such as a B. anthracis spores are destroyed by a phagocyte (cell which uptakes
and  destroys  foreign  material,  specifically in  this  case  a  macrophage).   Phagocytosis
begins when the foreign material comes into contact with the surface of the phagocyte's
receptors.   The  phagocyte  then  extends  its  membrane  around  the  spore  engulfing  it,
thereby using the first of the series of processes in phagocytosis, the uptake of the spore.
Once  inside  the  phagocyte  the second  process  in  phagocytosis  is  where the  spore  is
engulfed in a  compartment which is partially made up of the phagocyte's  membrane,
which is now termed the phagosome, this isolates the spore(s) and prepares it for the next
process.  The phagosome then comes in contact with a lysosome or a digestive enzyme
granule (more typically a lysosome).  The next process is when the lysosome fuses with
the  phagosome  developing  a  phagolysosome,  the  phagolysosome  then  begins  to
breakdown the phagosome.  This thereby destroys the spore, digesting the phagosome
gaining energy and generating waste material (Hampton et al., 1994). 
The macrophage is an aggressive phagocyte in that it will engulf large quantities
of contaminants.  This is since the macrophage does not rely on the receptor's recognition
of antigens when contacting the pathogens, since the macrophage also must uptake and
destroy  particles  as  well  as  chemical  and  radiological  contaminants.   However
macrophages act more slowly than other phagocytes such as neutrophils (entire process
taking typically on the order of hours rather than minutes) and do not process the foreign
material completely (Hampton  et al., 1994; Hasleton and Curry, 1996).  Macrophages
have been documented ingesting and initially processing bacteria, but occasionally live
bacteria are expelled in the waste material (Hampton  et al., 1994, Hasleton and Curry,
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1996).  This typically allows for monocytes (divides into either a macrophage or dendritic
cell) to be delivered to the macrophage's location that continues the protection, but an
aggressively  growing  and  robust  bacteria  such  as  B.  anthracis  can  gain  from  this
potentially advantageous scenario.     
The longer amount  of time that  the macrophage takes to progress through the
phagocytosis  process  is  also  advantageous  to  the  pathogenesis  of  B.  anthracis.
Associated with  B. anthracis and the spores are the toxin proteins associated with the
spores and vegetative cells.  The toxin proteins block phagosome-lysosome fusion and
slow or stop the destruction of the spores and vegetative cells within the macrophage.  
 4.1.1 Role of toxins in the subversion and lysis of alveolar macrophages
The toxin proteins comprise the means of subverting the host immune defenses
such as slowing or halting the phagocytosis process, and blocking interactions with other
immune particles and assist in degrading the health the host.  The three toxin proteins are
Figure 29: Depiction of the phagocytosis process
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the lethal  factor,  the oedema factor  and the protective antigen.   The  combinations of
proteins  produce  two  exotoxins  which  are  the  toxins  exacting  the  damage  to  the
macrophage and host (Dixon et al., 2000).
The lethal factor (LeTx) is the combination of the lethal toxin with protective
antigen (Dixon et al, 2000; Kimpel et al, 1994; Duesbery et al., 1998; Vitale et al., 1998).
In addition to degradation of the health of the host, LeTx interferes with the functioning
of the macrophage and eventually causes lysis of the macrophage within 2-6 hours after
exposure to LeTx (Dixon  et al, 2000; Kimpel  et al, 1994; Duesbery et al., 1998).  As
discussed earlier, the macrophage, unlike other leukocytes, takes a larger amount of time
in  order  to  perform  phagocytosis  (on  the  order  of  hours  rather  than  minutes  for
neutrophiles) (Hampton et al., 1994).  The combination of the larger amount of time for
the macrophage to complete the phagocytosis processes,  combined with the ability of
LeTx to block the lysosome-phagosome fusion, results in the macrophage becoming a
susceptible location for attack by inhaled B. anthracis.  
As discussed earlier, B. anthracis spores protect the organism from environmental
stress,  and  the  spores  will  not  germinate  into  vegetative  cells  until  a  conducive
environment  is  encountered  (Hedlund,  1988;  Wilson  et  al.,  2002).   The  internal
environment of the human host (specifically the blood) as well as the macrophage are
conducive  environments  for  vegetative  cell  survival  and  growth  (Burke  and  Lewis,
2002).   Since  LeTx  is  capable  of  blocking  the  lysosome-phagosome fusion,  thereby
reducing  or  eliminating  the  ability  of  the  macrophage  to  destroy  the  spores,  the
macrophage is also an ideal location for cell growth (Hedlund, 1988).  
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The macrophage is not devoid of the ability to destroy the spores and vegetative
cells,  despite this  ability being severely limited by the presence of  LeTx.   Since the
macrophage provides a moist warm environment with high concentration of electrolytic
compounds, the spores germinate readily and quickly.  Once the spores have germinated
the vegetative cells are also encountering an environment conducive to growth, therefore,
growth of the vegetative cells commences (Dixon et al., 2000; Guidi-Rontai, 2002).
As  has  been  shown,  the  cells  that  protect  the  host  from pathogens  and  other
inhaled contaminants  also provide an environment  which  allows for  germination and
growth of  B. anthracis.  The means modeling the pathogenesis of inhalational anthrax
more straightforward, with the internal environment of the macrophage being the main
system to be modeled.  Since the pathogenesis for inhalational anthrax is at a single target
location,  namely  the  alveoli  and  more  specifically  a  target  cell  in  the  alveolar
macrophages, with highly structured processes for uptake, germination and growth of B.
anthracis a descriptive model can be developed.
 4.2 Processes and systems modeled in the deterministic second stage
 4.2.1 Processes being modeled in the deterministic second stage
In order to model the pathogenesis of B. anthracis the main steps in the process
must be modeled.  Since the main portion of the pathogenesis process is phagocytosis this
is the process which will receive the focus.  As mentioned previously  The additional
aspects  of  B.  anthracis pathogenesis  include  the  macrophage(s),  which  are  motile,
transport  to the local  lymph vessels in order to initiate an acquired immune response
using the lymphatic system (Guidi-Rontani et al., 2002; Gutting et al., 2008).  However
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the transport of alveolar macrophages to the lymphatic system would include additional
factors that will complicate the model.  These complicating factors are not particularly
necessary since  the  germination  of  spores  and  growth  of  vegetative  cells  within  the
alveolar  macrophages,  and  the  eventual  lysis  of  the  macrophage  are  the  important
processes in the pathogenesis of B. anthracis (Guidi-Rontani et al., 2002; Hedlund, 1988;
Wilson et al., 2002).
As discussed earlier and depicted in Figure  28 the pathogenesis process begins
with the deposition of the spores on the surface of the macrophage.  Macrophages have
the ability to extend pseudopods, which are temporary extensions of a eukaryotic cell for
uptake of potential energy sources(Burke and Lewis, 2002; Huynh and Grinstein, 2006).
However, this ability is neglected since it would include a potentially complicating factor
into the model for a process which is not necessary to include.  Also since the uptake
process is rapid compared to the response time for development and use of pseudopods,
this ability can be ignored (Grinstein, 2006).  The deposition rate will be included into the
overall model, however, this rate will not require fitting via an optimization routine, since
it is available from prior work (Balásházy et al., 2008).  
Next, the macrophage engulfs and surrounds the spores in order to destroy them,
gaining energy and evacuating the waste material derived from the process.  This process
of  uptake  will  be  modeled  as  a  mass  transfer  process  across  the  macrophage  cell
membrane.   The  uptake  rate  will  be  fitted  to  data  of  spore  uptake  by  alveolar
macrophages (Hu et al., 2006)   
The spore must then germinate while avoiding inactivation by the macrophage.
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Both of these processes, as has been discussed, are due to the presence of LeTx.  The rate
of inactivation will be fitted using available data from studies with alveolar macrophages
(Hu et al., 2006), while the germination rate is given from previous work (Hanna et al.,
1993).  
Once the spores have germinated, vegetative  B.anthracis cells are now present
and available to grow within the alveolar macrophage.  While the vegetative cells can
grow  there  is  the  ability  for  the  macrophage  to  kill  these  cells  as  well,  until  the
macrophage is lysed.  These two processes will be modeled as well, with the growth rate
being fitted to available data of growth of vegetative cells within alveolar macrophages
(Hu et al., 2006), while the decay rate is available from prior work (Kang et al., 2005).
 4.2.2 Systems being modeled in the deterministic second stage
The  deterministic  second  stage  describes  those  systems  that  govern  the
pathogenesis processes of  B. anthracis.   Figure  30 shows the first of the systems that
need to be considered.   The first  stage models the transport  and deposition up to the
acinus,  or  the entrance to the alveolus.   Therefore,  this initial  system must  take into
account the volumetric tidal flow rate of air into the alveolus,  Q, the concentration of
spores outside of the acinus in the bulk fluid,  bronc (have not been transported into the
alveolus yet) and the concentration of spores which have passed through the acinus and
are now present in the bulk fluid within the alveolus, alv.     
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The next system that must be modeled is the interaction between the B. anthracis
spores and alveolar macrophages (Figure 31).  In this system the spores must deposit on
the outer membrane of the macrophage thereby being removed from bulk fluid in the
alveolus.  The spores must then be taken into the macrophage, by the process of uptake,
and then once inside the macrophage can either germinate or become inactivated (loss of
viability).  There exist four state variables in this system which must be modeled:
• Concentration of spores deposited on the surface of the macrophage (x)
• Concentration of spores taken into the macrophage (m)
• Concentration of spores inactivated in the macrophage (mi)
Figure 30: System diagram for spores
transported with the bulk fluid into the alveolus
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• Concentration of vegetative cells due to germination and growth (v)
From the system diagrams the state variables for the model have been determined.
Now the model to describe the relation between these state variables must be developed
for  a  numerical  solution  that  will  describe  the  pathogenesis  of  inhaled  B.  anthracis
spores.  Therefore the form of the model must be established and any constant parameters
which are necessary must be determined.   
 4.3 Derivation of the mass balance for the deterministic second stage
The model  to  depict  the interaction  between  B.  anthracis spores  and  alveolar
macrophages  must  take  into  account  the  mechanisms  involved  in  the  pathogenesis
processes.  The intermediate processes (deposition, uptake, inactivation, germination and
growth) depend on each other for the overall pathogenesis process to occur.  This means
that  without the spores being deposited on the  surface of  the macrophage the spores
cannot be taken into the macrophage, and without being taken into the macrophage the
spores  cannot  germinate  be inactivated,  thereby allowing vegetative  cells  to  grow or
decay in the macrophage.  
The second stage model will be tracking the amount of spores interacting with the
alveolar  macrophage,  and  the  vegetative  cells  developing  and  growing  within  the
macrophage.   Therefore  the  second  stage  model  will  require  construction  as  a  mass
balance.  This interdependence of intermediate processes means that a mass balance of
inhaled spores and vegetative cells will model these mechanisms.  The initial condition of
the mass balance being; when time is zero all concentrations are zero, bounded that when
time is greater than zero the concentrations are some value.  The mass balance will take
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into account the concentration of spores available to be inhaled into the alveolus during
inhalation (bronc) and therefore the concentration of spores in the bulk fluid inside the
alveolus (alv) in order to determine the concentration of spores deposited on the surface
of the alveolar macrophage (x)  based on a deposition rate  for  particles in the human
alveoli (kdep).  The spores which have deposited can be taken into the macrophage which
determines  the  concentration  of  spores  inside  the  alveolar  macrophage  (m)  which  is
governed  by  the  uptake  rate  constant(kup).   Once  spores  have  been  taken  into  the
macrophage  they  can  either  be  inactivated  thereby  producing  inactivated  spores  (mi)
governed by the inactivation rate constant (kina), or can be germinated governed by the
germination rate (kger), thus generating a concentration of vegetative cells (v).  Two more
mechanisms affect v, being the kinetics of cell growth and decay, governed by the growth
and  decay  rate  constants  (kgrow and  kdecay respectively).   The  set  of  mass  balances
constructed in order to take into account these state variables and constant parameters can
be seen in equation 45.  The volumetric flow rate (Q) initial concentration of spores (Cin)
volumes of the bronchioles (Vbronc) and alveoli (Valv) as well as the area of the alveolar
macrophage (Aam).    
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d bronc
dt
⋅V bronc=Q⋅C in−Q⋅ bronc +Q⋅ alv
d alv
dt
⋅V ao=Q⋅ bronc−Q⋅ alv− alv⋅kdep
dx
dt
= alv⋅k dep− x⋅k up
dm
dt
⋅V am= alv⋅k dep - x⋅k up ⋅Aam−k ger⋅m⋅V am−k ina⋅m⋅Vam
dmi
dt
V am=k ina⋅m⋅V am
dv
dt
⋅V am=k ger⋅m⋅V am + k grow⋅v⋅V am−kdecay⋅v⋅V am
         (45)
 4.4 Overview of numerical solutions to ordinary differential equations
As can be seen from the system in equation 45, the mass balance constructed is in
the form of a system of coupled ordinary differential equations (CSODE).  A CSODE is a
system of ordinary differential equations (ODEs) where the determination of one state
variable is dependent on the solution of another.  As can be seen in the simple example in
equation  46  in  order  to  determine  x1, x2 must  be  known,  this  dependence  defines  a
CSODE.   
dx1
dt
=x1 + 2x2
dx2
dt
=2x1−2x2
         (46)
There are two main approaches to solve differential equations (DE), an analytical
solution which is a closed form expression in terms of known functions (such as series,
limits, etc.).  There are also numerical solutions to DEs, which if a solution exists, rather
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than being represented by mathematical symbols and known functions, it is represented
as the numerical sequence of values of the state variables over time.  There are benefits
and  drawbacks  to  both  methods,  however,  for  complex  systems  (more  than  four
equations)  such as  is  the case of  the CSODE in equation 45 numerical  solutions are
typically more reliable and provide more information (Kreyszig, 1999; Zill, 2001).  
There are a number of methods of numerical solutions, however, there exists two
that  are  considered most  appropriate,  based on past  success  and  proof  of  robustness,
being the Euler and Runge Kutta methods (Ascher and Petzold, 1998).  The Euler method
is, like all numerical solutions prone to round-off errors, but specifically for the Euler
method experiences  truncation errors,  because  the  Euler  method  gives  a  straight  line
approximation  to  the  solution (Ascher  and  Petzold,  1998;  Zill,  2001).    The  explicit
fourth-order Runge Kutta method is considered a better choice and therefore especially in
MATLAB is the numerical solution method of choice.  
The explicit fourth-order Runge Kutta method is the algorithm used here.  This
algorithm is available in MATLAB for numerical  solutions of both stiff  and non-stiff
ODEs.  The fourth-order Runge-Kutta method chooses constants that are appropriate so
that the specified formula agrees with a 4-degree Taylor polynomial. 
 4.5 Optimization of parameters of the deterministic second stage
The mass balance model shown in equation 45 has six parameters (kdep, kup, kger,
kina, kgrow and kdecay).  Estimating some of the parameters from information available in the
open literature will reduce the uncertainty of estimating the remaining parameters by least
square fitting (Holzbecher, 2007; Zill, 2001), thereby, not requiring optimization.
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 4.5.1 Model parameters obtained from open literature
There are three known parameters that are available from the open literature.  As
has been discussed previously there has been a large amount of work determining the
deposition of particles in the respiratory system.  This allows for being able to draw the
deposition rate from the open literature (Heyder et al., 1986).  The difficulty on using just
this deposition rate, is that this is for deposition over the entirety of the alveolus.  The
deposition rate which is required is for alveolar macrophages.  The deposition rate from
Heyder et al., (1986) is multiplied by the ratio of the volumes of the alveolus and fifteen
alveolar macrophages (average number of alveolar macrophages, present in the alveolus
(Wallace  et al., 1992)).  This allows for a deposition rate of 0.0011  µm2 min-1 which is
specific to deposition of 1 µm particles depositing on alveolar macrophages.  Again the
use of pseudopods by the macrophage to engulf the spores on the alveolar surface is
being neglected for simplification.    
Prior work on on modeling the incubation time of B. anthracis has developed an
estimation  of  the  germination  rate  (Brookmeyer  et  al.,  2005).   From  the  work  of
Brookmeyer  et al., (2005) a rate of germination (units of min-1) was developed for the
purposes  of  modeling  the  incubation  period  of  inhaled  B.  anthracis spores.   The
germination rate of 0.005/min-1 was fit to available experimental data (Barnes, 1974) by
Brookmeyer et al., (2005).   
The decay rate is the last of the known parameter values.  Work by Kang et al.,
(2005) used the vegetative cell  form of the Sterne strain of  B. anthracis to inoculate
alveolar macrophages.  The concentration of the vegetative cells were measured every
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two hours up to twelve hours.  Then a first order decay rate was fitted to this data, which
is  used  in  this  work.   The  fitted  decay  rate  of  0.236  min-1 describes  the  decay  of
vegetative cells within the alveolar macrophages.    
 4.5.2 Model parameters requiring fitting
The remaining parameters (kup, kina and kgrow) require fitting to available data, since
these have not been fitted or modeled previously.  This will be performed by numerically
solving the CSODE shown in equation 45, using the fourth-order Runge Kutta method,
and optimizing (minimizing) the log of the sum of squared errors.  Equation 47 shows the
sum of squared errors (SSE) where; a dataset having  i indices (number of data points)
with the ith predicted value (ith model output) has the expected or known value from the
data at that ith index (time when the ith value is recorded), squared and summed over all
index values.  The logarithm (natural logarithm) of the sum of squared error, is taken so
that different sample sizes will not affect the fit of the model to the data.      
∑
i=1
n
 y i−y 
2
                                                     (47)
 4.5.3 Available data for fitting model parameters
The data available for growth, uptake and inactivation rate fitting was determined
for the Sterne strain of B. anthracis in murine (mouse) alveolar macrophages and all from
the  same  study  (Hu  et  al.,  2006).   The  Sterne  strain  despite  having  lost  one  of  its
virulence factors (pX01 plasmid) still  has LeTx (lethal  factor toxin) present which as
reviewed earlier allows the spores to germinate within the macrophage, and contributes to
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eventual macrophage lysis, which are the most important factors for this model of the
pathogenesis (Guidi-Rontani, et al., 1999; Hu et al., 2006).  
The  growth  of  the  Sterne  strain  in  human  alveolar  macrophages  has  been
demonstrated  in  prior  work  (Guidi-Rontani,  1999;  Ruthel  et  al.,  2004),  however,  the
quantitative data from these studies are unavailable.  Therefore data available for growth,
uptake and inactivation using murine macrophages has been used.  
An inside/outside differential staining protocol (Chen et al., 1996) was utilized by
Hu  et  al.,  (2006)  to  determine  the  amount  of  spores  taken  into  the  macrophage,
inactivated and grown within the macrophage.  Using a rhodamine-labeled phalloidin,
which then requires and examination under a fluorescence microscope the spores within
and outside the macrophage fluoresce with different colors, allowing for determination of
uptake.  This protocol also allows for determination of inactivated spores, since spores
introduced to the macrophage (not through uptake) being stained remain one florescent
color, while those inactivated by lysosomal action will change florescent color.  The same
is true for cells introduced to the macrophage, new cell growth differ in color compared
to those the macrophage was inoculated with under florescent microscopy.         
For the determination of growth of vegetative cells, macrophages were inoculated
with 500 stained vegetative cells of the Sterne strain.  Florescent microscopy was used to
monitor the growth of bacteria at 15. 30, 60 and 120 minutes post inoculation.  The data
gathered shown in Table  11 is the percent increase from the prior time, starting at zero
percent increase when time was zero.  
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Table 11: Growth rate data for vegetative cells inside
macrophages (Hu et al., 2006)
Time Interval Post
Inoculation (minutes)
Percent Increase of
Grown Vegetative Cells
15 30.2
30 15.3
60 8.8
120 3.8
Uptake was also determined using the inside/outside differential staining protocol
from Chen et al., (1996).  Hu et al., (2006) coated macrophages with 500 spores using the
differential staining protocol to monitor for spores taken into the macrophage on 2 hour
intervals using florescent microscopy.  The data presented by Hu et al., (2006) was in the
form of percent increase of spores taken into the macrophage from the prior time, starting
at zero percent increase for a time of zero (time of macrophage exposure) shown in Table
12. 
Table 12: Uptake rate data for spores deposited on
macrophage surfaces (Hu et al., 2006)
Time (hours)
Percent Increase of Spore
Uptake by Macrophage
2 34.2
4 20.6
6 16.8
8 11.4
10 14.4
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The data available for fitting an inactivation rate were gathered using the same
methods  as  those  for  growth  of  vegetative  cells.   Viable  spores  were  introduced  to
macrophages in a presence of D-alanine in order to inhibit germination of the spores so
that inactivation would be the only means of the spore changing stain color.  The data
shown in Table 13 shows the results from the inactivation experiments Hu et al., (2006).
The data is in the format of percent increase of killed spores from the the prior time,
again starting at zero percent increase at time zero.
Table 13: Inactivation rate data for macrophages
inoculated with spores (Hu et al., 2006)
Time Post
Inoculation (hours)
Percent Increase of Killed
Spores in the Macrophage
2 65.3
4 55.3
6 37.8
 4.5.4 Overview of optimized model parameters and their fit
 4.5.4.1 Choosing the best algorithm and optimization routine in MATLAB
There are a number of options and algorithms (finite sequence of instructions) to
choose from for an optimization routine.  MATLAB has a large selection of optimizers
and algorithms to choose from as well (as compared to other programming packages such
as  R).   In  choosing an optimizer  one must consider the workings of  an optimizer  in
general.   An optimizer  chooses  values  of  parameter(s)  starting  from an  initial  guess
dictated by the user, and depending on the algorithm used performs the instructions in the
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algorithm to optimize (minimize or maximize) the target function (i.e. likelihood, SSE,
etc.).  
The fminunc optimization routine in MATLAB has been used to optimized the log
of the SSE.  The fminunc optimizer is an unconstrained optimizer, this is important since
a constrained optimizer as the name implies uses constraints on the solution (such as
known upper level of the parameter(s)).  A unconstrained optimizer has greater freedom
to find parameter(s) which produce the optimum solution for the objective function.  The
fminunc uses the Hessian matrix in order to optimize the function defined, in this case the
log of sum of squared errors.
 4.5.4.2 Optimization and fit of model parameters
The CSODE from equation 48 was programmed into a MATLAB function file
with a stiff ODE solver (ode15s) so that the CSODE can be accessed reliably by the ODE
solver.  If the eigenvalues of an equation are not constant throughout each time step of the
integration then stability issues may arise in the solution.  A stiff ODE solver was chosen,
because of the model in equation 45 is an initial value problem, that may be affected by
speed of convergence.  The number of parameters and variables may allow for stability
concerns and loss of accuracy if too large of step sizes in the Runge Kutta method are
used.  A stiff solver uses as few steps as possible to obtain convergence in order to reduce
noise in the solution which can affect the optimization, and can have the step size fixed
by the user or left variable by the solver (Desch et al., 1998).  
The  solver  and  CSODE from equation 48  are  embedded  in  a  function m-file
which also determines the log of SSE.  Since the log of the SSE is the target function the
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function m-file containing the log of the SSE as well as the ODE solver and the CSODE
is  the  target  function  for  the  optimizer.   These  are  written  as  embedded  function  to
increase  the  ability  of  the  functions  to  communicate  with  each  other  more  reliably,
increase  computational  speed  and  to  decrease  the  memory requirements  (Holzbecher,
2007).   The  optimizer  starts  running  with  the  parameter  values  equal  to  the  initial
guesses,  the  access  the  Nelder-Mead  algorithm to  find  the  optimum parameters  that
minimize the log of the SSE.
The results of running the optimization routine can be seen in Table 12.  Table 12
shows the optimized parameters (kup,  kina, and kgrow).  Figures 32, 33 and 34 show the fit
the  model  takes  to  the  data  given  the  optimized  parameters  for  growth,  uptake  and
inactivation respectively.  The model has a good fit to the data with a log of the SSE of
-9.98 that corresponds to a 0.0046 percent difference between the modeled and measured
points, and the plots in Figures 32 through 34 show this graphically.  
Table 14: Parameter best estimates from the optimization routine
Parameter Best Estimate from Optimizer
kgrow 0.2354 min
-1
kup 1.0868 µm min
-1
kina 1.1808 min
-1
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Figure 33: Plot depicting the fit of uptake data to the fitted model
Figure 32: Plot depicting the fit of growth rate data to the fitted model
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A  form  of  rechecking  on  the  goodness  of  the  parameter  estimates  after
optimization is to examine the dispersion of the parameters.  If there is an unexpected
distribution to the residuals (other than normal) then knowledge of this distribution is
necessary (Desch et al., 1998).  A method of examining the dispersion of the parameters
is to compute the variance matrix of the parameters from the optimization.  This is simply
the inverse of the Hessian matrix (equation 48).  The Hessian matrix which is calculated
as part of the fminunc execution (Table 15) determines the local curvature of a function
having many variables by taking the second-order partial derivative of the function (f)
with respect to the nth argument (x1, x2, …, xn).  In reading the Hessian matrix essentially
the  inactivation  rate  parameter  causes  inflection  points  in  the  optimization  since  the
derivatives are zero unless the inactivation parameter is being compared to itself.      
Figure 34: Plot depicting the fit of inactivation data to the fitted model
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∂2 f
∂ x1∂ x2
⋯
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∂ x2
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⋯
∂2 f
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∂ xn∂ x1
∂2 f
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⋯
∂2 f
∂ xn
2
]                           (48)
The inverse of the Hessian matrix gives the variance matrix (Table 16) which is a
good descriptor of the dispersion of the parameter estimates (Nash and Smith, 1987).
The diagonal of the variance matrix should be close to one and the other entries should be
close to zero, in order to signify low dispersion of the parameter estimates (Desch et al.,
1998). 
Table 15: Hessian matrix outputted from completion of optimization
kup kina kgrow
kup 1.3284 0.0 -0.3974
kina 0.0 1.38924833 0.0
kgrow -0.3974 0.0 1.5123
Table 16: Variance matrix describing low diffusion of parameter estimates
kup kina kgrow
kup 0.8169 0.0 0.2147
kina 0.0 0.7198 0.0
kgrow 0.2146 0.0 0.7176
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The residuals need to be examined next, to determine if the residuals follow an
unexpected  distribution.   The  residuals  are  expected  to  follow a  normal  distribution
therefore the residuals from the optimization must be compared to a normal distribution
to  determine  if  they follow this  or  if  further  analyses  are  required  to  determine  the
unknown distribution they may follow.  This can be determined by developing normal
probability plots as shown in Figures 35,  36 and 37 for growth, uptake and inactivation
residuals respectively.  The residuals are determined while the optimization is performed
in order to capture all of the residuals (modeled value subtracted from the known value
from the data).  As can be seen in Figures 35 through 37 the residuals are very close to
the 45º angle line.  The 45º angle line is a perfect match to a normal distribution.  The
closer the residuals group on or to the line the closer to a normal distribution of the
residuals is obtained.  Based on these normal probability plots, further analyses of the
residuals is not necessary.      
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Figure 35: Normal probability plot of the residuals from the growth rate fit to data
Figure 36: Normal probability plot of the residuals from the uptake rate fit to the data
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 4.6 Future work towards a coupled two-stage model
As discussed previously,  since the infection process is comprised of two main
stages, transport  to a sensitive location and then the pathogenesis process,  the overall
model will be in two-stages as well.  The first stage as discussed earlier is the stochastic
model that will determine the amount of spores delivered to a sensitive location, being
the alveoli in the case of inhaled  B. anthracis spores.  The second stage has just been
discussed in the current chapter, where the pathogenesis of inhaled  B. anthracis spores
has been modeled deterministically.  In order to develop a model that takes both of these
into account the models must be coupled together in order to develop the modifications to
the dose to take into account both bulk fluid transport and the pathogenesis of inhaled B.
anthracis spores. 
This coupling will take the form of a large MATLAB function m-file, which will
execute  both  models.   The  first  stage  will  model  the  dose  delivered  to  the  terminal
Figure 37: Normal probability plot of the residuals from the inactivation rate fit to
the data
111
bronchioles  (outside  the  acinus)  after  one-hour  of  breathing.   This  estimation  of  the
delivered dose will be converted to a concentration outside of the acinus and used as the
initial concentration available for transport into the alveolus through the acinus (Cin in
equation 45).  The deterministic second stage will then execute and model the interaction
between B. anthracis and alveolar macrophages.  
Both  the  estimation  of  the  delivered  dose  and  the  pathogen  burden  will  be
compared to a current dose response data set available for rhesus monkeys, where the
dose response relationship has already been modeled using exposed dose.  Any benefits
in the fit of the exponential and beta Poisson dose response models to the data using the
modifications to the dose will be determined.       
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 CHAPTER 5 :   COUPLI G OF A TWO STAGE MODEL OF B ATHRACIS
TRA SPORT A D PATHOGE ESIS FOR THE ESTIMATIO  OF
PATHOGE  BURDE .
ABSTRACT
The overall infection process can be divided into two stages.  The first stage is the
transport and deposition of the pathogen to a sensitive location, which is the alveoli for
Bacillus  anthracis (B.  anthracis).   The  second  stage involves  the pathogenesis  of  B.
anthracis which  the  main  and  most  important  portion  is  the  interaction  between  B.
anthracis and alveolar  macrophages.   The coupling of  the two models allows for  an
overall model which can describe the infection process in both stages.  The affect of the
first stage, which estimates the delivered dose, on a test set of dose response data for
aerosol exposure is also discussed where the first stage has an effect on the exponential
and beta Poisson dose response model parameters, thereby allowing for an estimate of the
risk taking into account the delivered dose.  The coupled model results where the results
of the first stage are used to determine the initial concentration value for the second stage.
This coupled model, which determines the pathogen burden in the host also improved the
fit of the test dose response data for both the exponential and beta Poisson dose response
models.  This shows that the framework developed with a two stage model for modeling
the infection of inhaled B. anthracis affects the modeled dose response relationship, by
developing dose response parameters specific to pathogen burden.  In showing that this
framework has been able to develop dose response parameters specific to delivered dose
or pathogen burden the framework can be expanded further.   This framework can be
expanded  for  other  inhaled  pathogens  and  to  other  pathogens  such  as  waterborne
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pathogens which have a different exposure route.  
Keywords:   Bacillus  anthracis,  infection,  inhalation,  bioterrorism,  dose  response,
QMRA,  
 5.1 Review of the two-stage modeling framework
As discussed previously the infection process for Bacillus anthracis (B. anthracis)
is composed of two stages.  The first stage is the transport of the B. anthracis spores to
the alveoli, which is the sensitive location for development of the infection.  The second
stage is when the spores deposit in the alveoli where the infection process proceeds.  A
model that can depict the overall infection process must take into account both of these
stages.      
A  two  stage  approach  for  modeling  infection  dynamics  of  Salmonella
typhimurium (S. typhimurium) was developed in order to take into account heterogeneous
responses from homogeneous doses (Meynell and Maw, 1968).  This framework takes
into account the exposure and growth of S. typhimurium .  The work of Meynell and Maw
(1968) looked to answer why a heterogeneous response is observed from homogeneous
exposures.  They concluded that a two stage model of infection, which could account for
transport and replication of S. typhimurium after ingestion was capable of accounting for
the heterogeneous response from a homogeneous exposure.  The same strategy has also
been used in this work, in modeling a dose response relationship using the exposed dose
assumes a homogeneous dose.  The two stage model will alter this homogeneous dose to
a heterogeneous one which can better describe the delivered dose which affects the host.
The  first  stage  will  model  the  transport  of  B.  anthracis spores  through  the
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respiratory system.  This first stage has been developed as a stochastic model in order to
be able to account for the stochastic nature of a small number of spores being transported
in  the  bulk  fluid.   Therefore  the  stochastic  model  will  function  more  reliably  and
accurately with low numbers of spores, rather than a deterministic model which may not
adequately  describe  the  stochastic  variability  associated  with  low numbers  of  spores
(Baas et al., 2009; Ross, 2007).
The second stage will model the primary components of the pathogenesis of  B.
anthracis.  This stage will model the deposition of the spores on alveolar macrophages,
uptake, inactivation and germination of spores within the alveolar macrophages and the
growth and decay of B. anthracis vegetative cells within the alveolar macrophages.  With
this  stage  being  spatially  constrained  to  very  small  regions  (alveolus  and  alveolar
macrophages) the internal noise of a deterministic solution due to the stochastic nature of
modeling  small  amounts  of  spores  and  organisms  should  be  held  to  a  minimum
(Loettgers,  2007).   Therefore  the  second  stage  can  and  has  been  established  as  a
deterministic model.   
The two stages are coupled together when the results of the stochastic stage are
used  as  the  initial  concentration  values  for  the  deterministic  stage.   For  illustration
purposes Figure 38 shows the coupling of the two stages.  The results of the first stage,
specifically the dose in the bulk fluid in the respiratory bronchioles at the final time step,
when the stochastic model finishes will be used to determine the initial concentration for
the deterministic model.   
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 5.2 Overview of the stochastic first stage
As  discussed  previously  the  first  stage  of  the  coupled  model  will  model  the
physics of bulk fluid transport and deposition of inhaled spores.  As introduced earlier a
model of the bulk fluid transport and deposition of inhaled spores taking into account the
entire internal structure of the respiratory system is infeasible.  Therefore a simplification
must be made to the respiratory system in order to develop a model of the bulk fluid
transport  and  deposition  of  inhaled  spores.   Table  17 shows  the  three  region  model
developed for improved dosimetry for radiological risk assessment (Morrow et al., 1966).
The  three  region  model  was  developed  as  a  simplification  of  the  human respiratory
system based on the gross physiology of the human respiratory system. 
Table 17: Three region model of the human respiratory system (Morrow et al., 1966)
Included Anatomical Structures
Region
 umber
Region
Symbol
Region  ame
Nares, nasal cavity, oral cavity, nasopharynx,
laryngopharynx, larynx
1 R1 Nasopharynx
Trachea, bronchi, first branches of bronchioles 2 R2 Trachiobronchial
Respiratory bronchioles, acinus, alveolar sacs 3 R3 Pulmonary
Figure 38: Graphic depicting the coupling of the two stages together
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The  simplification  of  the  respiratory  system  allows  for  straightforward
construction of a stochastic model.  A Markov chain model (Markov model) has been
used for  the stochastic  model.   A Markov model is  a  method of stochastic modeling
which uses rates of loss of spores from each of the states.  Table 18 shows the eight states
of the Markov model where losses of spores from each of these states will be predicted
based on the transport and deposition physics of inhaled particles.    
Table 18: Eight states defined of the Markov chain model for the first stage
State  umber Description
1 Air in R1
2 Respiratory system surface in R1
3 Air in R2
4 Respiratory system surface in R2
5 Air in R3
6 Respiratory system surface in R3
7
Death  or  loss  of  viability  of  the  pathogen
during transport, and during or after deposition
8
Removal of pathogen from respiratory system
via exhalation through R1
The losses from each state are defined by loss rates determined by the physics of
spore  transport  and  deposition.   These  loss  rates  are  used  to  determine  transition
probabilities  that  reflect  spores  leaving  one  state  for  another.   The  probability  of  a
pathogen present in state-i to be transported to state-j within one time step (∆t) is defined
as tij ∆⋅λ , where λij is the rate of loss from pathogens in state-i, lost due to transport to
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state-j.  If the the loss rates for removal from state-i are summed, the overall rate at which
a pathogen will be transported from state-i (Nicas and Sun, 2006; Ross, 2007).   
Table 19: Loss rates from states in the Markov chain model
Loss Rate
Symbol
Loss From State Described Loss Rate Value (min-1)
λR 1-2 Pathogen transport from R1 to R2 2.789
λR 1s Deposition of pathogen in R1 1.126
λR 2-3 Pathogen transport from R2 to R3 2.252
λR 2-1 Pathogen transport from R2 to R1 0.0765
λR 2s Deposition of pathogen in R2 0.0765
λR 3-2 Pathogen transport from R3 to R2 6.713(10
-4)
λR 3s Deposition of pathogen in R3 0.00143
λdeath
* Death or loss of viability of pathogen 4.641(10-5)
λexh
Pathogen exhaled to external
environment
0.011
*: Death rate assumed same for all compartments
There are a total of 9 loss rates in order to take into account the losses from each
of the states via bulk fluid transport and deposition.  Each of the functional forms which
are used to obtain the point estimates shown in Table  19 have been discussed earlier.
These  loss  rates  were  used  to  develop  transition  probabilities  for  the  P matrix  as
discussed earlier with the estimates to transition probabilities shown in Table  20.   In
reading Table  20, what is being shown in the transition probabilities from one state to
another, a simple example on reading this table can highlight its use.  If looking at the cell
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associated to row 1 and column 2, this transition probability is the pathogen transitioning
from state one to state 2 (bulk fluid in R1 to bulk fluid in R2).  The P matrix is developed
based on the loss rates shown in Table  19 using a time step of 0.0003125 seconds and
multiplied by itself for each of these time steps, simulating the transition of the pathogen
from one state to another.  
Table 20: Point estimates of transition probabilities for the Markov matrix P
State
 umber
1 2 3 4 5 6 7 8
1 9.99(10-1) 1.93(10-7) 8.71(10-4) 0.00(100) 0.00(100) 0.00(100) 3.44(10-6) 0.00(100)
2 0.00(100) 1.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 3.44(10-6) 0.00(100)
3 3.52(10-4) 0.00(100) 9.99(10-1) 4.47(10-7) 7.03(10-4) 0.00(100) 3.44(10-6) 0.00(100)
4 0.00(100) 0.00(100) 0.00(100) 1.00(100) 0.00(100) 0.00(100) 3.44(10-6) 0.00(100)
5 0.00(100) 0.00(100) 2.39(10-5) 0.00(100) 1.00(100) 3.64(10-6) 3.44(10-6) 2.39(10-5)
6 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 1.00(100) 3.44(10-6) 0.00(100)
7 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 1.00(100) 0.00(100)
8 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 0.00(100) 1.00(100)
 5.2.1 Estimates of delivered dose from the stochastic first stage
The stochastic model is executed in order to simulate 60 minutes of respiration of
bacterial  containing  air  by the  exposed  host.   After  the  simulation of  60  minutes  of
respiration the total dose delivered to the respiratory bronchioles is obtained.  The 60
minutes of respiration is simulated as a demonstration; however, longer or shorter time
periods can be simulated by altering the number of time the  P matrix is multiplied by
itself, thereby increasing the time which is being simulated.  The simulation in the first
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stage can also be altered in order to simulate the variable exposures or expand towards
multiple exposures to multiple pathogens, or pathogens and chemical agents. 
As has been discussed earlier the infection process is in two stages.  First the dose
that the host is exposed to must be delivered to a sensitive location.  Since the stochastic
model is determining the delivered dose this can be used as an initial correction to the
exposed dose.   Within these 60 minutes of simulation before executing the remaining
portion of the coupled model it is assumed that the pathogenesis occurs after these first
60 minutes of simulation.
Because  the  same  correction  for  delivered  dose  is  being  estimated  from  the
stochastic model then a constant correction factor can be gleaned from these simulations.
This correction factor is obtained after the 60 minutes of respiration have been simulated
and the final delivered dose is estimated.  As can be seen in Figure 39 there is a linear
correction to the exposed dose, thereby allowing for a constant correction factor to be
developed.  The correction from exposed dose to delivered dose is 0.000834,  i.e. only
0.0823% of the exposed spores are delivered to respiratory bronchioles after 60 minutes
of respiration.   
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 5.2.2 Overview of dose response model fitting
The  fitting  of  the  dose  response  data  can  be  performed  using  the  maximum
likelihood estimation (MLE).  Using this method the predicted response (πi) shown in
equation 50 being a function of the dose (di) and model parameter(s) (Θ), in the case of
equation 48, r and equation 49, 50 and α.  This predicted response is directly compared
to the observed response (πio) which is a function of the observed positive responses (pi)
and total number of subjects (ni), obtained from the dose response data (equation 51). 
Exponential model: P response=1−exp−k⋅dose                   (48)
Beta Poisson model: P response=1−[1dose 50 ⋅2
1 /
-1]
−
             (49)
Figure 39: Dose correction from exposed to delivered dose from stochastic
model results
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i=P i d i ,   (50)
i
o
=
p i
ni
      (51)
Using  the  MLE  method,  the  model  parameter(s)  Θ are  adjusted  in  order  to
minimize the negative two log-likelihood ratio herein termed the deviance (Y) which is
shown in equation 52 (Haas et al., 1999; Morgan, 1992).  The deviance directly compares
the predicted response using the models to the observed response from the data.  
With the deviance minimized the goodness of fit must be investigated and shown
statistically significant.  In order to accomplish this, the minimized deviance is compared
to the chi-squared (χ2) distribution with degrees of freedom defined as the number of
parameters (m) subtracted from the number of doses (n).  The null hypothesis (the fit is
satisfactory) is rejected if the minimized deviance is greater than the upper 5th percentile
of the χ2 distribution.  
Y=−2∑ [ p i⋅ln
i
 o
i + ni - pi ⋅ln
1 -i
1 - o
i ]          (52)
 5.2.3 Effect  of  delivered  dose  from  stochastic  first  stage  on  dose  response
assessment
The results from using this correction factor can be seen in Table  21 where the
exposed  dose  has  been  converted  to  a  dose  delivered  to  the  respiratory bronchioles.
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These values were used to determine the effect of the modification to the dose on the
modeled dose response relationship.  First the modeled dose response relationship for the
unmodified exposed dose must be established.    
Table 21: Exposed dose and corrected delivered dose (Druett et al., 1953)
Exposed Dose (Spores) Delivered Dose (Spores)
70,320 58
77,040 64
108,720 90
137,520 114
155,520 129
160,800 134
240,000 200
300,000 250
398,400 332
Table  22 shows the dose response data with the unmodified exposed dose.  The
data  shown  in  Table  22 has  been  obtained  from  Druett  et  al.  (1953),  where  rhesus
monkeys  and  other  host  species  were  exposed  to  B.  anthracis with  varying  particle
diameters.   It  was  the  goal  of  Druett  et  al.  (1953)  to  establish  if  there  existed  a
relationship between aerosol size and the infectivity of inhaled pathogens.  The data in
Table 22 are specifically for rhesus monkeys exposed to an aerosol of 1 µm diameter B.
anthracis spores.   Prior  work  has  been  performed  on  modeling  the  dose  response
relationship as well as the relationship between aerosol diameter and the dose response
relationship (Bartrand  et al.,  2008).   Bartrand  et al.  (2008) determined that  there is  a
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relationship between the aerosol diameter and the dose response relationship.  Bartrand et
al (2008) showed that  when the aerosol diameter is changed, the lethal dose for fifty
percent of the population and ten percent of the population (LD50 and LD10) are changed
as well, requiring larger amount of exposed spores for larger aerosol diameters for the
same risk level.  The data in Table 22 was used to determine the best fitting dose response
model and the fit of the data was compared to that found in Bartand et al. (2008) in order
to determine that the code used for fitting of dose response models did not contain errors
and could replicate  the fit  previously published.   When performing this check it  was
found that using the same exposed dose data the exponential model fit of 11.253 was the
same as that reported in Bartrand et al. (2008).
Table 22: Unmodified dose response data for model fitting using exposed dose (Druett, et
al., 1953)
Exposed Dose
(Spores)
Positive Response
(Mortality of Host)
 egative Response
(Survival of Host)
 umber of Hosts
in Dose Group
70,320 1 7 8
77,040 4 4 8
108,720 5 3 8
137,520 6 2 8
155,520 5 3 8
160,800 3 5 8
240,000 8 0 8
300,000 7 1 8
398,400 8 0 8
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The comparison of the exponential and beta Poisson models can be seen in Table
23.  In this analysis the minimized deviance is compared the upper tailed chi-squared (χ2)
distribution with degrees of freedom equal to degrees of freedom equal to number of dose
groups (m)  minus the  number  of  parameters  in  the dose  response  model (n).   If  the
deviance is lower than the critical value of the  χ2 distribution then the model shows a
statistically significant goodness of fit to the data.  
In order to determine if the exponential or beta Poisson models is the better fitting
model  the difference between  the  deviances  (∆)  of  the exponential  and  beta  Poisson
model is compared to a χ2 distribution with one degree of freedom (Table 24).  The null
hypothesis in this analysis is that the simpler model (least number of parameters) is the
best fitting model.  Therefore since the χ2 distribution is an upper tailed distribution, if ∆
is greater than the χ2 critical value, then the null hypothesis cannot be accepted.  The best
fitting (exponential) dose response model fit to the data with confidence intervals can be
seen in Figure  40.  The estimations of the fitted natural  log of the k parameter from
10,000 bootstrap iterations can be seen in Figure 41   
Table 23: Goodness of fit test for the modeled dose response relationship using the
unmodified exposed dose
Model
Optimized
Parameter(s)
Minimized
Deviance
Degrees of
Freedom
χ2 Critical
Value
Conclusion
Exponential k = 0.00000716 11.253 8 15.51
Exponential is a good
fit to the data
Beta Poisson
α = 9,195.97
11.252 7 14.07
Beta Poisson is a good
fit to the data N50 = 96,750
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Table 24: Determination of best fitting dose response model for delivered dose
Model Minimized Deviance ∆ χ2 Critical Value Conclusion
Exponential 11.253
0.001 3.843
Exponential is best fitting
modelBeta Poisson 11.252
Figure 40: Exponential model fit to the unmodified exponential
dose response model
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Table  21 shows how the dose is modified form an exposed dose to a delivered
dose.   The  correction  factor  used  to  develop  Table  21 has  been  included  into  the
exponential and beta Poisson dose response models in order to develop dose response
parameters  which are specific  to  delivered dose.   As can be seen in  equation 53 the
exponential dose response parameter (k) has been modified to k* which is the exponential
dose response parameter which allows for the estimation of risk for the delivered dose.
This modified dose response parameter has been obtained by including the correction
factor (ηdd) converting from exposed dose to delivered dose.  Including ηdd into the beta
Poisson dose response model modifies α and 50 to be specific to the delivered dose as
Figure 41: Histogram of exponential k parameter after
10,000 bootstrap iterations for the unmodified
exponential dose response model
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can be seen in equation 54.   These modified dose response models have been optimized
using  MLE  as  described  previously  allowing  for  optimized  modified  dose  response
parameters for the delivered dose of B. anthracis spores.  
P response=1−exp −k *⋅dd⋅dose  (53)
P response=1−[1+ dose⋅dd 50* ⋅21/ 
*
-1]
−
*
        (54)
The optimized modified parameters can be seen in Table 25 and the re verification
of the fit can be seen in Tables 25 and 26.  The minimized deviance was not altered since
the  correction  from exposed  dose  to  delivered  dose  is  a  constant  factor  the  dose  is
corrected on a constant basis as well.  The best fitting dose response model (exponential)
can be seen in Figure  42 and the histogram of the modified exponential dose response
parameter (k*) can be seen in Figure 43. 
Table 25: Goodness of fit test for the modeled dose response relationship using the
modified delivered dose
Model
Optimized
Parameter(s)
Minimized
Deviance
Degrees of
Freedom
χ2 Critical
Value
Conclusion
Exponential k = 0.00859 11.253 8 15.51
Exponential model is a
good fit to the data
Beta
Poisson
α= 14,823.25
11.252 7 14.07
Beta Poisson model is a
good fit to the dataN50 = 81.173
128
Table 26: Determination of best fitting dose response model for delivered dose
Model Minimized Deviance ∆ χ2 Critical Value Conclusion
Exponential 11.253
0.001 3.843
Exponential is best fitting
modelBeta Poisson 11.252
Figure 42: Modified exponential dose response model for
delivered dose fit to the data
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 5.2.4 Extrapolation of first stage to other host species
Since the first stage model is a stochastic one, that uses the overall volume of the
different regions as well as the tube diameter to model the transport and deposition of the
spores.  The extrapolation from humans to animals can be compared as well.  This has
been accomplished by changing the volumes of the first second and third regions as well
as  the  mean  tube  diameters  for  these  regions  as  well  for;  guinea  pigs  and  rhesus
macaques.  These new values shown in Table 27 for the average mature male guinea pig
(Schreider  and  Hutchins,  1980)  as  well  as  the  average  mature  male  rhesus  macaque
(Matronen et al., 2001).  
Figure 43: Histogram of exponential k* parameter after
10,000 bootstrap iterations
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Table 27: Physiological parameters for guinea pig and
rhesus macaque respiratory system
Physiological
Dimension
Guinea Pig Rhesus Macaque
VR1 0.68 cm
3 38.7 cm3
VR2 0.36 cm
3 21.3 cm3
VR3 9.20 cm
3 700 cm3
dR1 0.32 cm 0.213 cm
dR2 0.26 cm 0.021 cm
dR3 0.026 cm 0.0076 cm
Q 1.05 cm3/min 5 cm3/min
B 1.05 cm3/min 5 cm3/min
Figure 44: Plot depicting linear correction factor from exposed dose to delivered
dose in the guinea pig
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With these values entered into the stochastic model, the estimate of delivered dose
to guinea pigs and rhesus macaques can be obtained and compared to humans.  Figure 44
shows a linear correction from exposed dose to delivered dose for guinea pigs with a dose
correction of delivered dose for guinea pigs (ηdd
gp) of 3.77(10-6).  Figure 45 shows a linear
correction from exposed dose to delivered dose for rhesus macaques (ηdd
rm) of 2.6(10-5).
This difference in the delivered dose correction allow for an explanation to the lethal dose
to fifty percent of the population (LD50) developed in Bartrand et al. (2008).  In Bartrand
et al. (2008) the LD50   for guinea pigs exposed to aerosolized B. anthracis spores  was
147,411 spores, as compared to 92,000 spores for the rhesus macaque.  This value at first
seems contrary to the knowledge that the guinea pig is a very susceptible host for  B.
anthracis (Smith, 1973).  Since a smaller fraction of the inhaled spores form an aerosol
Figure 45: Plot depicting linear correction factor from exposed dose to delivered
dose in the rhesus macaque
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challenge are able to reach the sensitive region of the guinea pig (alveoli) this accounts
for the large LD50 despite the increased susceptibility compared to other animals such as
the rhesus macaque.  
These differences of the dose correction factor between guinea pigs and rhesus
macaques  as  well  as  compared  to  humans,  can  be  attributed  to  the  much  higher
respiration rate for the animal as well as the regional volume difference.  Human adults
have an average  respiration rate of 13 breaths min-1, while rhesus monkeys are more than
double that with an average of 29-30 breaths min-1, and guinea pigs are ever greater than
that with a much wider range, the average being 60 breaths min-1.  Not only does the
respiration  rate  affect  the  delivered  dose  correction  factor  but  the  volumes  of  the
associated regions do as well.  Altering only one of the regions does not make a large
difference in the delivered dose correction (under a  multiple of 1.5) for both guinea pig
and rhesus macaque.  However if the other parameters remain unaltered, but all  three
region's volumes are altered (factor of 2 or 0.5) then the dose correction factor changes by
two orders of magnitude for both the guinea pig and rhesus macaque.  Also if the other
parameters are kept the same but the respiration rate is altered (factor of 2 or 0.5) again a
difference in two orders of magnitude can be seen.  These changes due to the alteration of
the dimensional parameters and flow rate can be seen in Table 33.  
By  looking  at  the  effects  of  the  different  parameters  on  the  delivered  dose
correction factor, it can be seen that the associated volumes and flow rates are affecting
the correction factor estimates the most.  Therefore it can be seen that the physiology and
the parameters of the respiratory system such as volume and respiration rate are vital to
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the correct working of the first stage model.  
Table 28: Effect of physiological parameters on delivered dose correction factor
Parameter Alteration Made Guinea Pig ηdd Rhesus Macaque ηdd
Control 3.7(10-6) 2.6(10-5)
2 (V) 2.3(10-4) 1.7(10--3)
0.5 (V) 1.0(10-8) 5.05(10-8)
2 (Q) 2.01(10-8) 5.05(10-8)
0.5 (Q) 2.98(10-4) 1.7(10-3)
2 (d) 1.3(10-5) 1.3(10-4)
0.5 (d) 1.4(10-6) 1.9(10-5)
2 (Q)&2 (V) 5.3(10-6) 2.5(10-5)
2 (Q)&2 (V)&2 (d) 1.5(10-5) 2.0(10-4)
Using the delivered dose correction factor for LD50 for the guinea pig and rhesus
monkey, the LD50 for the delivered dose (LD50
dd) in the guinea pig and rhesus macaque.
Table  29 shows this conversion from LD50 to the LD50
dd.   This conversion for LD50
dd
highlights the known difference in susceptibility of the guinea pig compared to the rhesus
macaque.   This  also  highlights  the  validity  of  the  single  hit  assumption  in  the  dose
response models used, since the exponential dose response model was the best fitting for
these original data sets, and where the LD50 was derived from.  
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Table 29: Conversion of LD50 to LD50
dd for guinea pigs and rhesus macaques
Host Animal
LD50 (spores) 
[confidence interval]
LD50
dd (spores)
[confidence interval]
Guinea pig 147,411;  [17,400, 357,700] 0.556;  [0.0644, 1.323]
Rhesus macaque 92,000;  [29,400, 154,560] 2.392;  [0.764, 4.019]
 5.3 Overview of the deterministic second stage and coupled model
The  deterministic  second  stage  models  two  systems  working  together  for  the
pathogenesis of  B. anthracis to occur.  The first system (Figure  46) governs the spores
entrance  into  the  alveolus  taking  into  account  the  concentration  of  spores  in  the
bronchioles (bronc) the volumetric flow rate into the alveolus (Q) and the concentration of
spores in the bulk fluid in the alveolus (alv).  Therefore modeling the first system will
include the two state variables; bronc and alv.
Figure 46: System diagram for spores transported
with the bulk fluid into the alveolus
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The  next  system  is  the  interaction  of  B.  anthracis spores  with  alveolar
macrophages, modeling the phagocytosis process (Figure 47).  Modeling this system will
assess the deposition on the alveolar macrophage outer membrane, thus removed from
the bulk fluid in the alveolus.  Then the spores are taken into the macrophage and either
germinated  or  inactivated,  and  if  germinated  having the  vegetative  cells  grow or  be
inactivated in the macrophage.  This means that the model for this system will have four
state variables which must be modeled:  
• Concentration of spores deposited on the surface of the macrophage (x)
• Concentration of spores taken into the macrophage (m)
• Concentration of spores inactivated in the macrophage (mi)
• Concentration of vegetative cells due to germination and growth (v)
As reviewed earlier, in order to model the overall system the interdependence on
intermediate processes (deposition occurring before uptake) as mass balance is the best
approach to modeling the overall systems derived as a mass balance in the form of a
coupled system of ordinary differential equations (CSODE).  In a CSODE, the behavior
of each state variable is coupled to the value(s) of one or more other  state  variables
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(equation 53).  
d bronc
dt
⋅V bronc=Q⋅C in−Q⋅ bronc +Q⋅ alv
d alv
dt
⋅V ao=Q⋅ bronc−Q⋅ alv− alv⋅kdep
dx
dt
= alv⋅k dep− x⋅k up
dm
dt
⋅V am= alv⋅k dep - x⋅k up ⋅Aam−k ger⋅m⋅V am−k ina⋅m⋅Vam
dmi
dt
V am=k ina⋅m⋅V am
dv
dt
⋅V am=k ger⋅m⋅V am + k grow⋅v⋅V am−kdecay⋅v⋅V am
               (53)
 5.3.1 Estimates of vegetative cell dose from the coupled model
As discussed earlier the infection process is a two stage process, where the spores
must  first  be  delivered  to  a  sensitive  location  and  then  engage  in  the  pathogenesis
process.   Once  the  stochastic  first  stage  simulates  60  minutes  of  breathing  the
concentration  of  spores  in  the  respiratory bronchioles  can be  estimated,  knowing the
delivered dose and the overall volume of the respiratory bronchioles.  This estimate of the
concentration of spores available for entrance into the alveolus is the Cin value in equation
56.
The deterministic stage of the coupled model is executed until 5 hours have been
simulated.  This length of execution is used since the macrophage is typically lysed after
4 to 6 hours of exposure to the LeTx protein associated with B. anthracis (Hanna et al.,
1993).  The range is dependent on the concentration of LeTx which is why a midpoint of
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the range is used. 
As with the correction from exposed to delivered dose discussed in section 5.2.1 
once the pathogen burden is determined from the coupled model the ratio of exposed
dose to pathogen burden can be determined.  And as with the delivered dose a constant
correction factor can be determined from the linear difference between pathogen burden
and exposed dose in Figure  48.  This correction factor unlike the delivered dose is an
increase  from the  exposed  dose as  would be  expected  from growth  of  bacilli  in  the
macrophages.   The correction factor  from exposed dose to pathogen burden is  1.528
which as can be seen from Figure 48 is a constant value for the exposed doses.  
 5.3.2 Effect of delivered dose from first stage on dose response assessment
The results from using the correction factor from the coupled model can be seen
Figure 48: Dose correction from exposed to pathogen burden from
deterministic model results
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in Table  30 where the exposed dose has been converted to a pathogen burden that is
experienced throughout the lungs, since all the alveoli are being modeled in the coupled
model.  The same method of determining the effect of the modified pathogen burden
correction factor in the exponential and beta Poisson dose response models established in
section 5.2.3  .   The  pathogen  burden  correction  factor  (ηpb)  was  used  to  modify the
exponential  and  beta  Poisson  dose  response  models,  allowing  for  pathogen  burden
specific dose response parameters, k for the exponential model and   and  50
for the beta Poisson model as can be seen in equations 55 and 56 respectively.    
Table 30: Exposed dose and corrected pathogen burden
Exposed Dose (Spores) Pathogen Burden (Bacilli)
70,320 107,449
77,040 117,717
108,720 166,124
137,520 210,130
155,520 237,634
160,800 245,702
240,000 366,720
300,000 458,400
398,400 608,755
P response =1−exp - k⋅pb⋅dose  (55)
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P response=1−[1+ dose⋅pb 50 ⋅21/ -1]
−
       (56)
As can be seen in Table 31 both the exponential and beta Poisson models display
a good fit  to the dose response data using pathogen burden rather than exposed dose.
And as can be seen in Table 32 the exponential model with confidence intervals (Figure
49) is the best fitting of the two dose response models.  Again the modified dose response
parameters are specific to the pathogen burden from the coupled model.  And again these
modifications  are  obtained  by  including  the  correction  factor  from  exposed  dose  to
pathogen  burden (ηpb)  into  the  dose  response  model.   The  modified models  are  then
optimized using MLE allowing for optimized modified parameters in Tables 31 and 32.
A histogram of the modified k parameter can be seen in Figure  50.  Again since the
correction from exposed dose to pathogen burden is derived from a constant correction
factor  the  overall  fit  cannot  be  affected.   Rather  the  parameters  and  therefore  the
estimated risk has been affected.  
Table 31: Goodness of fit test for the modeled dose response relationship using the
modified pathogen burden
Model
Optimized
Parameter(s)
Minimized
Deviance
Degrees of
Freedom
χ2 Critical
Value
Conclusion
Exponential k = 0.00000185 11.253 8 15.51
Exponential is a good
fit to the data
Beta Poisson
α = 11,290
11.252 7 14.07
Beta Poisson is a good
fit to the data N50 = 375,122
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Table 32: Determination of best fitting dose response model for pathogen burden
Model Minimized Deviance ∆ χ2 Critical Value Conclusion
Exponential 11.253
0.001 3.843
Exponential is best fitting
modelBeta Poisson 11.252
Figure 49: Modified exponential dose response model
for pathogen burden fit to the data
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 5.4 Evaluation of linear assumption for the low dose region of the dose response
Since  a  linear  correction  allows  for  a  change  in  the  estimation  of  the  dose
response model this emphasizes the assumption of the linear dose response relationship at
low doses, which is inherent to the dose response models used.  This support of the linear
low dose relationship can be tested simply by including an additional parameter into the
best fitting model.  
This additional parameter will raise the dose to a power, which will additionally
describe the correction from exposed dose to delivered dose or pathogen burden, similar
to the constant survival probability used for conditional dose response modeling.  This
parameter changes the exponential dose response model to what is seen in equation 57
and 58 for delivered dose and pathogen burden respectively.  The k parameter as well as
Figure 50: Histogram of exponential k
parameter after 10,000 bootstrap iterations
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the new x parameter are both optimized using the MLE method described earlier.  
P response=1-exp - k⋅dd⋅dose x   (57)
P response=1 -exp - k⋅pb⋅dosex   (58)
In this analysis if the additional parameter (x), allows an improved fit to the data
(difference in the deviances of the unmodified and modified models is greater than the
χ2critical  value at  one  degree of  freedom),  then the low dose region is  not  linear  as
currently assumed.  This would also show that perhaps further analysis into the linear
correction from exposed to  delivered dose and pathogen burden must  be investigated
further as well.  
Tables  33 and  34 shows that including the additional x parameter into the best
fitting dose response model does not allow for a statistically significant improvement in
the model fit to the data.  This results emphasizes and gives proof to the validity of the
linear assumption for the low dose relationship.  This also shows that the dose correction
can be used alone and does not require an additional parameter to be included into the
dose response model.    
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Table 33: Determination if additional parameter (x) can be justified for delivered dose
Model Parameter
Minimized
Deviance
∆
χ2 Critical
Value
Conclusion
Exponential k = 0.000859 11.252
1.35 3.843
Additional
parameter does not
improve fit
Modified
Exponential
k = 7.522(10-5)
9.901
x = 1.395
Table 34: Determination if additional parameter (x) can be justified for pathogen burden
Model Parameter
Minimized
Deviance
∆
χ2 Critical
Value
Conclusion
Exponential k = 0.000859 11.252
1.32 3.843
Additional
parameter does not
improve fit
Modified
Exponential
k = 4.155 (10-8)
9.931
x = 1.394
 5.5 Summary of the effect of the modified dose on the dose response assessment
The exposed dose has the exponential  dose response model as the best  fitting
model.  The best fitting model has not differed from the exponential when including the
correction for either delivered dose or pathogen burden.  This is due to the correction
being a constant factor affecting the dose thereby not affecting the observed probability
of response which the models must be fitted to.  Until the factors of delivered dose and
pathogen burden are included into the data gathering portion of animal model studies the
comparison of improvement of fit cannot be determined.  
The  delivered  dose  estimated  from the  first  stage  model  results  from a  dose
correction factor of 0.000834.  The coupled model allows for an estimation of pathogen
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burden which results from a dose correction factor of 1.528 both of these applied to the
exponential and beta Poisson dose response models.  The exponential and beta Poisson
dose  response  models  have  both  been  modified  to  include  the  delivered  dose  and
pathogen  burden  correction  factors.   These  modifications  have  allowed  for  the
development of the modified dose response parameters associated to the delivered dose
and pathogen burden.   This allows for a correction from exposed dose to both a delivered
dose and pathogen burden both of which allow an improved estimate of the risk from
aerosol exposure to B. anthracis spores. 
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 CHAPTER 6 : CO CLUSIO S A D RECOMME DATIO S FOR FUTURE
WORK
 6.1 Conclusions drawn from this work
The two stages of the infection processes required an overall model that could
take these stages into account.  Therefore a two stage model has effectively modeled the
two stages of the infection process as has been performed here, and shown to improve the
modeled dose response relationship.
The  first  stage  of  the  infection  process  being  the  bulk  fluid  transport  and
deposition  has  been  modeled  stochastically.   This  stochastic  model  for  bulk  fluid
transport and deposition has allowed for a modified exponential parameter (k*) and beta
Poisson  parameters  (α* and  50
*)  for  aerosol  challenge  dose  response  data.   This
modification was performed by including the delivered dose correction factor (ηdd) into
the exponential and beta Poisson dose response models.
The second stage of the infection process is  the pathogenesis, which has been
modeled with three parameters that required optimization to available pathogenesis data.
The rates  of  uptake and inactivation of  Bacillus.  anthracis  (B.  anthracis)  spores  and
growth of B. anthracis vegetative cells required fitting for the pathogenesis model.  These
rate constants were optimized and showed a good fit to the data available.
The two stages of the combined model together describe the infection process.
Therefore the two models making up the two stages required coupling in order to model
the  infection  process  of  inhaled  B.  anthracis.   The  coupled  model  allowed  for  the
development of pathogen burden specific dose response parameters for the exponential
model  k  and  the  beta  Poisson  model   and  50. This  modification  was
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accomplished  by  including  the  pathogen  burden  correction  factor  (ηpb)  into  the
exponential and beta Poisson dose response models.
These  modified  dose  response  parameters  for  both  the  exponential  and  beta
Poisson dose  response models  allows for  an  improvement  in  the estimate  of  risk  by
including the physiology and host-pathogen dynamics into the dose response models.  
This correction factor can be used directly in the dose response model and does
not require an additional parameter in the dose response model for its use.  This was
shown along with the validation of the assumption of the linear low dose relationship.  
 6.2 Recommendations for future research
The delivered dose as well as the pathogen burden should be included into animal
model  dosing  studies.   This  will  allow for  the  determination  of  whether  or  not  the
inclusion of delivered dose and pathogen burden correction factors affect the fit of the
dose response models. 
The stochastic model has been developed for B. anthracis spores, using bulk fluid
transport and deposition physics similar to non-biological particulate matter.  This has
been performed as a stochastic model, since stochastic models have been proven to model
the  transport  and  deposition  of  particles.   The  applicability  of  stochastic  models  for
modeling the transport and deposition of viruses has not been as extensively examined as
particulate matter and pathogens which can be modeled as such.  Therefore developing a
bulk fluid transport model for inhalation of viruses is advisable.
Certain pathogens have a more complex pathogenesis than that of  B. anthracis.
An example of this would be the 1918 H1N1 flu that caused the pandemic during World
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War I.   This particular strain replicates in the epithelial  cells  increasing the pathogen
burden as it is transported to the alveoli, and can continue this replication process despite
the host being initially exposed to only a small level of viral particles.  Modeling this type
of pathogen will allow for a much better understanding of the effect of pathogen load
compared to exposed dose. 
The  deterministic  stage  is  a  limited  portion of  the  overall  pathogenesis  of  B.
anthracis.  The main and most important portions of the pathogenesis of  B. anthracis
have been modeled (uptake, germination, inactivation, growth and decay).  However the
transport of the alveolar macrophage to the local lymph vessels has been ignored as a
simplifying assumption.  Including this into a new deterministic model will allow for a
more complete picture of the pathogenesis of inhaled B. anthracis.  
Trying  to  include  the  motile  nature  of  alveolar  macrophages  will  require  the
filling  of  a  number  of  data  and  knowledge  gaps.   The  mechanisms  of  macrophage
transport are not completely defined and the methods of transporting through epithelial
cell tissue are also missing knowledge.  These mechanisms must be clearly defined and
understood and the means of quantifying the transport of macrophages through epithelial
cell tissue to and into the lymph vessels must be established, with the data being made
available for use of modeling.
In including the motile nature of the alveolar macrophages an agent based model
(ABM) may be the most appropriate method.  Artificial neural network (ANN) models
have been used for inter-tissue transport, however, these typically require a large amount
of parameters in order to account for the known transport processes.  An ABM may allow
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for the stochastic nature of the transport to remain without requiring an excessively large
Markov model.  Also ABMs have been used in the past for pathogen transport through
soil matrices as well as inter-tissue transport, therefore, the ability for their use in this has
already been established.     
In  performing this work, it  has been attempted to find information on uptake,
inactivation, growth and decay of B. anthracis spores and vegetative cells within human
alveolar macrophages.   However these data are not currently available from the open
literature or from communication with experts.  Should this work be advanced for  B.
anthracis, the modeling efforts should work in tandem with experimental work in human
alveolar macrophages.   This will  allow the experimental  work to be informed by the
modeling effort to determine what data are required.  In turn, the modeling effort will be
informed by the experimental work with insights and increased knowledge of the systems
and processes involved.     
The use of either the first stage or the coupled model may be limited by the fact
that it is modeling the inhalational transport and deposition and the pathogenesis of  B.
anthracis.  In the event of a malicious release of B. anthracis a conservative response and
estimate  of  risk  is  the  likeliest  response.   However  this  work  has  shown  that  the
framework  established  is  accurate  and  able  to  improve  the  modeled  dose  response
relationship.  Therefore the development of such a model for another pathogen such as
Legionella pneumophila with an associated lower lethality and public dread , but similar
pathogenesis to that of B. anthracis is recommended.  
This  framework  can  be  used  for  additional  pathogens  and  the  beneficial  or
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detrimental effects to the modeled dose response relationship should be determined.  This
will allow for a family of models such as physiologically based pharmacokinetic (PBPK)
models for chemical risk assessment.  If this is the case the first stage will likely not need
to be adapted, unless it is found that viruses or other pathogens such as protozoa have
different transport and deposition physics than pathogens such as B. anthracis, which can
be  modeled  as  particulate  matter.   The  second  stage  will  need  to  be  rederived  and
parameters fitted to available data just as this case.  This rederivation will be required for
any additional pathogen with pathogenesis different from B. anthracis.  
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APPE DIX A: LIST OF ACRO YMS A D SYMBOLS USED I  THIS
THESIS
ABM: Agent based model
ANN: Artificial Neural Network
Aam: External surface area of alveolar macrophage
Ap: Surface area of particle
B: Human exhalation rate (units of volume per time)
B. anthracis: Bacillus anthracis, causative agent of anthrax
CAMRA: Center for Advancing Microbial Risk Assessment
CD: Coefficient of Drag
Cin: Initial concentration
CDC: Centers for Disease Control and Prevention
CFD: Computational Fluid Dynamics
CFU: Colony Forming Units
cm: Centimeters (unit of length)
cm2: Squared centimeters (unit of area)
cm3: Cubic centimeters (unit of volume)
CSODE: Coupled System of Ordinary Differential Equations
DIR1: Deposition rate from Brownian motions and inertial impaction for region-1
DIR2: Deposition rate from Brownian motions and inertial impaction for region-2
DIR3: Deposition rate from Brownian motions and inertial impaction for region-3
dp
: Aerodynamic diameter of spores
dR1: Mean tube diameter of region-1
dR2: Mean tube diameter of region-2
dR3: Mean tube diameter of region-3
fminunc: MATLAB optimization routine
g: Acceleration due to gravity
kdecay: Rate constant of decay of spores by macrophage 
kdep: Rate constant of deposition of spores on macrophage surfaces
kina: Rate constant of inactivation of spores by macrophages 
kger: Rate constant of germination of spores within macrophages
kgrow: Rate constant of growth of vegetative cells within macrophages
kup: Rate constant of uptake of spores from outside to inside macrophages
LRT: Lower respiratory tract
LeTx: Lethal factor toxin
m: Concentration of spores inside macrophage (units of spores per volume)
mi: Concentration of inactivated spores inside macrophage (units of spores per
volume)
MC: Markov chain
MCMC: Markov chain Monte Carlo
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MLE: Maximum Likelihood Estimation
mm: millimeters (unit of length)
mmHg: millimeters of mercury (unit of pressure)
alv: Concentration of spores in air in alveolus (units of spores per volume)
bronc: Concentration of spores in air in brinchioles (units of spores per volume)
NAS: National Academies of Science
NRC: National Research Council
ODE: Ordinary Differential Equation
P: Markov transition probabilities matrix
PBPK: Physiologically Based Pharmacokinetic 
Q: Inhalation flow rate (units of volume per time)
QMRA: Quantitative Microbial Risk Assessment
Re: Reynold's number
R1: Region-1
R2: Region-2
R3: Region-3
SRC: Syracuse Research Center
SSE: Sum of Squared Errors
µm: micron (unit of length)
URT: Upper respiratory tract
vts: Terminal settling velocity
VR1: Volume of region-1 (units of cubic length)
VR2: Volume of region-2 (units of cubic length)
VR3: Volume of region-3 (units of cubic length)
Vp: Volume of particles
x: Concentration of spores deposited on surface of macrophage (units of 
spores per area)
∆t: Time step
ρ: Density of fluid (units of mass per volume)
ρp: Density of particle (units of mass per volume)
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APPE DIX B: SOURCE CODE OF FIRST STAGE MARKOV CHAI 
MODEL
%==============================================================|
%---------------------------------------------HEADER-----------------------------------------------|
%==============================================================|
% BA_MC_2.m is the Markov chain model which will model the transport of    |
% pathogens through the respiratory tract.  This will determine the        |
% concentration of spores deposited or remaining in the air in the three   |
% regions of the respiratory tract.                                        |
% This one specifically pulls diffeerent delivered dose estimated from the |
% stochastic model from exposed doses from dose response data which CAMRA  |
% Project III has in the digital archives                                  |
% Written by Mark H. Weir for his dissertation work in the Department of   |
% Civil Architectural and Environmental Engineering, Drexel University     |
% in pursuit of a PhD in Environmental Engineering                         |
%==============================================================|
%==============================================================|
%    Dimensional parameters of spores and the three regions as well as time step size       |
%==============================================================
%                                                                                        
dp1 = 1;                                                                                
dp2 = 2;                                                                                
dp3 = 3;                              %Aerodynamic diameters of of spores in um         
dp4 = 4;                                                                                
dp5 = 5;                                                                                
VR1 = 89.63;                              %Volume of region 1 in cc also 89633.62 in cmm     
VR2 = 111.02492;                      %Volume of region 2 in cc also 111,024.92 in cmm   
VR3 = 1633.99;                          %Volume of region 3 in cc also 1,633,990.00 in cmm 
Q = 125;                                      %Volumetric inhalation flow rate in cc/min         
B = 125;                                      %Volumetric exhalation flow rate in cc/min         
Vts = 0.0018*(dp1^2)*(1+(0.166/dp1)); %Terminal settling velocity of spore in m/min
dR1 = 3.4;                                   %Effective diameter of region-one in cm            
dR2 = 1.467;                               %Effective diameter of region-two in cm            
dR3 = 0.18;                                 %Mean diameter for region-three in cm   
delta_t = 0.0003125;                       %Time step of 0.01 minutes
DI_R1 = 0.0022;                  %Impaction deposition rate in
     %Region 1 units of min^-1
DI_R2 = 0.0000;                  %Impaction deposition rate in  
     %Region 1 units of min^-1
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DI_R3 = 0.0038;                  %Impaction deposition rate in  
     %Region 1 units of min^-1
%==============================================================|
%==============================================================|
%                    Define loss rates for transition probabilities for Markov matrix                   |
%==============================================================|
lambda_R12 = (Q+B)/VR1; %Air transport loss rate from region-one to two in min^-1
lambda_R21 = B/VR2;     %Air transport loss rate from region-two to one in min^-1
lambda_R23 = (Q+B)/VR2; %Air transport loss rate from region-two to three in min^-1
lambda_R32 = B/VR3;     %Air transport loss rate from region-three to two in min^-1
lambda_exh = Q/VR3;      %Exhaust loss rate from respiratory tract in min^-1
lambda_R1s = Vts/dR1+DI_R1;    %Deposition rate for region-one;
lambda_R2s = Vts/dR2+DI_R2;    %Deposition rate for region-two;
lambda_R3s = Vts/dR3+DI_R3;    %Deposition rate for region-three;
lambda_death = 0.011;     %Death rate associated with a half life of approx one hour.
%==============================================================|
%                                            Generate the 8x8 Markov matrix                                           |
%==============================================================|
P = zeros(8,8);
%==============================================================|
%                                              Start Filling the Markov matrix                                           |
%==============================================================|
%--------------------------------------------------------------------------------------------------------|
%                          losses from State 1 thus column 1 of the Markov matrix                       |
%--------------------------------------------------------------------------------------------------------|
tloss1 = lambda_R12 + lambda_R1s + lambda_death;
p11 = exp(-tloss1*delta_t);
p12 = (lambda_R1s/tloss1)*(1-p11);
p13 = (lambda_R12/tloss1)*(1-p11);
p17 = (lambda_death/tloss1)*(1-p11);
%--------------------------------------------------------------------------------------------------------|
%                           losses from State 2 thus column 2 of the Markov matrix                      |
%--------------------------------------------------------------------------------------------------------|
tloss2 = lambda_death;
p22 = exp(-tloss2*delta_t);
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p27 = 1-p22;
%--------------------------------------------------------------------------------------------------------|
%                           losses from State 3 thus column 3 of the Markov matrix                       |
%------------------------------------------------------------------------                     ----------------|
tloss3 = lambda_R21 + lambda_R23 + lambda_R2s + lambda_death;
p33 = exp(-tloss3*delta_t);
p31 = (lambda_R21/tloss3)*(1-p33);
p34 = (lambda_R2s/tloss3)*(1-p33);
p35 = (lambda_R23/tloss3)*(1-p33);
p37 = (lambda_death/tloss3)*(1-p33);
%--------------------------------------------------------------------------------------------------------|
%                          losses from State 4 thus column 4 of the Markov matrix                        |
%--------------------------------------------------------------------------------------------------------|
tloss4 = lambda_death;
p44 = exp(-tloss4*delta_t);
p47 = 1-p44;
%--------------------------------------------------------------------------------------------------------|
%                          losses from State 5 thus column 5 of the Markov matrix                       |
%--------------------------------------------------------------------------------------------------------|
tloss5 = lambda_R32 + lambda_exh + lambda_R3s + lambda_death;
p55 = exp(-tloss5*delta_t);
p53 = (lambda_R32/tloss5)*(1-p55);
p56 = (lambda_R3s/tloss5)*(1-p55);
p57 = (lambda_death/tloss5)*(1-p55);
p58 = (lambda_exh/tloss5)*(1-p55);
%--------------------------------------------------------------------------------------------------------|
%                          losses from State 6 thus column 6 of the Markov matrix                       |
%--------------------------------------------------------------------------------------------------------|
tloss6 = lambda_death;
p66 = exp(-tloss6*delta_t);
p67 = 1-p66;
%--------------------------------------------------------------------------------------------------------|
%                          losses from State 7 thus column 7 of the Markov matrix                        |
%--------------------------------------------------------------------------------------------------------|
p77 = 1;
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%--------------------------------------------------------------------------------------------------------|
%                            losses from State 8 thus column 8 of the Markov matrix                     |
%--------------------------------------------------------------------------------------------------------|
p88 = 1;
%--------------------------------------------------------------------------------------------------------|
%               place the incremental pieces of the matrix into the overall 8x8 matrix             |
%--------------------------------------------------------------------------------------------------------|
P(1,1) = p11; P(1,2) = p12; P(1,3) = p13; P(1,7) = p17;
P(2,2) = p22; P(2,7) = p27;
P(3,1) = p31; P(3,3) = p33; P(3,4) = p34; P(3,5) = p35; P(3,7) = p37;
P(4,4) = p44; P(4,7) = p47;
P(5,3) = p53; P(5,5) = p55; P(5,6) = p56; P(5,7) = p57; P(5,8) = p58;
P(6,6) = p66; P(6,7) = p67;
P(7,7) = p77;
P(8,8) = p88;
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E = 70320;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                                         %6 minutes for 6001
Conc = zeros(600001,6);
                        
time(2,1) = 0.0003125;
Ptemp = P;
       
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc(n+1,1) = (E)*Ptemp(1,1);
    Conc(n+1,2) = (E)*Ptemp(1,3);
    Conc(n+1,3) = (E)*Ptemp(1,5);
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    Conc(n+1,4) = (E)*Ptemp(1,2);
    Conc(n+1,5) = (E)*Ptemp(1,4);
    Conc(n+1,6) = (E)*Ptemp(1,6);
    
end
%---------------------------------------------------------------------------------------------------------
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E2 = 77040;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                                          %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;
Conc2 = zeros(600001,6);
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc2(n+1,1) = (E2)*Ptemp(1,1);
    Conc2(n+1,2) = (E2)*Ptemp(1,3);
    Conc2(n+1,3) = (E2)*Ptemp(1,5);
    Conc2(n+1,4) = (E2)*Ptemp(1,2);
    Conc2(n+1,5) = (E2)*Ptemp(1,4);
    Conc2(n+1,6) = (E2)*Ptemp(1,6);
end
%--------------------------------------------------------------------------------------------------------
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E3 = 108720;           %Exposure concentration of spores released at time = 0
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time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                                         %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;
Conc3 = zeros(600001,6);
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc3(n+1,1) = (E3)*Ptemp(1,1);
    Conc3(n+1,2) = (E3)*Ptemp(1,3);
    Conc3(n+1,3) = (E3)*Ptemp(1,5);
    Conc3(n+1,4) = (E3)*Ptemp(1,2);
    Conc3(n+1,5) = (E3)*Ptemp(1,4);
    Conc3(n+1,6) = (E3)*Ptemp(1,6);      
end
%---------------------------------------------------------------------------------------------------------
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E4 = 137520;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                        %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;
Conc4 = zeros(600001,6);
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc4(n+1,1) = (E4)*Ptemp(1,1);
    Conc4(n+1,2) = (E4)*Ptemp(1,3);
    Conc4(n+1,3) = (E4)*Ptemp(1,5);
    Conc4(n+1,4) = (E4)*Ptemp(1,2);
    Conc4(n+1,5) = (E4)*Ptemp(1,4);
    Conc4(n+1,6) = (E4)*Ptemp(1,6);          
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end
%---------------------------------------------------------------------------------------------------------
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E5 = 155520;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                                         %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;
Conc5 = zeros(600001,6);
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc5(n+1,1) = (E5)*Ptemp(1,1);
    Conc5(n+1,2) = (E5)*Ptemp(1,3);
    Conc5(n+1,3) = (E5)*Ptemp(1,5);
    Conc5(n+1,4) = (E5)*Ptemp(1,2);
    Conc5(n+1,5) = (E5)*Ptemp(1,4);
    Conc5(n+1,6) = (E5)*Ptemp(1,6);          
end
%---------------------------------------------------------------------------------------------------------
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E6 = 160800;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                        %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;
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Conc6 = zeros(600001,6);
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc6(n+1,1) = (E6)*Ptemp(1,1);
    Conc6(n+1,2) = (E6)*Ptemp(1,3);
    Conc6(n+1,3) = (E6)*Ptemp(1,5);
    Conc6(n+1,4) = (E6)*Ptemp(1,2);
    Conc6(n+1,5) = (E6)*Ptemp(1,4);
    Conc6(n+1,6) = (E6)*Ptemp(1,6);          
end
%--------------------------------------------------------------------------------------------------------
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E7 = 240000;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                                         %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;
Conc7 = zeros(600001,6);
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc7(n+1,1) = (E7)*Ptemp(1,1);
    Conc7(n+1,2) = (E7)*Ptemp(1,3);
    Conc7(n+1,3) = (E7)*Ptemp(1,5);
    Conc7(n+1,4) = (E7)*Ptemp(1,2);
    Conc7(n+1,5) = (E7)*Ptemp(1,4);
    Conc7(n+1,6) = (E7)*Ptemp(1,6);          
end
%--------------------------------------------------------------------------------------------------------
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CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E8 = 300000;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                                        %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;
Conc8 = zeros(600001,6);
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc8(n+1,1) = (E8)*Ptemp(1,1);
    Conc8(n+1,2) = (E8)*Ptemp(1,3);
    Conc8(n+1,3) = (E8)*Ptemp(1,5);
    Conc8(n+1,4) = (E8)*Ptemp(1,2);
    Conc8(n+1,5) = (E8)*Ptemp(1,4);
    Conc8(n+1,6) = (E8)*Ptemp(1,6);          
end
%---------------------------------------------------------------------------------------------------------
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));  %Ensure that the rows in matix P sum to 1
end 
[CHECKP]
E9 = 398400;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                        %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;
Conc9 = zeros(600001,6);
for n = 2:600000
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    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc9(n+1,1) = (E9)*Ptemp(1,1);
    Conc9(n+1,2) = (E9)*Ptemp(1,3);
    Conc9(n+1,3) = (E9)*Ptemp(1,5);
    Conc9(n+1,4) = (E9)*Ptemp(1,2);
    Conc9(n+1,5) = (E9)*Ptemp(1,4);
    Conc9(n+1,6) = (E9)*Ptemp(1,6);          
end
%---------------------------------------------------------------------------------------------------------
MC_Dose =
[Conc(length(Conc),3);Conc2(length(Conc2),3);Conc3(length(Conc3),3);Conc4(length(
Conc4),3);Conc5(length(Conc5),3);Conc6(length(Conc6),3);Conc7(length(Conc7),3);Co
nc8(length(Conc8),3);Conc9(length(Conc9),3)];
MC_Surf_Dose =
[Conc(length(Conc),6);Conc2(length(Conc2),6);Conc3(length(Conc3),6);Conc4(length(
Conc4),6);Conc5(length(Conc5),6);Conc6(length(Conc6),6);Conc7(length(Conc7),6);Co
nc8(length(Conc8),6);Conc9(length(Conc9),6)];
EE = [E;E2;E3;E4;E5;E6;E7;E8;E9];
%Doses = [Conc(length(Conc),3); Conc2(length(Conc2),3); Conc3(length(Conc3),3);
Conc4(length(Conc4),3); Conc5(length(Conc5),3); Conc6(length(Conc6),3);
Conc7(length(Conc7),3); Conc8(length(Conc8),3); Conc9(length(Conc9),3); 
%Max_Doses = [max(Conc)];
figure
plot(EE,MC_Dose)
title('\bf\fontname{times}\fontsize{12}Exposed Dose Compared to Delivered Dose,
After 60 Minutes')
xlabel('\bf\fontname{times}\fontsize{12}Exposed Dose (Spores)')
ylabel('\bf\fontname{times}\fontsize{12}Delivered Dose (Spores)')
figure
scatter(EE,MC_Dose_Max)
title('\bf\fontname{times}\fontsize{12}Exposed Dose Compared to Maximum Delivered
Dose')
xlabel('\bf\fontname{times}\fontsize{12}Exposed Dose (Spores)')
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ylabel('\bf\fontname{times}\fontsize{12}Delivered Dose (Spores)')
MC_Dose_Correction = MC_Dose./EE;
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APPE DIX C: SOURCE CODE OF OPTIMIZATIO  OF PATHOGE ESIS
PARAMETERS 
function SSE_mvg = SSE_All(para)
function BA_AM_inter = BAAM(t,y,para)
BA_AM_inter = zeros(6,1);
global z; global Vbronc; global Aabar; global Aae; global Aao; 
global Vabar; global Vae; global Vao; global Aam; global Vam;
global Ap1; global Ap2; global Ap3; global Ap4; global padep;   
global Q;       % flow rates in um^3/hr over 480e6 alveoli in lung
global kdep;  % Deposition rate for spores on macrophages 
global kger;   % Germination rate available from open literature 
global kdec;   % Decay rate constant for cells in macrophages
mup = [0.235, 0.331, 0.419, 0.435, 0.412, 0.469, 0.554]; 
% percent uptake %from Hu etal (2006) Cellular Micro 8(10) Fig 1B 
%pg.1635   
mupt = [0, 2, 4, 6, 8, 10, 12]; 
 %time scale for the uptake data (hrs)
mina = [1.0, 0.653, 0.553, 0.378];
%percent inactivation from  Hu etal (2006) Cellular Micro 8(10) Fig 3B 
%pg.1638
minat = [0, 2, 4, 6];
time scale for the uptake data
vger = [0, 0.133, 0.437, 0.357, 0.160, 0.229]; 
% percent germination from %Hu etal (2006) Cellular Micro 8(10) Fig 2C 
%pg 1636|
vgert = [0, 2, 4, 6, 8, 10];    
%time scale for the germination data (hrs)
vgrw = [0.302, 0.1528, 0.0888, 0.0396];%[0.0396,0.0888,0.1528,0.302];
     BA_AM_inter(1,1) = ((Q*Cin)-(Q*y(1))+(Q*y(2)))/Vbronc;
    BA_AM_inter(2,1) = ((Q*y(1))-(Q*y(2))-(y(2)*kdep))/Vao;
   BA_AM_inter(3,1) = ((y(2)*kdep)-(y(3)*para(1)));
   BA_AM_inter(4,1) = (((y(3)*para(1)))*Aam-(kger*y(4)*Vam)-
                                                           (para(2)*y(5)*Vam))/Vam;
   BA_AM_inter(5,1) = ((para(2)*y(5)*Vam))/Vam;
     BA_AM_inter(6,1) = ((kger*y(4)*Vam)+(para(3)*y(6)*Vam)-
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(kdec*y(6)*Vam))/Vam;
end
%Ensure the the first step is not too large for the ODE solution
options4 = odeset('RelTol',1e-12,'InitialStep',0.0000003,'MaxStep',0.03);
dd = length(M);
[TT,YY] = ode15s(@(t,y)BAAM(t,y,para),[0.00002,0.002,0.25,0.5,1,2,3,4,5,6,8,10,12],
[M(dd,1),M(dd,2),M(dd,3),M(dd,4),M(dd,5),M(dd,6)],options4);
%--------------------------------------------------------------------------------------------------------|
%------------------------developing concentration values from data-----------------------------|
%--------------------------------------------------------------------------------------------------------|
    SSEmup2 = (Cin*(mup(2))); SSEmup4 = (SSEmup2(1,1)*(mup(3))); SSEmup6 =      
                        (SSEmup4(1,1)*(mup(4))); SSEmup8 = (SSEmup6(1,1)*(mup(5)));
    SSEmup10 = SSEmup8*(mup(6)*0.3); SSEmup12 = SSEmup10*(mup(7));
    SSEmid2 = (Cin*(mina(2))); SSEmid4 = (SSEmid2*(mina(3))); SSEmid6 =    
                       (SSEmid4*(mina(4)));
   
    SSEvgrqrt = (Cin*(vgrw(1))); SSEvgrhlf = (SSEmvgrqrt*(vgrw(2)));  SSEvgr1 = 
                         (SSEvgrhlf*(vgrw(3))); SSEvgr2 = (SSEvgr1*(vgrw(4)));
%--------------------------------------------------------------------------------------------------------|
%------------------------obtaining predicted values from system of ODEs---------------------|
%--------------------------------------------------------------------------------------------------------|
    SSEm2 = YY(6,4); SSEm4 = YY(8,4); SSEm6 = YY(10,4); SSEm8 = YY(11,4);
    SSEm10 = YY(12,4); SSEm12 = YY(13,4);
    
    SSEmi2 = YY(6,5); SSEmi4 = YY(8,5); SSEmi6 = YY(10,5);
    
    SSEv1qrt = YY(3,6); SSEvhlf = YY(4,6); SSEv1 = YY(5,6); SSEv2 = YY(6,6);
    
    SSEM = ((SSEmup2-SSEm2)^2)+((SSEmup4-SSEm4)^2)+((SSEmup6-SSEm6)^2)+  
                   ((SSEmup8-SSEm8)^2)+((SSEmup10-SSEm10)^2)+((SSEmup12-
                   SSEm12)^2);
    SSEmi = ((SSEmid2-SSEmi2)^2)+((SSEmid4-SSEmi4)^2)+((SSEmid6-SSEmi6)^2);
    SSEvg = ((SSEvgrqrt-SSEv1qrt)^2)+((SSEvgrhlf-SSEvhlf)^2)+((SSEvgr1-
                    SSEv1)^2)+((SSEvgr2-SSEv2)^2);
%==============================================================|
%***********      Function being Optimized in fminsearch or fminunc      ***********|
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%==============================================================|
    SSE_mvg = log(SSEM+SSEmi+SSEvg);                       
%==============================================================|
end
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APPE DIX D: SOURCE CODE OF COUPLED TWO STAGE MODEL
function MC  %Function defined so the function defining the ODEs can be used
%==============================================================|
%-----------------------------------------------HEADER---------------------------------------------|
%==============================================================|
% BA_MC.m is the Markov chain model which will model the transport of                      |
% pathogens through the respiratory tract.  This will determine the                                    |
% concentration of spores deposited or remaining in the air in the three                             |
% regions of the respiratory tract.                                                                                         |
% Written by Mark H. Weir for his dissertation work in the Department of                        |
% Civil Architectural and Environmental Engineering, Drexel University                          |
% in pursuit of a PhD in Environmental Engineering                                                          |
%==============================================================|
%==============================================================|
%    Dimensional parameters of spores and the three regions as well as time step size       |
%==============================================================|
dp1 = 0.0001;                                                                                
dp2 = 0.0002;                                                                                
dp3 = 0.0003;                              %Aerodynamic diameters of of spores in cm         
dp4 = 0.0004;
VR1 = 89.63;                              %Volume of region 1 in cc also 89633.62 in cmm     
VR2 = 111.02492;                      %Volume of region 2 in cc also 111,024.92 in cmm   
VR3 = 1633.99;                          %Volume of region 3 in cc also 1,633,990.00 in cmm 
Q = 125;                                      %Volumetric inhalation flow rate in cc/min         
B = 125;                                      %Volumetric exhalation flow rate in cc/min         
Vts = 0.0018*(dp1^2)*(1+(0.166/dp1)); %Terminal settling velocity of spore in m/min
dR1 = 3.4;                                                %Effective diameter of region-one in cm            
dR2 = 1.467;                                            %Effective diameter of region-two in cm            
dR3 = 0.18;                                              %Mean diameter for region-three in cm   
delta_t = 0.0003125;                                    %Time step of 0.01 minutes
%==============================================================|
%==============================================================|
%            Define loss rates for transition probabilities for Markov matrix            |
%==============================================================|
lambda_R12 = (Q+B)/VR1;   %Air transport loss rate from region-one to two in min^-1
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lambda_R21 = B/VR2;          %Air transport loss rate from region-two to one in min^-1
lambda_R23 = (Q+B)/VR2;  %Air transport loss rate from region-two to three in min^-1
lambda_R32 = B/VR3;          %Air transport loss rate from region-three to two in min^-1
lambda_exh = Q/(VR1+VR2+VR3); %Exhaust loss rate from respiratory tract in min^-1
lambda_R1s = Vts/dR1;                     %Deposition rate for region-one;
lambda_R2s = Vts/dR2;                     %Deposition rate for region-two;
lambda_R3s = Vts/dR3;                     %Deposition rate for region-three;
lambda_death = 0.000000464;            %Death rate from open literature
%==============================================================|
%                                            Generate the 8x8 Markov matrix                                           |
%==============================================================|
P = zeros(8,8);
%==============================================================|
%                                              Start Filling the Markov matrix                                           |
%==============================================================|
%--------------------------------------------------------------------------------------------------------|
%                      losses from State 1 thus column 1 of the Markov matrix                           |
%--------------------------------------------------------------------------------------------------------|
tloss1 = lambda_R12 + lambda_R1s + lambda_death;
p11 = exp(-tloss1*delta_t);
p12 = (lambda_R1s/tloss1)*(1-p11);
p13 = (lambda_R12/tloss1)*(1-p11);
p17 = (lambda_death/tloss1)*(1-p11);
%--------------------------------------------------------------------------------------------------------|
%                          losses from State 2 thus column 2 of the Markov matrix                       |
%--------------------------------------------------------------------------------------------------------|
tloss2 = lambda_death;
p22 = exp(-tloss2*delta_t);
p27 = 1-p22;
%--------------------------------------------------------------------------------------------------------|
%                          losses from State 3 thus column 3 of the Markov matrix                       |
%--------------------------------------------------------------------------------------------------------|
tloss3 = lambda_R21 + lambda_R23 + lambda_R2s + lambda_death;
p33 = exp(-tloss3*delta_t);
p31 = (lambda_R21/tloss3)*(1-p33);
p34 = (lambda_R2s/tloss3)*(1-p33);
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p35 = (lambda_R23/tloss3)*(1-p33);
p37 = (lambda_death/tloss3)*(1-p33);
%--------------------------------------------------------------------------------------------------------|
%                        losses from State 4 thus column 4 of the Markov matrix                         |
%--------------------------------------------------------------------------------------------------------|
tloss4 = lambda_death;
p44 = exp(-tloss4*delta_t);
p47 = 1-p44;
%--------------------------------------------------------------------------------------------------------|
%                       losses from State 5 thus column 5 of the Markov matrix                          |
%--------------------------------------------------------------------------------------------------------|
tloss5 = lambda_R32 + lambda_exh + lambda_R3s + lambda_death;
p55 = exp(-tloss5*delta_t);
p53 = (lambda_R32/tloss5)*(1-p55);
p56 = (lambda_R3s/tloss5)*(1-p55);
p57 = (lambda_death/tloss5)*(1-p55);
p58 = (lambda_exh/tloss5)*(1-p55);
%--------------------------------------------------------------------------------------------------------|
%                           losses from State 6 thus column 6 of the Markov matrix                      |
%--------------------------------------------------------------------------------------------------------|
tloss6 = lambda_death;
p66 = exp(-tloss6*delta_t);
p67 = 1-p66;
%--------------------------------------------------------------------------------------------------------|
%                         losses from State 7 thus column 7 of the Markov matrix                        |
%--------------------------------------------------------------------------------------------------------|
p77 = 1;
%--------------------------------------------------------------------------------------------------------|
%                         losses from State 8 thus column 8 of the Markov matrix                        |
%--------------------------------------------------------------------------------------------------------|
p88 = 1;
%--------------------------------------------------------------------------------------------------------|
%              place the incremental pieces of the matrix into the overall 8x8 matrix              |
%--------------------------------------------------------------------------------------------------------|
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P(1,1) = p11; P(1,2) = p12; P(1,3) = p13; P(1,7) = p17;
P(2,2) = p22; P(2,7) = p27;
P(3,1) = p31; P(3,3) = p33; P(3,4) = p34; P(3,5) = p35; P(3,7) = p37;
P(4,4) = p44; P(4,7) = p47;
P(5,3) = p53; P(5,5) = p55; P(5,6) = p56; P(5,7) = p57; P(5,8) = p58;
P(6,6) = p66; P(6,7) = p67;
P(7,7) = p77;
P(8,8) = p88;
CHECKP = zeros(8,1);
for i = 1:8
    CHECKP(i,1) = sum(P(i,:));     %Ensure that the rows in matrix P sum to 1
end 
CHECKP
E = 70320;           %Exposure concentration of spores released at time = 0
time = zeros(600001,1);   %time steps of 0.01 minutes adding up to 1 hour for 6001
                                          %6 minutes for 6001
time(2,1) = 0.0003125;
Ptemp = P;              %Establish a matrix identical to P so the original P matrix
                        %will not be overwritten during execution of the
                        %Markov chain
        function BA_AM_inter = BAAM(t,y,para)
            %Establish the ODEs for the BA macrophage interaction model
            BA_AM_inter = zeros(6,1);
            global Vbronc; global Vao;  global Aam;  global Vam; 
            global kdep; global kger; global kdec;   
            %para = [0.324899910207,1.5695455632,0.225880282779,0.236343080932];
            para = [1.0868423,1.18080467,0.2354105849,0.232]; %kdecay ~= 0.21875 min^-
1
            BA_AM_inter(1,1) = ((Q*Cin)-(2*Q*y(1))+(Q*y(2)))/Vbronc;
            BA_AM_inter(2,1) = ((Q*y(1))-(Q*y(2))-(y(2)*kdep))/Vao;
            BA_AM_inter(3,1) = ((y(2)*kdep)-(y(3)*para(1)));
            BA_AM_inter(4,1) = (((y(2)*kdep)-(y(3)*para(1)))*Aam-(kger*y(4)*Vam)-
                                               (para(2)*y(4)*Vam))/Vam;
            BA_AM_inter(5,1) = ((para(2)*y(4)*Vam))/Vam;
            BA_AM_inter(6,1) = ((kger*y(4)*Vam)+(para(3)*y(6)*Vam)-
                                               (kdec*y(6)*Vam))/Vam;
182
        end
for n = 2:600000
    time(n+1,1) = n/10000;
    Ptemp = Ptemp*P;
    Conc(n+1,1) = (E/VR1)*Ptemp(1,1);
    Conc(n+1,2) = (E/VR2)*Ptemp(1,3);
    Conc(n+1,3) = (E/VR3)*Ptemp(1,5);
    Conc(n+1,4) = (E/VR1)*Ptemp(1,2);
    Conc(n+1,5) = (E/VR2)*Ptemp(1,4);
    Conc(n+1,6) = (E/VR3)*Ptemp(1,6);
end
        Cin = Conc(length(Conc),3);  %Draw concentration in region-three from Markov 
                                                         %chain
        options2 = odeset('RelTol',1e-12,'InitialStep',0.0000003,'MaxStep',0.0003);
        %establish how the ODE solver runs
        [T,M] = ode15s(@BAAM,[0,0.00002],[0 0 0 0 0 0],options2);
        %Start the ODE solver with 0
        dd20 = length(M);
        Cin = 0;
        %Cin
        options  = odeset('RelTol',1e-12,'InitialStep',0.00003,'MaxStep',0.03);
        [T,Y] = ode15s(@BAAM,
        [0.00002,0.002,0.25,0.5,1,2,3,4,5,6,8,10,12,60,120,180,240,300,360,600],
        [M(dd20,1),M(dd20,2),M(dd20,3),M(dd20,4),M(dd20,5),M(dd20,6)], options);
figure
loglog(T,Y(:,1),'--',T,Y(:,2),'--',T,Y(:,3),'-',T,Y(:,4),'-',T,Y(:,5),'-',T,Y(:,6),'.-')
title('\bf\fontname{times}\fontsize{12}Concentrations of Bacillus anthracis')
xlabel('\bf\fontname{times}\fontsize{12}Time in Minutes')
ylabel('\bf\fontname{times}\fontsize{12}Concentration in Bacilli/cm^{3}')
legend('Spore Concentration in Air in Bronchioles','Spores Concentration in Air in
Alveoli','Spore Concentraion on Macrophage Surface','Spore Concentration Within
Macrophage','Inactivated Spores Concentration Within Macrophage','Vegetative Cell
Concentration Within Macrophage')
figure
loglog(T,Y(:,6),'-')
title('\bf\fontname{times}\fontname{12}Concentration of Vegetative Cells in
Macrophage')
xlabel('\bf\fontname{times}\fontsize{12}Time(Minutes)')
ylabel('\bf\fontname{times}\fontsize{12}Vegetative Cell Concentration (cells/\mu
m^{3})')
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figure
plot(time,Conc(:,1),'-', time, Conc(:,2),'--',time,Conc(:,3),'.-')
title('\bf\fontname{times}\fontsize{12}Respiratory Tract Concentration from 1,000,000
Spores/m^{3} Exposure')
xlabel('\bf\fontname{times}\fontsize{12}Time in Minutes')
ylabel('\bf\fontname{times}\fontsize{12}Spore Concentration in Spores/m^{3}')
legend('Concentration in Region-1 Air','Concentration in Region-2 Air','Concentration in
Region-3 Air')
figure
plot(time,Conc(:,4),'-',time,Conc(:,5),'--',time,Conc(:,6),'.-')
title('\bf\fontname{times}\fontsize{12}Respiratory Tract Concentration from 1,000,000
Spores/m^{3} Exposure')
xlabel('\bf\fontname{times}\fontsize{12}Time in Minutes')
ylabel('\bf\fontname{times}\fontsize{12}Spore Concentration in Spores/m^{3}')
legend('Concentration in Region-1 Surface','Concentration in Region-2
Surface','Concentration in Region-3 Surface')
end
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APPE DIX E: SOURCE CODE OF BOOTSTRAP CODE USED FOR DOSE
RESPO SE MODEL FITTI G
#=========================================================|
#------------------------------------------HEADER------------------------------------------|
#=========================================================|
#CAMRA_bootstrap_v5.r is an R statistical programming package                        |
#source code for initializing the bootstrap technique in R for              |
#generation of confidence intervals for both the exponential and                          |
#beta Poisson dose response models for risk estimation of                          |
#exposure to pathogens              |
#Written for CAMRA by: Mark H. Weir, Timothy A. Bartrand and  |
#Charles N. Haas, Department of the Civil Architectural and Environmental         |
#Engineering, Drexel University                           |
#Version 1 started on 1 July 2005 version 5 finished on 1 September 2006            |
#=========================================================|
#=========================================================|
#--Draw in dose response data and assign the needed values from the data---|
#=========================================================|
DR_Data <- read.table("BA_RM.RData",header=TRUE) 
 
dose <- DR_Data$dose
pos <- DR_Data$pos   
neg <- DR_Data$neg
oprob <- pos/(pos+neg)
   
#=========================================================|
#=========================================================|
#-----------Load required libraries to perform MLE and bootstrap-----------|
#=========================================================|
require(stats4)          
require(boot)         
#=========================================================|
#=========================================================|
#------------------       ----Define the dose response models.--------            ------------|
#---    -expntl.dr ---> exponential model and bp.dr ---> beta Poisson model---      -|
#=========================================================|
expntl.dr <- function(k,x,dose) 1-exp(-k*1.528*dose^x) #1 - exp(-k*1.528*dose)
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bp.dr <- function(alpha,N50,dose) 1-(1+(dose*1.528/N50)*(2^(1/alpha)-1))^(-
alpha)
#=========================================================|
#=========================================================|
#---------------Define functions for deviances of dose-response model---------------| 
#---------------------------------fits to experimental data----------------------------------|
#---------deviance.expntl --> deviance of the exponential model to the data --------|
#-------------dev.bp --> deviance of the beta Poisson model to the data--------------|
#=========================================================|
        
deviance.expntl <- function(obspos, obsneg, logk, logx,dose)                   
{                                                                         
      eps = 1e-15; #ensures that the function will not divide by zero
      k = exp(logk)
x = exp(logx)
      obsf = obspos/(obspos + obsneg);
      pred = expntl.dr(k,x,dose);
      y1 = sum(obspos*log(pred/(obsf+eps)));
      y2 = sum(obsneg*log((1-pred+eps)/(1-obsf+eps)))
      return(-1*(y1+y2))
}
dev.bp <- function (obspos, obsneg, logalpha, logN50, dose)
{
eps = 1e-15;
alpha = exp(logalpha)
N50 = exp(logN50)
obsf = obspos/(obspos+obsneg);
pred = bp.dr(alpha,N50,dose);
y1 = sum(obspos*log(pred/(obsf+eps)));
      y2 = sum(obsneg*log((1-pred+eps)/(1-obsf+eps)))
      return(-1*(y1+y2))
}
#=========================================================|
#=========================================================|
#-------------First run an MLE routine to obtain intial fitting estimates---------------|
#-------------------for both exponential and beta Poisson models-----------------------|
#=========================================================|
      
results2<-mle(deviance.expntl, start=list(logk=-11,logx=0), 
    method = 'BFGS',fixed = list(obspos=pos,obsneg=neg,dose=dose))
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print(summary(results2))
j<-coef(results2)
logk=j["logk"]
logx=j["logx"]
print("k parameter (not logk the eponential has already been taken)")
k = exp(logk)
x = exp(logx)
print(k)
print(x)
resultsbp <- mle(dev.bp,start=list(logalpha=-0.2, logN50=10),
method='BFGS',fixed=list(obspos=pos,obsneg=neg,dose=dose))
print(summary(resultsbp))
jb<-coef(resultsbp)
logalpha=jb["logalpha"]
logN50=jb["logN50"]
print(list(exp(logalpha),exp(logN50)))
#=========================================================|
#=========================================================|
#---------------Run bootstrap routine for number of dictated iterations----------------|
#-----------------First is the exponential model then the beta Poisson------------------|
#=========================================================|
iterations=500  
bootparms<-matrix(nrow=iterations,ncol=5)
for (iter in 1:iterations) {
      bootdataframe=DR_Data
total=bootdataframe$pos+bootdataframe$neg
fobs=bootdataframe$pos/total
bootpos<-rbinom(0+fobs,total,fobs)  # draw random sample
bootdataframe$pos<-bootpos          # replace and form bootstrap sample
results_boot<-mle(deviance.expntl,start=list(logk=-11,logx=0), method = 
'BFGS', fixed = list(obspos=bootdataframe$pos, obsneg=total-
bootdataframe$pos, dose=bootdataframe$dose))
            results_boot
L<-logLik(results_boot)
L<-2*L[[1]]
jb<-coef(results_boot)
            logk_est <- jb["logk"]
logx_est <- jb["logx"]
k_est <- exp(jb["logk"])
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x_est <- exp(jb["logx"])
bootparms[iter,1] <- logk_est
bootparms[iter,2] <- k_est 
bootparms[iter,3] <- logx_est
bootparms[iter,4] <- x_est
bootparms[iter,5] <- L
  ##    if (k_est > 0.0 ) {
  ##       bootdataframe
  ##       k_est
  ##       stop } 
  ## print(bootpos)
  ## print(iter)
}    
colnames(bootparms)<-c("ln(k)","k parameter","ln(x)","x parameter","-2  
ln(Likelihood)")
n=500 
bootparms_bp<-matrix(nrow=n,ncol=5)
for (iter2 in 1:n) {
      bootdataframe=DR_Data
total=bootdataframe$pos+bootdataframe$neg
fobs=bootdataframe$pos/total
bootpos<-rbinom(0+fobs,total,fobs)  # draw random sample
bootdataframe$pos<-bootpos          # replace and form bootstrap sample
results_boot_bp<-mle(dev.bp,start=list(logalpha=-0.2, logN50=10),
      method = 'BFGS', fixed = list(obspos=bootdataframe$pos,
      obsneg=total-bootdataframe$pos,dose=bootdataframe$dose))
      results_boot_bp
LL<-logLik(results_boot_bp)
LL<-2*L[[1]]
jbp<-coef(results_boot_bp)
      logN50_est <- jbp["logN50"]
logalpha_est <- jbp["logalpha"]
N50_est <- exp(jbp["logN50"])
alpha_est <- exp(jbp["logalpha"])
bootparms_bp[iter2,1] <- logalpha_est
bootparms_bp[iter2,2] <- alpha_est
bootparms_bp[iter2,3] <- logN50_est
bootparms_bp[iter2,4] <- N50_est
bootparms_bp[iter2,5] <- LL
}    
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colnames(bootparms_bp)<-c("ln(alpha)","alpha","ln(N50)","N50","-2 
ln(Likelihood)")
#=========================================================|
#=========================================================|
#-------------Plot the results of the bootstrap routine of the exponential--------------|
#=========================================================|
#--------------histogram of exponential k parameters from the bootstrap-------------|
X11()
par(cex=1.2,mai=c(1.0,1.2,0.58,0.15),font.lab=1)
hist(bootparms[,1],breaks=20,plot=TRUE,xlab="ln(k)",main=" ")
#hhplot <- hist(bootparms[,1],breaks=20,plot=TRUE,xlab="ln(k)",main=" ")
#hhplot
x11()
par(cex=1.2,mai=c(1.0,1.2,0.58,0.15),font.lab=1)
hist(bootparms[,3],breaks=20,plot=TRUE,xlab="ln(x)",main=" ")
#----------------Plot the exponential model with confidence intervals-----------------|
ndiv <- 700
klist <- exp(bootparms[,1])
xlist <- exp(bootparms[,3])
dmin <- min(dose)/100
ldmin <- log10(dmin)
dmax <- max(dose)*10
ldmax <- log10(dmax)
diff <- (ldmax - ldmin)/ndiv
bestfit<-matrix(nrow=ndiv+1,ncol=1)
plot01<-matrix(nrow=ndiv+1,ncol=1)
plot05<-matrix(nrow=ndiv+1,ncol=1)
plot95<-matrix(nrow=ndiv+1,ncol=1)
plot99<-matrix(nrow=ndiv+1,ncol=1)
plotdose <- matrix(nrow=ndiv+1,ncol=1)
for (iter in 0:ndiv+1) {
   pdose <- 10^(ldmin + (iter-1)*diff)
   plotdose[iter] <- pdose
   bestfit[iter] <- expntl.dr(exp(logk),exp(logx),pdose)
   spread<- expntl.dr(klist,xlist, pdose)
   CIs <- quantile(spread,probs=c(0.005,0.025,0.975,0.995)) 
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   plot01[iter] <- CIs[1]
   plot05[iter] <- CIs[2]
   plot95[iter] <- CIs[3]
   plot99[iter] <- CIs[4]}
x11(height=7,width=7)
par(cex=1.1,cex.lab=1.4,mai=c(1.2, 1.2,0.15,0.25),
    cex.axis=1.1,mgp=c(2.5,0.75,0), font.lab=1)
plot(dose,pos/(pos+neg),log="x",xlab=expression(Dose ~~ (Bacilli)),
     ylab="Response (Mortality)",ylim=c(0,1),pch=17, xlim=c(dmin,dmax))
lines(plotdose,bestfit,lwd=2)
lines(plotdose,plot01,lty=2,lwd=2)
lines(plotdose,plot05,lty=3,lwd=2)
lines(plotdose,plot95,lty=3,lwd=2)
lines(plotdose,plot99,lty=2,lwd=2)
par(cex=1.3)
legend(500,1,legend=c("best fit model","95% confidence","99% confidence"),
     lty=c(1,3,2),bty="n",y.intersp=1.4)
#=========================================================|
#=========================================================|
#-------------------Output the 95 and 99% CIs for the parameter (k)-------------------|
#=========================================================|
logk_CI <- quantile(bootparms[,1],probs=c(0.005,0.025,0.05,0.95,0.975,0.995))
k_CI <- exp(logk_CI)
k_CI
logx_CI <- quantile(bootparms[,3],probs=c(0.005,0.025,0.05,0.95,0.975,0.995))
x_CI <- exp(logx_CI)
x_CI
#=========================================================|
#=========================================================|
#-------------Plot the results of the bootstrap routine of the beta Poisson-------------|
#=========================================================|
#---------Scatter plot of beta Poisson parameters from the bootstrap---------|
X11()
par(cex=1.2,mai=c(1.2,1.2,0.5,0.15),font.lab=1)
plot(bootparms_bp[,1],bootparms_bp[,3],xlab=expression(ln(alpha)),ylab=expres
sion(ln(N[50])))
#-----------Plot the beta Poisson model with confidence intervals------------|
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ndiv <- 700
alphalist <- exp(bootparms_bp[,1])
N50list <- exp(bootparms_bp[,3])
dmin <- min(dose)/100
ldmin <- log10(dmin)
dmax <- max(dose)*10
ldmax <- log10(dmax)
diff <- (ldmax - ldmin)/ndiv
bestfit_bp<-matrix(nrow=ndiv+1,ncol=1)
plot01_2<-matrix(nrow=ndiv+1,ncol=1)
plot05_2<-matrix(nrow=ndiv+1,ncol=1)
plot95_2<-matrix(nrow=ndiv+1,ncol=1)
plot99_2<-matrix(nrow=ndiv+1,ncol=1)
plotdose <- matrix(nrow=ndiv+1,ncol=1)
for (iter in 0:ndiv+1) {
   pdose <- 10^(ldmin + (iter-1)*diff)
   plotdose[iter] <- pdose
   bestfit_bp[iter] <- bp.dr(exp(logalpha),exp(logN50),pdose)
   spread <- bp.dr(alphalist,N50list, pdose)
   CI <- quantile(spread,probs=c(0.005,0.025,0.975,0.995)) 
   plot01_2[iter] <- CI[1]
   plot05_2[iter] <- CI[2]
   plot95_2[iter] <- CI[3]
   plot99_2[iter] <- CI[4]}
x11(height=7,width=7)
par(cex=1.1,cex.lab=1.4,mai=c(1.2, 1.2,0.15,0.3),
    cex.axis=1.1,mgp=c(2.5,0.75,0), font.lab=1)
plot(dose,pos/(pos+neg),log="x",xlab=expression(Dose ~~ (Bacilli)),
     ylab="Response (Mortality)",ylim=c(0,1),pch=17, xlim=c(dmin,dmax))
lines(plotdose,bestfit_bp,lwd=2)
lines(plotdose,plot01_2,lty=2,lwd=2)
lines(plotdose,plot05_2,lty=3,lwd=2)
lines(plotdose,plot95_2,lty=3,lwd=2)
lines(plotdose,plot99_2,lty=2,lwd=2)
par(cex=1.3)
legend(500,1,legend=c("beta Poisson model","95% confidence","99%
confidence"),
     lty=c(1,3,2),bty="n",y.intersp=1.4)
#=========================================================|
191
#---------------------Output the 95 and 99% CIs for alpha and N50--------------------|
#=========================================================|
alpha_CI <-  
quantile(bootparms_bp[,1],probs=c(0.005,0.025,0.05,0.95,0.975,0.995))
ealpha_CI <- exp(alpha_CI)
ealpha_CI
N50_CI <- 
quantile(bootparms_bp[,3],probs=c(0.005,0.025,0.05,0.95,0.975,0.995))
eN50_CI <- exp(N50_CI)
eN50_CI
#=========================================================|
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